ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR

WIPO Patent Application WO/2008/152099

A2

The present invention relates to aryl/ hetarylamide derivativ es of the general formula (I), process for their preparation, and the use thereof for the manufacture of pharmaceutical compositions for the treatment of disorders and indications connected with the EP2 receptor.

WO/2003/106418	INDOLE, INDAZOLE, AND BENZAZOLE DERIVATIVE
WO/2012/055814	COMPOUND INDUCING LBPA ACCUMULATION FOR INHIBITING CELL-TO-CELL TRANSMISSION OF HIV
WO/2002/005797	USE OF DOPAMINE D¿2?/D¿3? RECEPTOR AGONISTS TO TREAT FIBROMYALGIA

BUCHMANN, Bernd (Erdmannstr. 44, Hohen Neuendorf, 16540, DE)
BRÄUER, Nico (Reuterallee 7a, Falkensee, 14612, DE)
KOPPITZ, Marcus (Scharnhorststr. 28, Berlin, 10115, DE)
PETERS, Olaf (Langenhainer Strasse 8, Tabarz, 99891, DE)
EIS, Knut (Fichtenweg 1, Berlin, 13587, DE)
TER LAAK, Antonius (Hedwigstr. 11, Berlin, 12159, DE)
LINDENTHAL, Bernhard (Wilkestr. 19, Berlin, 13507, DE)
LANGER, Gernot (Mainstr. 32, Falkensee, 14612, DE)
WINTERMANTEL, Tim (Monbijouplatz 9, Berlin, 10178, DE)

EP2008/057396

December 18, 2008

June 12, 2008

Click for automatic bibliography generation  

BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (Müllerstr. 178, Berlin, 13353, DE)
BUCHMANN, Bernd (Erdmannstr. 44, Hohen Neuendorf, 16540, DE)
BRÄUER, Nico (Reuterallee 7a, Falkensee, 14612, DE)
KOPPITZ, Marcus (Scharnhorststr. 28, Berlin, 10115, DE)
PETERS, Olaf (Langenhainer Strasse 8, Tabarz, 99891, DE)
EIS, Knut (Fichtenweg 1, Berlin, 13587, DE)
TER LAAK, Antonius (Hedwigstr. 11, Berlin, 12159, DE)
LINDENTHAL, Bernhard (Wilkestr. 19, Berlin, 13507, DE)
LANGER, Gernot (Mainstr. 32, Falkensee, 14612, DE)
WINTERMANTEL, Tim (Monbijouplatz 9, Berlin, 10178, DE)

A61K31/4045; A61K31/4155; A61K31/4178; A61K31/4184; A61K31/4192; A61K31/4196; A61K31/422; A61K31/427; A61K31/4406; A61K31/4409; A61K31/4439; A61K31/4709; A61K31/4985; A61K31/501; A61K31/506

View/Download PDF      PDF Help

Claims: 1. A compound of the formula I in which A is an aryl or heteroaryl radical which may optionally be substituted one or more times by R 3 and/or R 4 , R 1 is a hydrogen, a d-Cβ-alkyl radical which may optionally be substituted, R 2 is a hydrogen, halogen, cyano, an -S(O) q -CH 3 , where q is 0-2, a Ci-C 4 -alkoxy radical or Ci-C6-alkyl, where this radical can be substituted in any way, R J is a hydrogen, halogen, amino, an -S(O) p -CrC 6 -alkyl group, where p is 0-2, a d-Cβ-acyl, NH-CO-NH 2 , -O-CO-NH(Ci-C 6 -alkyl), -0-CO-N(Cr C 6 -alkyl) 2 or N H-CO-Ci -Cβ-alkyl radical, a d-Cβ-alkyl which may optionally be substituted one or more times, identically or differently, by d-Cβ-acyl, Ci-C 6 -alkoxy, hydroxy, cyano, CO 2 -(d-C 6 -alkyl), N-(Ci-C 6 -alkyl) 2 , C 5 -Ci 2 - heteroaryl, COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl) or by CO-N(Cr C 6 -alkyl) 2 , a Ci-C6-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO 2 -(Ci-C6- alkyl), N-(Ci-C 6 -alkyl) 2> NH-Ca-Cβ-cycloalkyl, COOH, CO-NH 2 , CO- NH(Ci-C 6 -alkyl) or by CO-N(Ci-C 6 -alkyl) 2 , an O-C6-Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a CH 2 O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , an O-C 5 -Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a hydroxy, cyano, O-CO-(d-C 6 -alkyl), CO-NH(C 5 -Ci 2 -heteroaryl), NH-(Ci-C 6 -alkyl), N-(Ci-C 6 -alkyl) 2> a C6-Ci 2 -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC 6 -alkyl, C 3 -C 6 - cycloalkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, C 6 -Ci 2 -aryl, C 5 -Ci 2 -heteroaryl, hydroxy, CH 2 -OH, cyano, CH 2 -CN, amino, CO 2 -(Ci-C 6 -alkyl), N- (Ci-C 6 -alkyl) 2 , NHSO 2 CH 3 , SO 2 NH 2 , SO 2 NH(Ci-C 6 -alkyl), SO 2 N(Ci-C 6 -alkyl) 2> COOH, CO-NH 2 , CO-N H(C 1 -C 6 -alkyl), CO- N(Ci-C 6 -alkyl) 2 , CO-NH(C 5 -Ci 2 -heteroaryl), NH-CO(Ci-C 6 -alkyl), CH 2 -NH-CO(Ci-C 6 -alkyl), NH-CO(C 5 -Ci 2 -heteroaryl), CH 2 -NH- CO(C 5 -Ci 2 -heteroaryl), styryl, or an -S(O) n -CH 3 , where r is 0-2, or two adjacent positions may be substituted by -0-CH 2 -O- or -O- C(CH 3 ) 2 -O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by C-i-Cβ-alkyl, if R 2 is cyano or if R 1 and/or R 2 is identically or differently a CrC 6 -alkyl radical, where at least one of the radicals is substituted at least once, or if R 4 is -S(O) p -Ci-C 6 -alkyl, where p is 0-2, Ci-C 6 -acyl-, -O- CO-NH(Ci-C 6 -alkyl), -O-CO-N(Ci-C 6 -alkyl) 2 , C 6 -Ci 2 -aryloxy, C 5 - Ci 6 -heteroaryloxy, hydroxy, cyano or N-(Ci-C 6 -alkyl) 2 , a monocyclic Cs-Cz-heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, CF 3 , C 1 - Cβ-acyl, Ci-C 6 -alkoxy, hydroxy, CH 2 -OH, cyano, CO 2 -(Ci-C 6 -alkyl), N-(Ci-C 6 -alkyl) 2> COOH, CO-NH 2 , CO-N H(C 1 -C 6 -alkyl) or CO- N(Ci-C 6 -alkyl) 2 , a bi- or tricyclic Cs-Ci 2-heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-Cθ-alkyl, Ci-Cθ-acyl, Ci-Cθ-alkoxy, hydroxy, cyano, CO 2 -(Cr Ce-alkyl), N-(Ci-C 6 -alkyl) 2> COOH, CO-NH 2 , CO-NH(C r C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , or a C3-C6-cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C 6 -alkyl, hydroxy, cyano, CO 2 -(Ci-C 6 -alkyl) > C r C 6 -acyl, N-(Ci-C 6 -alkyl) 2> COOH, CO- NH 2 , CO-NH(Ci-C 6 -alkyl), CO-N(Ci-C 6 -alkyl) 2 or Ci-C 6 -alkoxy, is a hydrogen, halogen, amino, -S(O) p -Ci-C 6 -alkyl, where p is 0-2, a d-Cβ-acyl, NH-CO-NH 2 , N H-CO-Ci -C 6 -alkyl, -0-CO-NH(CrC 6 - alkyl), -O-CO-N(Ci-C 6 -alkyl) 2 or Ci-C 6 -alkyl group which may optionally be substituted one or more times, identically or differently, by CrC 6 -acyl, CrC 6 -alkoxy, hydroxy, cyano, CO 2 -(Cr Cβ-alkyl), N-(Ci-C 6 -alkyl) 2> C 5 -Ci 2 -heteroaryl, COOH, CO-NH 2 , CO- NH(Ci-C 6 -alkyl) or by CO-N(Ci-C 6 -alkyl) 2> a Ci-Cθ-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO 2 -(CrC 6 - alkyl), N-(Ci-C 6 -alkyl) 2> NH-C 3 -C 6 -cycloalkyl, COOH, CO-NH 2 , CO- NH(CrC 6 -alkyl) or by CO-N(Ci-C 6 -alkyl) 2> an O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a CH 2 O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , an O-C5-Ci 6 -heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a hydroxy, cyano, O-CO-(CrC 6 -alkyl), CO-NH(C 5 -Ci 2 -heteroaryl), NH-(CrC 6 -alkyl), N-(Ci-C 6 -alkyl) 2> a C 6 -Ci 2 -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC 6 -alkyl, C 3 -C 6 - cycloalkyl, CrC 6 -acyl, CrC 6 -alkoxy, C 6 -Ci 2 -aryl, C 5 -Ci 2 -heteroaryl, hydroxy, CH 2 -OH, cyano, CH 2 -CN, amino, CO 2 -(d-C 6 -alkyl), N- (Ci-C 6 -alkyl) 2 , NHSO 2 CH 3 , SO 2 NH 2 , SO 2 NH(Ci-C 6 -alkyl), SO 2 N(Ci-C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl), CO- N(CrC 6 -alkyl) 2 , CO-NH(C 5 -C 12 -heteroaryl), NH-CO(C r C 6 -alkyl), CH 2 -NH-CO(Ci-C 6 -alkyl), NH-CO(C 5 -Ci 2 -heteroaryl), CH 2 -NH- CO(C 5 -Ci 2 -heteroaryl), styryl, or an -S(O) n -CH 3 , where r is 0-2, or two adjacent positions may be substituted by -0-CH 2 -O- or -O- C(CH 3 ) 2 -O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by C-i-Cβ-alkyl, if R 2 is cyano or if R 1 and/or R 2 is identically or differently a C-i-Cβ-alkyl radical, where at least one of the radicals is substituted at least once, a monocyclic Cs-Cz-heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, CF 3 , Ci- C 6 -acyl, CrC 6 -alkoxy, hydroxy, CH 2 -OH, cyano, CO 2 -(C r C 6 -alkyl), N-(Ci-C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl) or CO- N(Ci-C 6 -alkyl) 2 , a bi- or tricyclic Cs-Ci 2 -heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C 6 -alkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, hydroxy, cyano, CO 2 -(Ci- C 6 -alkyl), N-(Ci-C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , or a C 3 -C 6 -cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C 6 -alkyl, hydroxy, cyano, CO 2 -(Ci-C 6 -alkyl), Ci-C 6 -acyl, N-(Ci-C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl), CO-N(Ci-C 6 -alkyl) 2 or d- C 6 -alkoxy, R 3 and R 4 are either in ortho,meta position or meta,para position relative to one another and together have the meaning -O-CO-S-, -S-CO-O-, CH 2 -CO-O-, 0-CO-CH 2 -, -CH 2 -CO-NH-, -NH-CO-CH 2 -, -O-CO-NH- , -NH-CO-O-, -CO-CH 2 -(CH 2 ) m -, -CH 2 -(CH 2 ) m -CO-, -O-(CH 2 ) m -O-, - 0-C-(CHs) 2 -O-, -CH 2 -(CH 2 ) m -CH 2 -, where m is 1 -3, Y is a -(CH 2 ) n - group, where n is 1 -3, and the isomers, diastereomers, enantiomers and salts thereof, and cyclodextrin clathrates, where the following compounds are excluded: N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3,4-dimethoxybenzamide N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-methylbenzamide 4-bromo-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide. 2. The compound as claimed in claim 1 , where A is an aryl or heteroaryl radical which may optionally be substituted one or more times by R 4 and/or R 3 , R 1 is a hydrogen or Ci-C 6 -alkyl radical which may be substituted one or more times by halogen, R 2 is a hydrogen, halogen, cyano, an -S(O) q -CH 3 , where q is 0-2, a Ci-C 4 -alkoxy radical or Ci-C6-alkyl radical which may be substituted one or more times by halogen, R 3 is a hydrogen, halogen, amino, -S(O) p -Ci-C 6 -alkyl, where p is 0-2, a d-Cβ-acyl, NH-CO-NH 2 , NH-CO-d-Cβ-alkyl, -0-CO-NH(Ci-C 6 - alkyl), -O-CO-N(Ci-C 6 -alkyl) 2 , or Ci-C 6 -alkyl group which may optionally be substituted one or more times, identically or differently, by d-Cβ-acyl, Ci-C 6 -alkoxy, hydroxy, cyano, CO 2 -(Ci- Cβ-alkyl), N-(d-C 6 -alkyl) 2> C 5 -Ci 2 -heteroaryl, COOH, CO-NH 2 , CO- NH(Ci-C 6 -alkyl) or by CO-N(d-C 6 -alkyl) 2> a CrC 6 -alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO 2 -(Ci-C 6 - alkyl), N-(Ci-C 6 -alkyl) 2 , NH-Ca-Cβ-cycloalkyl, COOH, CO-NH 2 , CO- NH(Ci-C 6 -alkyl) or by CO-N(Ci-C 6 -alkyl) 2 , an O-C6-Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a CH 2 O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , an O-C 5 -Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a hydroxy, cyano, O-CO-(d-C 6 -alkyl), CO-NH(C 5 -Ci 2 -heteroaryl), NH-(Ci-C 6 -alkyl), N-(Ci-C 6 -alkyl) 2> a C6-Ci 2 -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC 6 -alkyl, C 3 -C 6 - cycloalkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, C 6 -Ci 2 -aryl, C 5 -Ci 2 -heteroaryl, hydroxy, CH 2 -OH, cyano, CH 2 -CN, amino, CO 2 -(Ci-C 6 -alkyl), N- (Ci-C 6 -alkyl) 2 , NHSO 2 CH 3 , SO 2 NH 2 , SO 2 NH(Ci-C 6 -alkyl), SO 2 N(Ci-C 6 -alkyl) 2> COOH, CO-NH 2 , CO-N H(C 1 -C 6 -alkyl), CO- N(Ci-C 6 -alkyl) 2 , CO-NH(C 5 -Ci 2 -heteroaryl), NH-CO(Ci-C 6 -alkyl), CH 2 -NH-CO(Ci-C 6 -alkyl), NH-CO(C 5 -Ci 2 -heteroaryl), CH 2 -NH- CO(C 5 -Ci 2 -heteroaryl), styryl, or an -S(O) n -CH 3 , where r is 0-2, or two adjacent positions may be substituted by -0-CH 2 -O- or - O-C(CH 3 ) 2 -O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by C-i-C 6 -alkyl, if R 2 is cyano or if R 1 and/or R 2 is identically or differently a CrC 6 -alkyl radical, where at least one of the radicals is substituted at least once, or if R 4 is -S(O) p -Ci-C 6 -alkyl, where p is 0-2, Ci-C 6 -acyl-, -O- CO-NH(Ci-C 6 -alkyl), -O-CO-N(Ci-C 6 -alkyl) 2 , C 6 -Ci 2 -aryloxy, C 5 - Ci 6 -heteroaryloxy, hydroxy, cyano or N-(Ci-C 6 -alkyl) 2 , a monocyclic Cs-Cz-heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, by CF 3 , d-Cβ-acyl, Ci-C 6 -alkoxy, hydroxy, CH 2 -OH, cyano, CO 2 -(Ci-C 6 - alkyl), N-(C r C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(C r C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , a bi- or tricyclic Cs-Ci 2-heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-Cθ-alkyl, Ci-Cθ-acyl, Ci-Cθ-alkoxy, hydroxy, cyano, CO 2 -(Cr Ce-alkyl), N-(Ci-C 6 -alkyl) 2> COOH, CO-NH 2 , CO-NH(C r C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , or a C3-C6-cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C 6 -alkyl, hydroxy, cyano, CO 2 -(Ci-C 6 -alkyl) > C r C 6 -acyl, N-(Ci-C 6 -alkyl) 2> COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl), CO-N(Ci-C 6 -alkyl) 2 or Ci-C 6 -alkoxy, is a hydrogen, halogen, amino, -S(O) p -Ci-C 6 -alkyl, where p is 0-2, a d-Cβ-acyl, NH-CO-NH 2 , N H-CO-Ci -C 6 -alkyl, -0-CO-NH(CrC 6 - alkyl), -O-CO-N(Ci-C 6 -alkyl) 2 , or Ci-C 6 -alkyl group which may optionally be substituted one or more times, identically or differently, by CrC 6 -acyl, CrC 6 -alkoxy, hydroxy, cyano, CO 2 -(Cr Cβ-alkyl), N-(Ci-C 6 -alkyl) 2> C 5 -Ci 2 -heteroaryl, COOH, CO-NH 2 , CO- NH(Ci-C 6 -alkyl) or by CO-N(Ci-C 6 -alkyl) 2> a Ci-Cθ-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO 2 -(CrC 6 - alkyl), N-(Ci-C 6 -alkyl) 2> NH-C 3 -C 6 -cycloalkyl, COOH, CO-NH 2 , CO- NH(CrC 6 -alkyl) or by CO-N(Ci-C 6 -alkyl) 2> an O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a CH 2 O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , an O-C5-Ci 6 -heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a hydroxy, cyano, O-CO-(CrC 6 -alkyl), CO-NH(C 5 -Ci 2 -heteroaryl), NH-(CrC 6 -alkyl), N-(Ci-C 6 -alkyl) 2> a C 6 -Ci 2 -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC 6 -alkyl, C 3 -C 6 - cycloalkyl, CrC 6 -acyl, CrC 6 -alkoxy, C 6 -Ci 2 -aryl, C 5 -Ci 2 -heteroaryl, hydroxy, CH 2 -OH, cyano, CH 2 -CN, amino, CO 2 -(d-C 6 -alkyl), N- (Ci-C 6 -alkyl) 2> NHSO 2 CH 3 , SO 2 NH 2 , SO 2 NH(Ci-C 6 -alkyl), SO 2 N(Ci-C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl), CO- N(Ci-C 6 -alkyl) 2> CO-NH(C 5 -C 12 -heteroaryl), NH-CO(C r C 6 -alkyl), CH 2 -NH-CO(Ci-C 6 -alkyl), NH-CO(C 5 -Ci 2 -heteroaryl), CH 2 -NH- CO(C 5 -Ci 2 -heteroaryl), styryl, or an -S(O) n -CH 3 , where r is 0-2, or two adjacent positions may be substituted by -0-CH 2 -O- or -O- C(CHa) 2 -O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by C-i-Cβ-alkyl, if R 2 is cyano or if R 1 and/or R 2 is identically or differently a C-i-Cβ-alkyl radical, where at least one of the radicals is substituted at least once, a monocyclic Cs-Cz-heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, by CF 3 , C-i-Cβ-acyl, CrC 6 -alkoxy, hydroxy, CH 2 -OH, cyano, CO 2 -(CrC 6 - alkyl), N-(Ci-C 6 -alkyl) 2> COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , a bi- or tricyclic Cs-Ci 2 -heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C 6 -alkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, hydroxy, cyano, CO 2 -(Cr Cβ-alkyl), N-(Ci-C 6 -alkyl) 2> COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , or a C 3 -C 6 -cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C 6 -alkyl, hydroxy, cyano, CO 2 -(Ci-C 6 -alkyl), Ci-C 6 -acyl, N-(Ci-C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl), CO-N(Ci-C 6 -alkyl) 2 or d- C 6 -alkoxy, R 3 and R 4 are either in ortho,meta position or meta,para position relative to one another and together have the meaning of -O-CO-S-, -S-CO- O-, CH 2 -CO-O-, 0-CO-CH 2 -, -CH 2 -CO-NH-, -NH-CO-CH 2 -, -O-CO- NH-, -NH-CO-O-, -CO-CH 2 -(CH 2 ) m -, -CH 2 -(CH 2 ) m -CO-, -O-(CH 2 ) m - O-, -0-C-(CHs) 2 -O-, -CH 2 -(CH 2 ) m -CH 2 -, where m is 1 -3, Y is a -(CH 2 ) n - group, where n is 1 -3, and the isomers, diastereomers, enantiomers and salts thereof, and cyclodextrin clathrates. 3. The compound as claimed in claim 1 -2, where A is an aryl or heteroaryl radical which may optionally be substituted one or more times by R 4 and/or R 3 , R 1 is a hydrogen or a d-Cβ-alkyl group which is substituted one or more times by halogen, R 2 is a hydrogen, halogen, cyano, an -S(O) q -CH 3 , where q is 0-2, a Ci-C 4 -alkoxy radical or a Ci-C6-alkyl group which is substituted one or more times by halogen, R 3 is a hydrogen, halogen, amino, -S(O) P -CH 3 , where p is 0-2, an -S-CF 3 , SO 2 NH 2 , Ci-C 6 -acyl, NH-CO-NH 2 , NH-CO-d-Cβ-alkyl, -O-CO-NH(Ci-C 6 -alkyl), -O-CO-N(C r C 6 -alkyl) 2 , or C r C 6 -alkyl group which may optionally be substituted one or more times, identically or differently, by Ci-C 4 -acyl, Ci-C 4 -alkoxy, hydroxy, cyano, CO 2 -(Ci-C 4 -alkyl), N-(Ci-C 4 -alkyl) 2 , C 5 -Ci 2 -heteroaryl, COOH, CO-NH 2 , CO-N H(C 1 -C 4 -alkyl) or by CO-N(C r C 4 -alkyl) 2 , a Ci-Cθ-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO 2 -(Ci-C 6 - alkyl), N-(Ci-C 6 -alkyl) 2> NH-Ca-Cβ-cycloalkyl, COOH, CO-NH 2 , CO- NH(Ci-C 6 -alkyl) or by CO-N(Ci-C 6 -alkyl) 2> an O-C6-Ci2-aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a CH 2 O-C6-Ci2-aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , an O-C 5 -Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a hydroxy, cyano, O-CO-(Ci-C 6 -alkyl), CO-NH(C 5 -Ci 2 -heteroaryl), NH-(CrC 6 -alkyl), N-(CrC 6 -alkyl) 2 , a C6-Ci 2 -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by d-Cβ-alkyl, C3-C6- cycloalkyl, C-i-Cβ-acyl, d-Cβ-alkoxy, C 6 -Ci 2 -aryl, C 5 -Ci 2 -heteroaryl, hydroxy, CH 2 -OH, cyano, CH 2 -CN, amino, CO 2 -(C r C 6 -alkyl), N- (Ci-C 6 -alkyl) 2 , NHSO 2 CH 3 , SO 2 NH 2 , SO 2 NH(Ci-C 6 -alkyl), SO 2 N(Ci-C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl), CO- N(Ci-C 6 -alkyl) 2 , CO-NH(C 5 -Ci 2 -heteroaryl), NH-CO(Ci-C 6 -alkyl), CH 2 -NH-CO(CrC 6 -alkyl), NH-CO(C 5 -C 12 -heteroaryl), CH 2 -NH- CO(C 5 -Ci 2 -heteroaryl), styryl, or an -S(O) n -CH 3 , where r is 0-2, or two adjacent positions may be substituted by -0-CH 2 -O- or -0-C(CHs) 2 -O-, a monocyclic C 5 -C 7 -heteroaryl which may optionally be substituted one or more times, identically or differently, by C-i-Cβ-alkyl, if R 2 is cyano or if R 1 and/or R 2 is identically or differently a C-i-Cβ-alkyl radical, where at least one of the radicals is substituted at least once by halogen, or if R 4 is -S(O) p -CrC 6 -alkyl, where p is 0-2, d- Cβ-acyl, -O-CO-NH(Ci-C 6 -alkyl), -O-CO-N(Ci-C 6 -alkyl) 2 , C 6 -Ci 2 - aryloxy, Cs-Ciθ-heteroaryloxy, hydroxy, cyano or N-(Ci-C6-alkyl) 2 , a monocyclic Cs-C 7 -heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, by CF 3 , Ci-C 4 -acyl, Ci-C 4 -alkoxy, hydroxy, CH 2 -OH, cyano, CO 2 -(Ci-C 4 - alkyl), N-(Ci-C 4 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl) or CO-N(Ci-C 4 -alkyl) 2, or a bi- or tricyclic C 8 -Ci 2 -heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-Cθ-alkyl, Ci-Cθ-acyl, Ci-Cθ-alkoxy, hydroxy, cyano, CO 2 -(Ci- C 6 -alkyl), N-(Ci-C 6 -alkyl) 2> COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , or a C 3 -C 6 -cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C 4 -alkyl, hydroxy, cyano, CO 2 -(Ci-C 4 -alkyl), Ci-C 4 -acyl, N-(Ci-C 4 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl), CO-N(Ci-C 4 -alkyl) 2 or Ci-C 4 - alkoxy, is a hydrogen, halogen, amino, -S(0) p -Ci-C6-alkyl, where p is 0-2, a d-Cβ-acyl, NH-CO-NH 2 , N H-CO-Ci -C 6 -alkyl, -0-CO-NH(Ci-C 6 - alkyl), -O-CO-N(Ci-C 6 -alkyl) 2 , or d-C 6 -alkyl group which may optionally be substituted one or more times, identically or differently, by Ci-C 6 -acyl, Ci-C 6 -alkoxy, hydroxy, cyano, CO 2 -(Ci- Cβ-alkyl), N-(Ci-C 6 -alkyl) 2> C 5 -Ci 2 -heteroaryl, COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl) or by CO-N(C r C 6 -alkyl) 2, a Ci-Cθ-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO 2 -(Ci-C 6 - alkyl), N-(Ci-C 6 -alkyl) 2> NH-C 3 -C 6 -cycloalkyl, COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl) or by CO-N(C r C 6 -alkyl) 2, an O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2, a CH 2 O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2, an O-C 5 -Ci 6 -heteroaryl, which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a hydroxy, cyano, O-CO-(Ci-C 6 -alkyl), CO-NH(C 5 -Ci 2 -heteroaryl), NH-(Ci-C 6 -alkyl), N-(C r C 6 -alkyl) 2 or a C 6 -Ci 2 -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C 6 -alkyl, C 3 -C 6 - cycloalkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, C 6 -Ci 2 -aryl, C 5 -Ci 2 -heteroaryl, hydroxy, CH 2 -OH, cyano, CH 2 -CN, amino, CO 2 -(C r C 6 -alkyl), N-(Ci-C 6 -alkyl) 2 , NHSO 2 CH 3 , SO 2 NH 2 , SO 2 NH(Ci-C 6 -alkyl), SO 2 N(Ci-C6-alkyl) 2j COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl), CO- N(Ci-C 6 -alkyl) 2 , CO-NH(C 5 -Ci 2 -heteroaryl), NH-CO(Ci-C 6 -alkyl), CH 2 -NH-CO(Ci-C 6 -alkyl), NH-CO(C 5 -Ci 2 -heteroaryl), CH 2 -NH- CO(C 5 -C 12 -heteroaryl), styryl, or an -S(O) n -CH 3 , where r is 0-2, or two adjacent positions may be substituted by -0-CH 2 -O- or -0-C(CHs) 2 -O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by CrC 6 -alkyl, if R 2 is cyano or if R 1 and/or R 2 is identically or differently a d-Cβ-alkyl radical, where at least one of the radicals is substituted at least once by halogen, a monocyclic C 5 -C 7 -heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, by CF 3 , d-Cβ-acyl, Ci-C 6 -alkoxy, hydroxy, CH 2 -OH, cyano, CO 2 -(Ci-C 6 - alkyl), N-(Ci-C 6 -alkyl) 2> COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , or a bi- or tricyclic Cs-Ci 2 -heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-Cθ-alkyl, Ci-Cθ-acyl, Ci-Cθ-alkoxy, hydroxy, cyano, CO 2 -(Ci- Cβ-alkyl), N-(Ci-C 6 -alkyl) 2> COOH, CO-NH 2 , CO-NH(C r C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , or a C3-C6-cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C 6 -alkyl, hydroxy, cyano, CO 2 -(C r C 6 -alkyl), C r C 6 -acyl, N-(C r C 6 -alkyl) 2 , COOH, CO- NH 2 , CO-NH(Ci-C 6 -alkyl), CO-N(Ci-C 6 -alkyl) 2 or Ci-C 6 -alkoxy, R 3 and R 4 are either in ortho,meta position or meta,para position relative to one another and together have the meaning -O-CO-S-, -S-CO-O-, CH 2 -CO-O-, 0-CO-CH 2 -, -CH 2 -CO-NH-, -NH-CO-CH 2 -, -O-CO-NH- , -NH-CO-O-, -CO-CH 2 -(CH 2 ) m -, -CH 2 -(CH 2 ) m -CO-, -O-(CH 2 ) m -O-, - 0-C-(CHs) 2 -O-, -CH 2 -(CH 2 ) m -CH 2 -, where m is 1-3, Y is a -(CH 2 )n- group, where n is 1 -3, and the isomers, diastereomers, enantiomers and salts thereof, and cyclodextrin clathrates. 4. The compound as claimed in claim 1 -3, where A is an aryl or heteroaryl radical which may optionally be substituted one or more times by R 4 and/or R 3 , R 1 is a hydrogen or a d-Cs-alkyl group which is substituted one or more times by halogen, R 2 is a hydrogen, halogen, cyano, an -S(O) q -CH 3 , where q is 0-2, a Ci-C 4 -alkoxy radical or Ci-C6-alkyl group which is substituted one or more times by halogen, R 3 is a hydrogen, halogen, amino, -S(O) P -CH 3 , where p is 0-2, an -S-CF 3 , d-Cβ-acyl, NH-CO-NH 2 , NH-CO-d-Cβ-alkyl, -O-CO- NHCH 3 , -O-CO-N(CH 3 ) 2 or d-C 6 -alkyl group which may optionally be substituted one or more times, identically or differently, by d- C 4 -acyl, Ci-C 4 -alkoxy, hydroxy, cyano, CO 2 -(Ci -C 4 -alkyl), N-(Cr C 4 -alkyl) 2 , C 5 -d 2 -heteroaryl, COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl) or by CO-N(Ci-C 4 -alkyl) 2 , a d-Cθ-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO 2 -(CrCs- alkyl), N-(d-C 6 -alkyl) 2> NH-C 3 -C 6 -cycloalkyl, COOH, CO-NH 2 , CO- NH(d-C 6 -alkyl) or by CO-N(d-C 6 -alkyl) 2 , an O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2, a CH 2 O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2, an O-C5-Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a hydroxy, cyano, O-CO-(d-C 6 -alkyl), CO-NH(C 5 -Ci 2 -heteroaryl), NH-(CrC 6 -alkyl), N-(C r C 6 -alkyl) 2 , a C6-Ci 2 -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C 6 -alkyl, C 3 -C 6 - cycloalkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, C 6 -Ci 2 -aryl, C 5 -Ci 2 -heteroaryl, hydroxy, CH 2 -OH, cyano, CH 2 -CN, amino, CO 2 -(CrC 6 -alkyl), N- (Ci-C 6 -alkyl) 2 , NHSO 2 CH 3 , SO 2 NH 2 , SO 2 NH(Ci-C 6 -alkyl), SO 2 N(Ci-C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl), CO- N(Ci-C 6 -alkyl) 2 , CO-NH(C 5 -Ci 2 -heteroaryl), NH-CO(Ci-C 6 -alkyl), CH 2 -NH-CO(CrC 6 -alkyl), NH-CO(C 5 -C 12 -heteroaryl), CH 2 -NH- CO(C 5 -Ci 2 -heteroaryl), styryl, or an -S(O) n -CH 3 , where r is 0-2, or two adjacent positions may be substituted by -0-CH 2 -O- or -O-C(CH 3 ) 2 -O-, a monocyclic C 5 -C 7 -heteroaryl which may optionally be substituted one or more times, identically or differently, by d-C θ -alkyl, if R 2 is cyano or if R 1 and/or R 2 is identically or differently a C-i-Cβ-alkyl radical, where at least one of the radicals is substituted at least once by halogen, or if R 4 is -S(O) p -Ci-C 6 -alkyl, where p is 0-2, d-Cβ-acyl-, -O-CO-NH(Ci-C 6 -alkyl), -O-CO-N(Ci-C 6 -alkyl) 2> C 6 -Ci 2 -aryloxy, C 5 -Ci 6 -heteroaryloxy, hydroxy, cyano or N-(CrC 6 - alkyl) 2 , a monocyclic C 5 -C 7 -heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, by CF 3 , Ci-C 4 -acyl, Ci-C 4 -alkoxy, hydroxy, CH 2 -OH, cyano, CO 2 -(Ci-C 4 - alkyl), N-(Ci-C 4 -alkyl) 2> COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl) or CO-N(Ci-C 4 -alkyl) 2 , a bi- or tricyclic Cs-Ci 2 -heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C 6 -alkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, hydroxy, cyano, CO 2 -(Ci- Ce-alkyl), N-(C r C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(C r C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , or a C3-C6-cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C 4 -alkyl, hydroxy, cyano, CO2-(Ci-C 4 -alkyl), Ci-C 4 -acyl, N-(Ci-C 4 -alkyl) 2 , COOH, CO-NH 2 , CO-N H(C 1 -C 4 -alkyl), CO-N(C r C 4 -alkyl) 2 or C 1 -C 4 - alkoxy, is a hydrogen, halogen, amino, -S(O) P -CH 3 , where p is 0-2, an -S-CF 3 , C r C 6 -acyl, NH-CO-NH 2 , NH-CO-C r C 6 -alkyl, -O-CO- NHCH 3 , -O-CO-N(CH 3 ) 2 , or C-i-Cβ-alkyl group which may optionally be substituted one or more times, identically or differently, by C 1 - C 4 -acyl, CrC^alkoxy, hydroxy, cyano, CO 2 -(C 1 -C 4 -alkyl), N-(C 1 - C 4 -alkyl) 2 , C 5 -C 12 -heteroaryl, COOH, CO-NH 2 , CO-NH(C r C 4 -alkyl) or by CO-N^-C^alkyl)^ a C-i-Cβ-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO 2 -(C 1 -C 6 - alkyl), N-(C r C 6 -alkyl) 2 , NH-C 3 -C 6 -cycloalkyl, COOH, CO-NH 2 , CO- NH(C 1 -C 6 ^IkYl) or by CO-N^rCe-alkyl)^ an O-C6-C 12 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2, a CH 2 O-C 6 -C 12 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , an O-C 5 -C 16 -heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a hydroxy, cyano, O-CO-(C r C 6 -alkyl), CO-NH(C 5 -C 12 -heteroaryl), N-tCrCe-alkyl), N-^rCe-alkyl^, a C6-C 12 -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by C-i-Cβ-alkyl, C 3 -C6- cycloalkyl, C-i-C θ -acyl, C-i-C θ -alkoxy, C 6 -C 12 -aryl, C 5 -C 12 -heteroaryl, hydroxy, CH 2 -OH, cyano, CH 2 -CN, amino, COHCrCe-alkyl), N- (CrCe-alkyl^, NHSO 2 CH 3 , SO 2 NH 2 , SO 2 NH(C 1 -C 6 -alkyl), SO 2 N(C 1 -C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-N H(C 1 -C 6 -alkyl), CO- N(CrC 6 -alkyl) 2 , CO-NH(C 5 -C 12 -heteroaryl), NH-CO(C r C 6 -alkyl), CHs-NH-COtCrCe-alkyl), NH-CO(C 5 -C 12 -heteroaryl), CH 2 -NH- CO(C 5 -Ci2-heteroaryl), styryl, or an -S(O) n -CH 3 , where r is 0-2, or two adjacent positions may be substituted by -0-CH 2 -O- or -0-C(CHs) 2 -O-, a monocyclic C 5 -C 7 -heteroaryl which may optionally be substituted one or more times, identically or differently, by Ci-C 6 -alkyl, if R 2 is cyano or if R 1 and/or R 2 is identically or differently a Ci-C 6 -alkyl radical, where at least one of the radicals is substituted at least once by halogen, a monocyclic Cs-Ci 2 -heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, by CF 3 , Ci-C 4 -acyl, Ci-C 4 -alkoxy, hydroxy, CH 2 -OH, cyano, CO 2 -(Ci-C 4 - alkyl), N-(C r C 4 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(C r C 4 -alkyl) or CO-N(Ci-C 4 -alkyl) 2, a bi- or tricyclic Cs-Ci 2 -heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC 6 -alkyl, C r C 6 -acyl, C r C 6 -alkoxy, hydroxy, cyano, CO 2 -(Cr C 6 -alkyl), N-(Ci-C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , or a C3-C6-cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC 4 -alkyl, hydroxy, cyano, CO 2 -(Ci-C 4 -alkyl), Ci-C 4 -acyl, N-(Ci-C 4 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl), CO-N(Ci-C 4 -alkyl) 2 or Ci-C 4 - alkoxy, R 3 and R 4 are either in ortho,meta position or meta,para position relative to one another and together have the meaning -O-CO-S-, -S-CO-O-, CH 2 -CO-O-, 0-CO-CH 2 -, -CH 2 -CO-NH-, -NH-CO-CH 2 -, -O-CO-NH- , -NH-CO-O-, -CO-CH 2 -(CH 2 ) m -, -CH 2 -(CH 2 ) m -CO-, -O-(CH 2 ) m -O-, - 0-C-(CHs) 2 -O-, -CH 2 -(CH 2 ) m -CH 2 -, where m is 1 -3, Y is a -(CH 2 )n- group, where n is 1 -3, and the isomers, diastereomers, enantiomers and salts thereof, and cyclodextrin clathrates. 5. The compound as claimed in claim 1 -4, where is a phenyl, naphthyl or heteroaryl radical which may optionally be substituted once or twice by R 3 and/or R 4 , R 1 is a hydrogen or a Ci-Cs-alkyl group which may be substituted one or more times by halogen, R 2 is a hydrogen, halogen, cyano, an -S(O) q -CH 3 , where q is 0-2, a Ci-C 4 -alkoxy radical or Ci-C 6 -alkyl group, R 3 is a hydrogen, halogen, amino, -S(O) P -CH 3, where p is 0-2, an -S-CF 3 , d-Cβ-acyl, NH-CO-NH 2 , NH-CO-d-Cβ-alkyl, -O-CO- NHCH 3 , -O-CO-N(CH 3 ) 2 , or Ci-C 6 -alkyl group which may optionally be substituted once, twice, three, four or five times, identically or differently, by CrC 4 -acyl, CrC 4 -alkoxy, hydroxy, cyano, CO 2 -(Cr C 4 -alkyl), N-(d-C 4 -alkyl) 2> C 5 -Ci 2 -heteroaryl, COOH, CO-NH 2 , CO- NH(Ci-C 4 -alkyl) or by CO-N(d-C 4 -alkyl) 2 , a Ci-Cθ-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO 2 -(Ci -C 6 - alkyl), N-(Ci-C 6 -alkyl) 2> NH-C 3 -C 6 -cycloalkyl, COOH, CO-NH 2 , CO- NH(Ci-C 6 -alkyl) or by CO-N(d-C 6 -alkyl) 2 , an O-C6-Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2, a CH 2 O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2, an O-C 5 -Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2, a hydroxy, cyano, O-CO-(d-C 6 -alkyl), CO-NH(C 5 -Ci 2 -heteroaryl), NH-(Ci-C 6 -alkyl) > N-(Ci-C 6 -alkyl) 2> a C6-Ci2-aryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC 6 -alkyl, C 3 -C 6 - cycloalkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, C 6 -Ci 2 -aryl, C 5 -Ci 2 -heteroaryl, hydroxy, CH 2 -OH, cyano, CH 2 -CN, amino, CO 2 -(Ci-C 6 -alkyl), N- (Ci-C 6 -alkyl) 2 , NHSO 2 CH 3 , SO 2 NH 2 , SO 2 NH(Ci-C 6 -alkyl), SO 2 N(CrC 6 -alkyl) 2 , COOH, CO-NH 2 , CO-N H(C 1 -C 6 -alkyl), CO- N(Ci-C 6 -alkyl) 2 , CO-NH(C 5 -Ci 2 -heteroaryl), NH-CO(Ci-C 6 -alkyl), CH 2 -NH-CO(Ci-C 6 -alkyl), NH-CO(C 5 -Ci 2 -heteroaryl), CH 2 -NH- CO(C 5 -Ci 2 -heteroaryl), styryl, or an -S(O) n -CH 3 , where r is 0-2, or two adjacent positions may be substituted by -0-CH 2 -O- or -O-C(CH 3 )2-O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by d-C θ -alkyl, if R 2 is cyano or if R 1 and/or R 2 is identically or differently a CrC 4 -alkyl radical, where at least one of the radicals is substituted at least once by halogen, or if R 4 is -S(O) p -Ci-C 4 -alkyl, where p is 0-2, Ci-C 4 -acyl-, -O-CO-NH(Ci-C 4 -alkyl), -O-CO-N(Ci-C 4 -alkyl) 2 , C 6 -Ci 2 -aryloxy, C 5 -Ci 6 -heteroaryloxy, hydroxy, cyano or N-(CrC 4 - alkyl) 2 , a monocyclic Cs-Cz-heteroaryl which may be substituted at least once or else twice, three, four or five times, identically or differently, by halogen, by CF 3 , Ci-C 4 -acyl, C r C 4 -alkoxy, hydroxy, CH 2 -OH, cyano, CO 2 -(Ci -C 4 -alkyl), N-(Ci-C 4 -alkyl) 2 , COOH, CO- NH 2 , CO-NH(Ci-C 4 -alkyl) or CO-N(Ci-C 4 -alkyl) 2, or a bi- or tricyclic Cs-Ci 2 -heteroaryl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by Ci-C 6 -alkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, hydroxy, cyano, CO 2 -(Ci-C 6 -alkyl), N-(Ci-C 6 -alkyl) 2 , COOH, CO- NH 2 , CO-NH(Ci-C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , a C 3 -C 6 -cycloalkyl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by d- C 4 -alkyl, hydroxy, cyano, CO 2 -(Ci-C 4 -alkyl), Ci-C 4 -acyl, N-(CrC 4 - alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl), CO-N(Ci-C 4 -alkyl) 2 or Ci-C 4 -alkoxy, is a hydrogen, halogen, amino, -S(O) P -CH 3 , where p is 0-2, an -S-CF 3 , Ci-C 6 -acyl, NH-CO-NH 2 , NH-CO-d-Ce-alkyl, -O-CO- NHCH 3 , -O-CO-N(CH 3 ) 2 , or Ci-C 6 -alkyl group which may optionally be substituted once, twice, three, four or five times, identically or differently, by Ci-C 4 -acyl, Ci-C 4 -alkoxy, hydroxy, cyano, CO 2 -(Ci- C 4 -alkyl), N-(Ci-C 4 -alkyl) 2 , C 5 -Ci 2 -heteroaryl, COOH, CO-NH 2 , CO- NH(Ci-C 4 -alkyl) or by CO-N(Ci-C 4 -alkyl) 2, a CrC 6 -alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO 2 -(Ci-C 6 - alkyl), N-(Ci-C 6 -alkyl) 2 , NH-C 3 -C 6 -cycloalkyl, COOH, CO-NH 2 , CO- NH(Ci-C 6 -alkyl) or by CO-N(Ci-C 6 -alkyl) 2, an O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2, a CH 2 O-C6-Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , an O-C 5 -Ci 6 -heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a hydroxy, cyano, O-CO-(Ci-C 6 -alkyl), CO-NH(C 5 -Ci 2 -heteroaryl), NH-(Ci-C 6 -alkyl), N-(Ci-C 6 -alkyl) 2 or a C 6 -Ci 2 -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C 6 -alkyl, C 3 -C 6 - cycloalkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, C 6 -Ci 2 -aryl, C 5 -Ci 2 -heteroaryl, hydroxy, CH 2 -OH, cyano, CH 2 -CN, amino, CO 2 -(Ci-C 6 -alkyl), N- (Ci-C 6 -alkyl) 2 , NHSO 2 CH 3 , SO 2 NH 2 , SO 2 NH(C r C 6 -alkyl), SO 2 N(Ci-C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl), CO- N(Ci-C 6 -alkyl) 2 , CO-NH(C 5 -Ci 2 -heteroaryl), NH-CO(Ci-C 6 -alkyl), CH 2 -NH-CO(Ci-C 6 -alkyl), NH-CO(C 5 -Ci 2 -heteroaryl), CH 2 -NH- CO(C 5 -Ci 2 -heteroaryl), styryl, or an -S(O) n -CH 3 , where r is 0-2, or two adjacent positions may be substituted by -0-CH 2 -O- or -0-C(CHs) 2 -O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by CrC 6 -alkyl, if R 2 is cyano or if R 1 and/or R 2 is identically or differently a Ci-C 4 -alkyl radical, where at least one of the radicals is substituted at least once by halogen, a monocyclic C 5 -C 7 -heteroaryl which may be substituted at least once or else twice, three, four or five times, identically or differently, by halogen, by CF 3 , Ci-C 4 -acyl, Ci-C 4 -alkoxy, hydroxy, CH 2 -OH, cyano, CO 2 -(Ci -C 4 -alkyl), N-(Ci-C 4 -alkyl) 2> COOH, CO- NH 2 , CO-NH(CrC 4 -alkyl) or CO-N(C r C 4 -alkyl) 2, or a bi- or tricyclic Cs-Ci 2 -heteroaryl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by Ci-C 6 -alkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, hydroxy, cyano, CO 2 -(C r C 6 -alkyl), N-(Ci-C 6 -alkyl) 2> COOH, CO- NH 2 , CO-NH(Ci-C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 or a C3-C6-cycloalkyl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by Ci- C 4 -alkyl, hydroxy, cyano, CO 2 -(C r C 4 -alkyl), C r C 4 -acyl, N-(CrC 4 - alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl), CO-N(Ci-C 4 -alkyl) 2 or Ci-C 4 -alkoxy, R 3 and R 4 are either in ortho,meta position or meta,para position relative to one another and together have the meaning of -O-CO-S-, -S-CO-O-, CH 2 -CO-O-, 0-CO-CH 2 -, -CH 2 -CO-NH-, -NH-CO-CH 2 -, -O-CO-NH-, -NH-CO-O-, -CO-CH 2 -(CH 2 ) m -, -CH 2 - (CH 2 ) m -CO-, -O-(CH 2 ) m -O-, -0-C-(CHs) 2 -O-, -CH 2 -(CH 2 ) m -CH 2 -, where m is 1 -3, Y is a -(CH 2 )n- group, where n is 1 -3, and the isomers, diastereomers, enantiomers and salts thereof, and cyclodextrin clathrates. 6. The compound as claimed in claim 1 -5, where is a phenyl, naphthyl or heteroaryl radical which may optionally be substituted once or twice by R 3 and/or R 4 , R 1 is a hydrogen or a d-Cβ-alkyl radical which is substituted one or more times by halogen, R 2 is a hydrogen, halogen, cyano, an -S(O) q -CH 3 , where q is 0-2, a Ci-C 4 -alkoxy radical or Ci-C6-alkyl radical which is substituted one or more times by halogen, R 3 is a hydrogen, halogen, amino, -S(O) P -CH 3, where p is 0-2, an -S-CF 3 , d-Cβ-acyl, NH-CO-NH 2 , NH-CO-d-Cβ-alkyl, -O-CO- NHCH 3 , -O-CO-N(CH 3 ) 2 , or d-Cβ-alkyl group which may optionally be substituted once, twice, three, four or five times, identically or differently, by Ci-C 4 -acyl, Ci-C 4 -alkoxy, hydroxy, cyano, CO 2 -(Ci- C 4 -alkyl), N-(d-C 4 -alkyl) 2> C 5 -Ci 2 -heteroaryl, COOH, CO-NH 2 , CO- NH(Ci-C 4 -alkyl) or by CO-N(d-C 4 -alkyl) 2 , a CrC 4 -alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO 2 -(Ci-C 4 - alkyl), N-(d-C 4 -alkyl) 2> NH-C 3 -C 6 -cycloalkyl, COOH, CO-NH 2 , CO- NH(Ci-C 4 -alkyl) or by CO-N(d-C 4 -alkyl) 2 , an O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2, a CH 2 O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , an O-C 5 -Ci 6 -heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a hydroxy, cyano, O-CO-(Ci-C 4 -alkyl), CO-NH(C 5 -Ci 2 -heteroaryl), NH-(Ci-C 4 -alkyl), N-(Ci-C 4 -alkyl) 2 or a C6-Ci2-aryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC 6 -alkyl, C 3 -C 6 - cycloalkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, C 6 -Ci 2 -aryl, C 5 -Ci 2 -heteroaryl, hydroxy, CH 2 -OH, cyano, CH 2 -CN, amino, CO 2 -(Ci-C 6 -alkyl), N- (Ci-C 6 -alkyl) 2 , NHSO 2 CH 3 , SO 2 NH 2 , SO 2 NH(Ci-C 6 -alkyl), SO 2 N(CrC 6 -alkyl) 2 , COOH, CO-NH 2 , CO-N H(C 1 -C 6 -alkyl), CO- N(Ci-C 6 -alkyl) 2 , CO-NH(C 5 -Ci 2 -heteroaryl), NH-CO(Ci-C 6 -alkyl), CH 2 -NH-CO(Ci-C 6 -alkyl), NH-CO(C 5 -Ci 2 -heteroaryl), CH 2 -NH- CO(C 5 -Ci 2 -heteroaryl), styryl, or an -S(O) n -CH 3 , where r is 0-2, or two adjacent positions may be substituted by -0-CH 2 -O- or -O-C(CH 3 ) 2 -O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by Ci-C 6 -alkyl, if R 2 is cyano or if R 1 and/or R 2 is identically or differently a CrC 4 -alkyl radical, where at least one of the radicals is substituted at least once by halogen, or if R 4 is -S(O) p -Ci-C 4 -alkyl, where p is 0-2, Ci-C 4 -acyl-, -O-CO-NH(Ci-C 4 -alkyl), -O-CO-N(Ci-C 4 -alkyl) 2 , C 6 - Ci 2 -aryloxy, C 5 -Ci 6 -heteroaryloxy, hydroxy, cyano or N-(CrC 4 - alkyl) 2 , a monocyclic Cs-Cz-heteroaryl which may be substituted at least once or else twice, three, four or five times, identically or differently, by halogen, by CF 3 , Ci-C 4 -acyl, C r C 4 -alkoxy, hydroxy, CH 2 -OH, cyano, CO 2 -(Ci -C 4 -alkyl), N-(Ci-C 4 -alkyl) 2 , COOH, CO- NH 2 , CO-NH(Ci-C 4 -alkyl) or CO-N(Ci-C 4 -alkyl) 2, or a bi- or tricyclic Cs-Ci 2 -heteroaryl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by Ci-C 6 -alkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, hydroxy, cyano, CO 2 -(Ci-C 6 -alkyl), N-(Ci-C 6 -alkyl) 2 , COOH, CO- NH 2 , CO-NH(Ci-C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , or a C 3 -C 6 -cycloalkyl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by d- C 4 -alkyl, hydroxy, cyano, CO 2 -(Ci-C 4 -alkyl), Ci-C 4 -acyl, N-(CrC 4 - alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl), CO-N(Ci-C 4 -alkyl) 2 or Ci-C 4 -alkoxy, is a hydrogen, halogen, amino, -S(O) P -CH 3 , where p is 0-2, an -S-CF 3 , Ci-C 6 -acyl, NH-CO-NH 2 , NH-CO-d-Ce-alkyl, -O-CO- NHCH 3 , -O-CO-N(CH 3 ) 2 , or Ci-C 6 -alkyl group which may optionally be substituted once, twice, three, four or five times, identically or differently, by Ci-C 4 -acyl, Ci-C 4 -alkoxy, hydroxy, cyano, CO 2 -(Ci- C 4 -alkyl), N-(Ci-C 4 -alkyl) 2 , C 5 -Ci 2 -heteroaryl, COOH, CO-NH 2 , CO- NH(Ci-C 4 -alkyl) or by CO-N(Ci-C 4 -alkyl) 2, a CrC 4 -alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO 2 -(Ci-C 4 - alkyl), N-(Ci-C 4 -alkyl) 2 , NH-C 3 -C 6 -cycloalkyl, COOH, CO-NH 2 , CO- NH(Ci-C 4 -alkyl) or by CO-N(Ci-C 4 -alkyl) 2, an O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2, a CH 2 O-C6-Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , an O-C 5 -Ci 6 -heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a hydroxy, cyano, O-CO-(Ci-C 4 -alkyl), CO-NH(C 5 -Ci 2 -heteroaryl), NH-(Ci-C 4 -alkyl), N-(Ci-C 4 -alkyl) 2 or a C 6 -Ci 2 -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C6-alkyl, C 3 -C6- cycloalkyl, Ci-C θ -acyl, Ci-C θ -alkoxy, C 6 -Ci 2 -aryl, C 5 -Ci 2 -heteroaryl, hydroxy, CH 2 -OH, cyano, CH 2 -CN, amino, CO 2 -(Ci-C 6 -alkyl), N- (Ci-C 6 -alkyl) 2 , NHSO 2 CH 3 , SO 2 NH 2 , SO 2 NH(C r C 6 -alkyl), SO 2 N(Ci-C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 6 -alkyl), CO- N(Ci-C 6 -alkyl) 2 , CO-NH(C 5 -Ci 2 -heteroaryl), NH-CO(Ci-C 6 -alkyl), CH 2 -NH-CO(Ci-C 6 -alkyl), NH-CO(C 5 -Ci 2 -heteroaryl), CH 2 -NH- CO(C 5 -Ci 2 -heteroaryl), styryl, or an -S(O) n -CH 3 , where r is 0-2, or two adjacent positions may be substituted by -0-CH 2 -O- or -0-C(CHs) 2 -O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by CrC 6 -alkyl, if R 2 is cyano or if R 1 and/or R 2 is identically or differently a Ci-C 4 -alkyl radical, where at least one of the radicals is substituted at least once by halogen, a monocyclic C 5 -C 7 -heteroaryl which may be substituted at least once or else twice, three, four or five times, identically or differently, by halogen, by CF 3 , Ci-C 4 -acyl, Ci-C 4 -alkoxy, hydroxy, CH 2 -OH, cyano, CO 2 -(Ci -C 4 -alkyl), N-(Ci-C 4 -alkyl) 2> COOH, CO- NH 2 , CO-NH(CrC 4 -alkyl) or CO-N(C r C 4 -alkyl) 2, or a bi- or tricyclic Cs-Ci 2 -heteroaryl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by Ci-C 6 -alkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, hydroxy, cyano, CO 2 -(C r C 6 -alkyl), N-(Ci-C 6 -alkyl) 2> COOH, CO- NH 2 , CO-NH(Ci-C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 or a C3-C6-cycloalkyl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by Ci- C 4 -alkyl, hydroxy, cyano, CO 2 -(C r C 4 -alkyl), C r C 4 -acyl, N-(CrC 4 - alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl), CO-N(Ci-C 4 -alkyl) 2 or Ci-C 4 -alkoxy, R 3 and R 4 are either in ortho,meta position or meta,para position relative to one another and together have the meaning of -O-CO-S-, -S-CO-O-, CH 2 -CO-O-, 0-CO-CH 2 -, -CH 2 -CO-NH-, -NH-CO-CH 2 -, -O-CO-NH-, -NH-CO-O-, -CO-CH 2 -(CH 2 ) m -, -CH 2 - (CH 2 ) m -CO-, -O-(CH 2 ) m -O-, -0-C-(CHs) 2 -O-, -CH 2 -(CH 2 ) m -CH 2 -, where m is 1 -3, Y is a -(CH 2 )n- group, where n is 1 -3, and the isomers, diastereomers, enantiomers and salts thereof, and cyclodexthn clathrates. 7. The compound as claimed in claim 1 -6, where is a phenyl, naphthyl or heteroaryl radical which may optionally be substituted once or twice by R 3 and/or R 4 , R 1 is a hydrogen or a Ci-C 4 -alkyl radical which is substituted once, twice or three times by chlorine, fluorine, or bromine, R 2 is a hydrogen, chlorine, fluorine, bromine, cyano, an OCH 3 group or a Ci-C 4 -alkyl radical which is substituted once, twice or three times by chlorine, fluorine or bromine, R 3 is a hydrogen, halogen, amino, -S(O) P -CH 3, where p is 0-2, an -S-CF 3 , d-Cβ-acyl, NH-CO-NH 2 , NH-CO-d-Cβ-alkyl, -O-CO- NHCH 3 , -O-CO-N(CH 3 ) 2 , or d-Cβ-alkyl group which may optionally be substituted once or twice, identically or differently, by CrC 4 - acyl, Ci-C 4 -alkoxy, hydroxy, cyano, CO 2 -(Ci -C 4 -alkyl), N-(CrC 4 - alkyl) 2 , C 5 -Ci 2 -heteroaryl, COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl) or by CO-N(CrC 4 -alkyl) 2, a CrC 4 -alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO 2 -(CrC 4 - alkyl), N-(d-C 4 -alkyl) 2> NH-C 3 -C 6 -cycloalkyl, COOH, CO-NH 2 , CO- NH(CrC 4 -alkyl) or by CO-N(d-C 4 -alkyl) 2 , an O-C 6 -C-ι 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2, a CH 2 O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , an O-C 5 -Ci 6 -heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , a hydroxy, cyano, O-CO-(Ci-C 4 -alkyl), CO-NH(C 5 -Ci 2 -heteroaryl), NH-(Ci-C 4 -alkyl), N-(Ci-C 4 -alkyl) 2 or a C6-Ci2-aryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C 6 -alkyl, C 3 -C 6 - cycloalkyl, Ci-C 6 -acyl, Ci-C 6 -alkoxy, C 6 -Ci 2 -aryl, C 5 -Ci 2 -heteroaryl, hydroxy, CH 2 -OH, cyano, CH 2 -CN, amino, CO 2 -(Ci-C 6 -alkyl), N-(Ci-C 6 -alkyl) 2 , NHSO 2 CH 3 , SO 2 NH 2 , SO 2 NH(Ci-C 6 -alkyl), SO 2 N(Ci-C 6 -alkyl) 2> COOH, CO-NH 2 , CO-N H(C 1 -C 6 -alkyl), CO- N(Ci-C 6 -alkyl) 2 , CO-NH(C 5 -Ci 2 -heteroaryl), NH-CO(Ci-C 6 -alkyl), CH 2 -NH-CO(Ci-C 6 -alkyl), NH-CO(C 5 -Ci 2 -heteroaryl), CH 2 -NH- CO(C 5 -Ci 2 -heteroaryl), styryl, or an -S(O) n -CH 3 , where r is 0-2, or two adjacent positions may be substituted by -0-CH 2 -O- or -O-C(CH 3 ) 2 -O-, a monocyclic Cs-d-heteroaryl which may optionally be substituted one or more times, identically or differently, by d-Cβ-alkyl, if R 2 is cyano or if R 1 and/or R 2 is a CF 3 radical, or if R 4 is -S(O) p -CrC 6 - alkyl, where p is 0-2, Ci-C 4 -acyl-, -O-CO-NH(Ci-C 4 -alkyl), -O-CO- N(Ci-C 4 -alkyl) 2 , C6-Ci 2 -aryloxy, Cs-C-m-heteroaryloxy, hydroxy, cyano or N-(Ci-C 4 -alkyl) 2 , a monocyclic C 5 -C 7 -heteroaryl which may be substituted at least once or twice, identically or differently, by halogen, by CF 3 , Ci-C 4 - acyl, Ci-C 4 -alkoxy, hydroxy, CH 2 -OH, cyano, CO 2 -(Ci -C 4 -alkyl), N- (Ci-C 4 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl) or CO-N(Cr C 4 -alkyl) 2 , or a bi- or tricyclic Cs-Ci 2 -heteroaryl which may optionally be substituted once or twice, identically or differently, by halogen, by d-Cβ-alkyl, d-Cβ-acyl, d-Cβ-alkoxy, hydroxy, cyano, CO 2 -(Ci -Cβ- alkyl), N-(C r C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(C r C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , or a C 3 -C6-cycloalkyl which may optionally be substituted once or twice, identically or differently, by halogen, by Ci-C 4 -alkyl, hydroxy, cyano, CO 2 -(C r C 4 -alkyl), C r C 4 -alkyl, N-(C r C 4 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl), CO-N(Ci-C 4 -alkyl) 2 or Ci-C 4 - alkoxy, is a hydrogen, halogen, amino, -S(O) P -CH 3, where p is 0-2, an -S-CF 3 , Ci-C 6 -acyl, NH-CO-NH 2 , NH-CO-d-Cβ-alkyl, -O-CO- NHCH 3 , -O-CO-N(CH 3 ) 2 , or Ci-C 6 -alkyl group which may optionally be substituted once or twice, identically or differently, by CrC 4 - acyl, CrC 4 -alkoxy, hydroxy, cyano, CO 2 -(Ci -C 4 -alkyl), N-(CrC 4 - alkyl) 2 , C 5 -Ci 2 -heteroaryl, COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl) or by CO-N(CrC 4 -alkyl) 2, a Ci-C 4 -alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO 2 -(CrC 4 - alkyl), N-(Ci-C 4 -alkyl) 2> NH-C 3 -C 6 -cycloalkyl, COOH, CO-NH 2 , CO- NH(CrC 4 -alkyl) or by CO-N(Ci-C 4 -alkyl) 2 , an O-C 6 -Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2, a CH 2 O-C6-Ci 2 -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2 , an O-C5-Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH 2, a hydroxy, cyano, O-CO-(CrC 4 -alkyl), CO-NH(C 5 -Ci 2 -heteroaryl), NH-(CrC 4 -alkyl), N-(CrC 4 -alkyl) 2 or a C6-Ci 2 -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC 6 -alkyl, C 3 -C 6 - cycloalkyl, d-Cβ-acyl, d-Cβ-alkoxy, C 6 -Ci 2 -aryl, C 5 -Ci 2 -heteroaryl, hydroxy, CH 2 -OH, cyano, CH 2 -CN, amino, CO 2 -(Ci-C 6 -alkyl), N- (CrC 6 -alkyl) 2 , NHSO 2 CH 3 , SO 2 NH 2 , SO 2 NH(Ci-C 6 -alkyl), SO 2 N(Ci-C 6 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(d-C 6 -alkyl), CO- N(CrC 6 -alkyl) 2 , CO-NH(C 5 -Ci 2 -heteroaryl), NH-CO(Ci-C 6 -alkyl), CH 2 -NH-CO(CrC 6 -alkyl), NH-CO(C 5 -Ci 2 -heteroaryl), CH 2 -NH- CO(C 5 -Ci 2 -heteroaryl), styryl, or an -S(O) n -CH 3 , where r is 0-2, or two adjacent positions may be substituted by -0-CH 2 -O- or -0-C(CHs) 2 -O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by d-Cβ-alkyl, if R 2 is cyano or if R 1 and/or R 2 is a CF 3 radical, a monocyclic C 5 -C 7 -heteroaryl which may be substituted at least once or twice, identically or differently, by halogen, by CF 3 , Ci-C 4 - acyl, Ci-C 4 -alkoxy, hydroxy, CH 2 -OH, cyano, CO 2 -(Ci -C 4 -alkyl), N-(Ci-C 4 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl) or CO- N(C-I -C 4 -alkyl) 2 , or a bi- or tricyclic Cs-Ci 2 -heteroaryl which may optionally be substituted once or twice, identically or differently, by halogen, by Ci-Cθ-alkyl, Ci-Cθ-acyl, Ci-Cθ-alkoxy, hydroxy, cyano, CO 2 -(Ci -Cβ- alkyl), N-(Ci-C 6 -alkyl) 2> COOH, CO-NH 2 , CO-NH(C r C 6 -alkyl) or CO-N(Ci-C 6 -alkyl) 2 , or a C 3 -C 6 -cycloalkyl which may optionally be substituted once or twice, identically or differently, by halogen, by Ci-C 4 -alkyl, hydroxy, cyano, CO 2 -(C r C 4 -alkyl), C r C 4 -acyl, N-(C r C 4 -alkyl) 2 , COOH, CO-NH 2 , CO-NH(Ci-C 4 -alkyl), CO-N(Ci-C 4 -alkyl) 2 or Ci-C 4 - alkoxy, R 3 and R 4 are either in ortho,meta position or meta,para position relative to one another and together have the meaning of -O-CO-S-, -S-CO-O-, CH 2 -CO-O-, 0-CO-CH 2 -, -CH 2 -CO-NH-, -NH-CO-CH 2 -, -O-CO-NH-, -NH-CO-O-, -CO-CH 2 -(CH 2 ) m -, -CH 2 - (CH 2 Jm-CO-, -O-(CH 2 ) m -O-, -0-C-(CHa) 2 -O-, -CH 2 -(CH 2 ) m -CH 2 -, where m is 1 -3, Y is a -(CH 2 )n- group, where n is 1 -3, and the isomers, diastereomers, enantiomers and salts thereof, and cyclodextrin clathrates. 8. The compound as claimed in the preceding claims selected from a group which comprises the following compounds: 1. biphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 2. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3,4,5-thmethoxybenzamide 3. 4-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 4. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-methylbenzamide 5. 2-chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 6. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-trifluoromethylbenzamide 7. 3-chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 8. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-methoxybenzamide 9. 4-chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 10. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-methylbenzamide 11.4-tert-butyl-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 12. benzo[1 ,3]dioxole-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 13.thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 14. quinoxaline-6-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 15. δ-phenylpyridine^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 16.5-phenyl-1 H-pyrrole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 17. N-[2-(4,7-difluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4-dimethoxybenzamide 18. (±)-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4- methanesulfinylbenzamide 19. N-[2-(7-fluoro-1 H-indol-3-yl)ethyl]-3,4-dimethoxybenzamide 20. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-[1 ,2,41WaZoI-I - ylmethylbenzamide 21.thieno[2,3-b]pyrazine-6-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 22. N-[2-(7-fluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4-dimethoxybenzamide 23. N-[2-(4-chloro-7-fluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4- dimethoxybenzannide 24. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-nnethanesulfonylbenzannide 25. N-[2-(4-bromo-7-fluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4- dimethoxybenzamide 26.1 H-benzotriazole-5-carboxylic acid [2-(4,7-difluoro-2-methyl-1 H-indol-3- yl)ethyl]amide 27.1 H-indole-2-carboxylic acid [2-(4,7-difluoro-2-methyl-1 H-indol-3- yl)ethyl]amide 28.4'-fluorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 29. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-N'-pyridin-3-yl- terephthalamide 30.4-amino-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 31.5-bromofuran-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 32. N-[2-(7-fluoro-2,4 dimethyl-1 H-indol-3-yl)ethyl]-isonicotinamide 33. N-[2-(7-fluoro-2,4 dimethyl-1 H-indol-3-yl)ethyl]benzamide 34.2-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl) ethyl]benzamide 35.3-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 36.1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 37. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-6-methylnicotinamide 38. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-methoxybenzamide 39.4-ethoxy-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 40. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-hydroxy-3,5- dimethoxybenzannide 41.1 H-benzotriazole-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 42.5-methylthiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 43.1 H-pyrrole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 44. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-methylaminobenzamide 45.thiophene-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 46.6-cyano-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]nicotinannide 47.1 H-benzoinnidazole-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 48. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-trifluoromethylbenzamide 49. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-hydroxy-3- methoxybenzannide 50.4-dimethylannino-N-[2-(7-fluoro-2,4-dinnethyl-1 H-indol-3-yl)ethyl]benzannide 51.4-cyano-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzannide 52. isoxazole-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 53.4-acetyl-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 54.4-chloro-3-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzannide 55.4-chloromethyl-N-[2-(7-fluoro-2,4-dinnethyl-1 H-indol-3-yl)ethyl]benzannide 56. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3,5-dimethylbenzamide 57.3,4-difluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 58. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-propylbenzamide 59. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-hydroxy-4- methylbenzannide 60.2,3-difluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 61.3,5-difluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 62. naphthalene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide θS.S-chlorothiophene^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 64.6-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]nicotinamide 65.3-chloromethyl-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 66.4-butoxy-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 67.4-acetoxy-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzannide 68. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-methylsulfanylbenzamide 69.4-cyano-2-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 70. isoquinoline-1 -carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 71. isoquinoline-1 -carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 72. isoquinoline-1 -carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 73.3,5-dichloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 74.quinoline-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 75.quinoline-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 76.4-hydroxy-2-phenyl-2H-pyrazole-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 77. benzo[b]thiophene-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 78. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-hydroxybenzamide 79. pyrazine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]amide δO.furan-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 81.quinoline-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 82.2-chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]nicotinamide 83.4-benzyloxy-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 84.5-bromo-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]nicotinamide 85.1 H-indole-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide δθ.S-bromothiophene^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 87.2-chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3,4- dimethoxybenzamide 88.2-methylfuran-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 89.1 H-imidazole-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 90.4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro-2,4- dimethyl-1 H-indol-3-yl)ethyl]amide 91.4'-bromobiphenyl-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 92.2-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-6-iodobenzamide 93.2,3-dihydrobenzofuran-7-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 94.3-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-methylbenzamide 95. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2,5-dimethylbenzamide 96.5-acetylthiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 97.quinoline-8-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]annide 98.2-phenyl-2H-pyrazole-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide θθ.θ-phenylpyrimidine^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 100. i-methyl-I H-indole-S-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 101. 2-pyridin-3-ylthiazole-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 102. 2,5-dimethyl-2H-pyrazole-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 103. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2- phenoxymethylbenzamide 104. 2,3-dihydrobenzofuran-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 105. I H-indole-e-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 106. 2-bromo-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4,5- dimethoxybenzannide 107. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-pyrrolidin-1 -ylbenzamide 108. quinoline-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 109. 5-phenyl-1 H-pyrazole-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 110. pyridazine-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 111. 5-phenyl-2H-pyrazole-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 112. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-5-pyrrol-1 -ylnicotinamide 113. pyrimidine-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 114. benzo[b]thiophene-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 115. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-piperidin-1 -ylbenzamide 116. pyrazolo[1 ,5-a]pyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 117. quinoxaline-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 118. 3-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2- methoxybenzannide 119. 3-chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2- methylbenzannide 120. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-phenoxbenzamide 121. thiazole-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 122. 2-chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3- methylbenzannide 123. 3-chloro-2-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]benzamide 124. 5-methoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 125. 5-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 126. 5-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 127. 4-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 128. 6-methoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 129. 4-methoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 130. 4-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 131. 7-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 132. 6-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 133. 6-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 134. 5-methoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3- yl)ethyl]amide 135. 1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]amide 136. 5-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]amide 137. 5-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3- yl)ethyl]amide 138. 6-methoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3- yl)ethyl]amide 139. 4-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3- yl)ethyl]amide 140. 4-dimethylamino-N-[2-(7-fluoro-1 H-indol-3-yl)ethyl]benzamide 141. N-[2-(7-fluoro-1 H-indol-3-yl)ethyl]-4-pyrrolidin-1 -ylbenzamide 142. I H-indole-θ-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]amide 143. 4-methoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3- yl)ethyl]amide 144. 4-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]amide 145. 6-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]amide 146. 6-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3- yl)ethyl]amide 147. 7-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3- yl)ethyl]amide 148. 5-bromo-2,3-dihydrobenzofuran-7-carboxylic acid [2-(7-fluoro-2,4- dimethyl-1 H-indol-3-yl)ethyl]annide 149. 4-(1 H-benzoimidazol-2-yl)-N-[2-(7-fluoro-1 H-indol-3-yl)ethyl]benzamide 150. 4-(1 H-benzoimidazol-2-yl)-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]benzamide 151. N-[2-(4-cyano-7-fluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4- dimethoxybenzannide 152. [1 ,1 ';4',1 "]terphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 153. S'-methylbiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 154. 3'-fluoro-4'-methylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 155. 2'-fluoro-4'-methylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 156. 4'-hydroxymethylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 157. 4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-biphenyl-4- carboxylic acid 158. 4'-tert-butylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 159. 4'-chlorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 160. 3',4\5'-trimethoxybiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 161. S'-trifluoronnethoxybiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 162. 4'-trifluoromethoxybiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 163. S'-hydroxybiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 164. 4'-methanesulfinylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 165. S'-cyanomethylbiphenyM-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 166. 2'-acetylaminobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 167. 3'-fluoro-4'-methoxybiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 168. 3'-chloro-4'-fluorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 169. 3',4'-difluorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 170. 3',5'-difluorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 171. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-(5-hydroxymethyl- thiophen-2-yl)-benzamide 172. S'-methanesulfonylbiphenyM-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 173. 4-fluoro-4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- biphenyl-3-carboxylic acid 174. 4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-3-methoxy- biphenyl-4-carboxylic acid methyl ester 175. 5-fluoro-4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethylcarbamoyl]biphenyl-3-carboxylic acid 176. 3-chlorobiphenyl-4,4'-dicarboxylic acid 4-amide 4'-{[2-(7-fluoro-2,4- dimethyl-1 H-indol-3-yl)ethyl]annide} 177. 3-chlorobiphenyl-4,4'-dicarboxylic acid 4'-{[2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide} 4-nnethylannide 178. S'-dimethylsulfannoylbiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 179. biphenyl-3,4'-dicarboxylic acid 4'-{[2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide} 3-thiazol-2-ylamide 180. 4'-methylsulfannoylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 181. 4'-dimethylsulfamoylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 182. biphenyl-3,4'-dicarboxylic acid 3-diethylamide 4'-{[2-(7-fluoro-2,4- dimethyl-1 H-indol-3-yl)ethyl]annide} 183. biphenyl-4,4'-dicarboxylic acid 4-diethylamide 4'-{[2-(7-fluoro-2,4- dimethyl-1 H-indol-3-yl)ethyl]annide} 184. 4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]biphenyl-3- carboxylic acid 185. biphenyl-4,4'-dicarboxylic acid 4-amide 4'-{[2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide} 186. S'-methylsulfamoylbiphenyW-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 187. S'-trifluoromethylbiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 188. 4'-methylsulfanylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 189. 4'-acetylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 190. 3'-aminobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 191. S'-acetylbiphenyM-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 192. S'-fluorobiphenyM-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 193. [1 ,1 ';3',1"]terphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 194. S'-hydroxymethylbiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 195. 4-benzo[b]thiophen-3-yl-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]benzamide 196. 4'-trifluoromethylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 197. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-((E)-styryl)benzamide 198. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-quinolin-6-ylbenzamide 199. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-(6-methoxypyridin-3-yl)- benzamide 200. biphenyl-3,4'-dicarboxylic acid 4'-{[2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide} 3-methylannide 201. biphenyl-4,4'-dicarboxylic acid 4'-{[2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide} 4-methylannide 202. 2'-fluorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 203. 2'-methylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 204. S'-acetylaminobiphenyM-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 205. 4-benzo[1 ,3]dioxol-5-yl-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]benzamide 206. S'-cyanobiphenyW-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide 207. 4'-cyanomethylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 208. biphenyl-3,4'-dicarboxylic acid 3-amide 4'-{[2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide} 209. 3',5'-dimethylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 210. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-quinolin-3-ylbenzamide 211. 4'-acetylaminobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 212. S'-fluoro-δ'-nnethoxybiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 213. δ-fluorobiphenyl-S^'-dicarboxylic acid 4'-{[2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide} 3-methylannide 214. 3'-(acetylaminonnethyl)biphenyl-4-carboxylic acid [2-(7-fluoro-2,4- dimethyl-1 H-indol-3-yl)ethyl]annide 215. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-(1 -methyl-1 H-indol-5- yl)benzamide 216. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-(1 -methyl-1 H-indol-2- yl)benzamide 217. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-5-pyrrol-1 -ylnicotinamide 218. N-[2-(4-cyano-7-fluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4-dimethoxy- benzamide 219. 5-benzyloxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 220. 5-hydroxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 221. 5-methoxybenzofuran-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 222. 6-hydroxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 223. N-[2-(7-fluoro-2-methyl-4-trifluoromethyl-1 H-indol-3-yl)ethyl]- 3,4-dimethoxybenzamide 224. SH-benzotriazole-δ-carboxylic acid [2-(7-fluoro-2-methyl-4-thfluoromethyl- 1 H-indol-3-yl)ethyl]amide 225. 5-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2-methyl- 4-trifluoromethyl-1 H-indol-3-yl)ethyl]amide 226. quinoxaline-6-carboxylic acid [2-(7-fluoro-2-methyl-4-trifluoromethyl-1 H- indol-3-yl)ethyl]amide 227. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}acetic acid methyl ester 228. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}butanoic acid ethyl ester 229. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}pentanoic acid ethyl ester 230. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}hexanoic acid ethyl ester 231. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}acetic acid methyl ester 232. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}butanoic acid ethyl ester 233. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}pentanoic acid ethyl ester 234. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}hexanoic acid ethyl ester 235. 6-bromopyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 236. 5-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide 237. 4-bromopyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 238. 6-bromo-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]nicotinamide 239. {S-^^-fluoro^^-dimethyl-I H-indol-S-yOethylcarbamoyllphenoxyJacetic acid methyl ester 240. 4-{3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}butanoic acid ethyl ester 241. 5-{3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}pentanoic acid ethyl ester 242. 2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}acetic acid 243. 4-{2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}butanoic acid 244. 5-{2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}pentanoic acid 245. 6-{3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}hexanoic acid ethyl ester 246. 5-{2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}pentanoic acid 247. 6-{2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}hexanoic acid 248. 4-{2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}butanoic acid 249. 6-{2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}hexanoic acid 250. 4-{3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}butanoic acid 251. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}acetic acid 252. 4-{4-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxyjbutanoic acid ethyl ester 253. 5-{4-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}pentanoic acid ethyl ester 254. 6-{4-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}hexanoic acid ethyl ester 255. 6-{3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}hexanoic acid 256. 4-{4-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxyjbutanoic acid 257. 5-{4-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}pentanoic acid 258. 6-{4-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}hexanoic acid 259. 5-{3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}pentanoic acid 260. 2-bromo-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]isonicotinamide 261. {4-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]phenoxy}acetic acid 262. 5-bromo-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 263. 6-bromo-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 264. δ-bromopyridine^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 265. 6-(3-carbamoylphenyl)pyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 266. 6-(3-nnethylcarbannoylphenyl)pyπdine-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 267. 6-(3-hydroxyphenyl)pyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 268. 4-(3-carbamoylphenyl)pyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 269. 4-(3-methylcarbamoylphenyl)pyridine-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 270. 4-(3-hydroxyphenyl)pyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 271. 4-(4-methylcarbamoylphenyl)pyridine-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 272. 5-chloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 273. benzofuran-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 274. 5-chloro-benzofuran-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 275. 4-bromo-3-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- benzamide 276. 4-chloro-4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- biphenyl-3-carboxylic acid 277. {3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]phenoxy}acetic acid 278. 5-(3-carbamoylphenyl)pyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 279. 5-(3-methylcarbamoylphenyl)pyridine-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 280. 5-(3-hydroxyphenyl)pyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 281. 6-(3-carbamoylphenyl)-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- nicotinamide 282. N-p-CZ-fluoro^^-dimethyl-I H-indol-S-yOethyll-e-CS-methylcarbamoyl- phenyl)nicotinamide 283. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-6-(3-hydroxyphenyl)- nicotinamide 284. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-6-(4-methylcarbamoyl- phenyl)nicotinamide 285. 5-(3-carbamoylphenyl)-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- nicotinamide 286. N-p-CZ-fluoro^^-dimethyl-I H-indol-S-yOethyll-δ-CS-methylcarbamoyl- phenyl)nicotinamide 287. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-5-(3-hydroxyphenyl)- nicotinamide 288. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-5-(4-methylcarbamoyl- phenyl)nicotinamide 289. 2-(3-carbamoylphenyl)-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- isonicotinamide 290. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-(3-methylcarbamoyl- phenyl)isonicotinamide 291. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-(3-hydroxyphenyl)- isonicotinamide 292. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-(4-methylcarbamoyl- phenyl)isonicotinamide 293. benzo[b]thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 294. quinoline-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 295. [1 ,8]naphthyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 296. isoquinoline-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 297. 5-pyridin-2-yl-thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 298. 5-trifluoromethoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 299. 5-fluoro-1 H-indole-2-carboxylic acid [2-(4,7-difluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide 300. biphenyl-3,4'-dicarboxylic acid 4'-{[2-(4,7-difluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide} 3-methylannide 301. 6-(3-trifluoromethoxyphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 302. 5-(4-methylcarbannoylphenyl)pyπdine-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 303. 4'-methoxybiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 304. 4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- 3-methoxybiphenyl-4-carboxylic acid 305. 4'-methoxybiphenyl-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 306. 4-(4-methylcarbannoylphenyl)thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 307. 4-(3-methylcarbannoylphenyl)thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 308. 4-(3-methylcarbannoylphenyl)thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 309. 4-(3-hydroxyphenyl)thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 310. 4-(3-carbamoylphenyl)thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 311. 4-bromothiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 312. 2-fluorobiphenyl-4,4'-dicarboxylic acid 4-{[2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide} 4'-methylamide 313. 2'-fluorobiphenyl-3,4'-dicarboxylic acid 3-amide 4'-{[2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide} 314. 2-fluoro-3'-hydroxybiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 315. 2'-fluorobiphenyl-3,4'-dicarboxylic acid 4'-{[2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide} 3-methylannide 316. S-^-methylcarbamoylphenylJ-I H-indole^-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 317. δ-bronnothiophene^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 318. 3'-hydroxybiphenyl-4-carboxylic acid [2-(7-fluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide 319. biphenyl-4,4'-dicarboxylic acid 4'-{[2-(7-fluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide} 4-methylannide 320. 4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- 3-hydroxybiphenyl-4-carboxylic acid methyl ester 321. N-[2-(7-fluoro-2-methyl-1 H-indol-3-yl)ethyl]-6-(3-methylcarbamoylphenyl)- nicotinamide 322. biphenyl-3,4'-dicarboxylic acid 4'-{[2-(7-fluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide} 3-methylannide 323. 5-(3-carbamoylphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 324. 5-(3-hydroxyphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 325. δ^-methylcarbamoylphenylJ-I H-indole^-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 326. δ^S-methylcarbamoylphenylJthiophene^-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 327. 5-(3-carbamoylphenyl)thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 328. 5-(3-hydroxyphenyl)thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 329. 5-(4-methylcarbamoylphenyl)thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 330. 6-(3-nnethylcarbannoylphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 331. 6-(3-carbamoylphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 332. 6-(3-hydroxyphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 333. 6-(4-methylcarbamoylphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 334. 3'-cyano-2'-fluorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 335. 5-chloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide 336. 5-chloro-1 H-indole-2-carboxylic acid [2-(4,7-difluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide 337. 5-chloro-1 H-indole-2-carboxylic acid [2-(4-chloro-7-fluoro-2-methyl-1 H- indol-3-yl)ethyl]amide 338. 5-trifluoromethyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 339. 6-methanesulfonyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 340. 7-chloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 341. 4-chloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 342. 6-chloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 343. 7-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 344. 5-bromo-1 H-indole-2-carboxylic acid [2-(7-fluoro-4-methyl- 2-trifluoromethyl-1 H-indol-3-yl)ethyl]amide 345. 5-trifluoromethyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-4-methyl- 2-trifluoromethyl-1 H-indol-3-yl)ethyl]amide 346. 5-chloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-4-methyl- 2-trifluoromethyl-1 H-indol-3-yl)ethyl]amide 347. 5-trifluoromethoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-4-methyl- 2-trifluoromethyl-1 H-indol-3-yl)ethyl]amide 348. N-[2-(7-fluoro-4-methyl-2-trifluoromethyl-1 H-indol-3-yl)ethyl]- 3,4-dimethoxybenzannide 349. biphenyl-3,4'-dicarboxylic acid 4'-{[2-(4-chloro-7-fluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide} 3-methylannide 350. 5-fluoro-1 H-indole-2-carboxylic acid [2-(4-chloro-7-fluoro-2-methyl-1 H- indol-3-yl)ethyl]amide 351. 5-trifluoromethoxy-1 H-indole-2-carboxylic acid [2-(4-chloro-7-fluoro- 2-methyl-1 H-indol-3-yl)ethyl]amide 352. 4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- 3-hydroxybiphenyl-4-carboxylic acid 353. 4-bromo-N-[2-(4-fluoro-2,7-dimethyl-1 H-indol-3-yl)ethyl]benzamide 354. 4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 355. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-hydroxybenzamide 356. 3'-(2,5-dioxoimidazolidin-4-yl)biphenyl-4-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 357. 3-bromo-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 358. 5-bromobenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 359. 6-bromobenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 360. 6-trifluoromethylbenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 361. 6-trifluoromethoxybenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 362. 5-trifluoromethoxybenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 363. benzothiazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 364. 5-chlorobenzothiazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 365. 6-chlorobenzothiazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 366. 5-fluorobenzothiazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 367. 6-fluorobenzothiazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 368. 5-trifluoromethylbenzothiazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 369. 6-trifluoromethylbenzothiazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 370. 5-trifluoromethoxybenzothiazole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 371. 6-trifluoromethoxybenzothiazole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 372. δ-bronnobenzothiazole^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 373. e-bromobenzothiazole^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 374. benzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 375. 5-chlorobenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 376. 6-chlorobenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 377. 5-fluorobenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 378. 6-fluorobenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 379. 5-trifluoromethylbenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 380. 6-trifluoromethylbenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 381. 5-trifluoromethoxybenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 382. 6-trifluoromethoxybenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 383. 5-bromobenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 384. 6-bromobenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 385. I H-benzinnidazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 386. 5-chloro-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 387. 6-chloro-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 388. 5-fluoro-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 389. 6-fluoro-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 390. 5-trifluoromethyl-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 391. 6-trifluoromethyl-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 392. 5-trifluoromethoxy-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 393. 6-trifluoromethoxy-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 394. 5-bromo-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 395. 6-bromo-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 396. 5-trifluoromethylsulfanyl-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 397. 5,6-dichloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 398. 5-chloro-6-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 399. 5-fluoro-6-chloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 400. 5,6-difluoro-i H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 401. 4,6-dichloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 402. 4,6-difluoro-i H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 403. 5-acetylamino-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 404. 6-acetylamino-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 405. 5-(2,2-dimethylpropionylamino)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 406. 6-(2,2-dimethylpropionylamino)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 407. 5-trifluoroacetylamino-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 408. 6-trifluoroacetylamino-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 409. 5-isopropyloxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 410. 6-isopropyloxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 411. 5-isopropyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 412. 6-trifluoromethyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 413. 4,5,6,7-tetrahydro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 414. 3-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 415. 5-trifluoromethylbenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 416. 5-fluorobenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 417. 5-amino-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 418. 6-amino-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 419. 6-dimethylcarbamoylnnethoxy-i H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 420. 5-dimethylcarbamoylnnethoxy-i H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 421. 6-methylcarbamoylnnethoxy-i H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 422. 5-methylcarbamoylnnethoxy-i H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 423. 6-carbamoylmethoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 424. 5-carbamoylmethoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 425. 6-tert-butyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 426. 5-tert-butyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 9. The use of the compounds as claimed in claims 1 -8 for the manufacture of medicaments which comprise at least one of the compounds of the formula I. 10. A medicament as set forth in claim 9 with suitable formulating substances and carriers. 11. The use of the medicaments as set forth in claim 9 and 10, wherein the medicament is used for the treatment and prophylaxis of disorders. 12. The use as claimed in claim 10 for the treatment and prophylaxis of disorders connected with the EP 2 receptor. 13. The use as claimed in claim 10 for the treatment and prophylaxis of fertility impairments. 14. The use as claimed in claim 10 for the treatment and prophylaxis of painful menstruation. 15. The use as claimed in claim 10 for the treatment and prophylaxis of endometriosis. 16. The use of the compounds as claimed in claim 1 -8 for modulating the EP 2 receptor. 17. The use as claimed in claim 10 for the treatment and prophylaxis of pain. 18. The use of the compounds as claimed in claim 1 -8 and of the medicaments as set forth in claim 9 for controlling fertility/contraception. 19. The use as claimed in claim 10 for the treatment and prophylaxis of osteoporosis. 20. The use as claimed in claim 10 for the treatment and prophylaxis of cancer. 21. The use of the compounds of the general formula I as claimed in claims 1 -8 in the form of a pharmaceutical product for enteral, parenteral, vaginal and oral administration.

Aryl/hetarylamides as modulators of the EP ₂ receptor

The present invention relates to aryl/hetarylamide derivatives as EP ₂ receptor modulators, process for their preparation, and their use as medicaments.

It has long been known that prostaglandins are key molecules in the processes of female reproductive biology such as, for example, control of ovulation, of fertilization, of nidation, of decidualization (e.g. placenta formation) and of menstruation. Prostaglandins likewise play an important part in the pathological changes in the reproductive tract, including menorrhagia, dysmenorrhea, endometriosis and cancer. The mechanism by which prostaglandins bring about these changes has not yet been completely elucidated. Recent results indicate that prostaglandins, their receptors and signal transduction pathways thereof are involved in processes such as angiogenesis, apoptosis, proliferation, and in inflammatory/antiinflammatory and immunological processes.

The effects of prostaglandins are mediated by their G protein-coupled receptors which are located on the cell surface. Prostaglandin E ₂ (PGE ₂ ) is of particular interest, having a wide variety of cellular effects through binding to functionally different receptor subtypes, namely the EPi, EP ₂ , EP ₃ and EP ₄ receptors. The receptor subtypes to which prostaglandin E ₂ binds appear to be of particular interest for the receptor-mediated effects which are involved in the control of fertility. It has thus been possible to show that the reproductive functions in EP ₂ knockout mice (EP ₂ ^" ' ^" ), i.e. in mice no longer having a functional PGE ₂ receptor of the EP ₂ subtype, are impaired, and that these animals have a smaller "litter size" (Matsumoto et al., 2001 , Biology of Reproduction 64, 1557-1565). It was likewise possible to show that these EP ₂ knockout mice (Hizaki et al. Proc Natl Acad Sci U. S. A. 1999 Aug 31 ; 96(18):10501 -10506) show distinctly reduced cumulus expansion and severe subfertility, which is to be regarded as causally connected with diminished reproductive processes such as ovulation and fertilization.

The EP ₂ receptor accordingly represents an important target for developing medicaments for controlling female fertility. The existence of the 4 subclasses of the PGE ₂ receptor opens up the possibility of targeted development of

selectively active compounds. However, to date, scarcely any selective EP ₂ receptor ligands which bind to the EP ₂ subtypes of the PGE ₂ receptor are known, since most known compounds also bind to the other PGE ₂ receptor subtypes such as, for example, to the EP ₄ receptor.

EP ₂ receptor antagonists are described, for example in the application US2005059742 (Jabbour, Medical Research Concil). A method in which an EP ₂ and/or an EP ₄ antagonist can be employed for the treatment of menorrhagia and dysmenorrhea is claimed. AH6809 is disclosed as antagonist of the EP ₂ or EP ₄ receptor, but no other specific antagonists and no new compounds are disclosed.

In an earlier application of the same group (EP1467738), EP ₂ or EP ₄ antagonists are claimed for the treatment of pathological conditions such as, for example, allergic disorders, Alzheimer's disease, pain, abortion, painful menstruation, menorrhagia and dysmenorrhea, endometriosis, bone disorders, ischemia etc. The described compounds are, however, distinguished by a particularly high affinity for the EP ₃ receptor. A further application (WO04/032964) describes novel compounds which are likewise distinguished by a particularly high affinity for the EP ₃ receptor, but also have EP ₂ -antagonistic effects and which are used for the treatment and prophylaxis of allergic disorders.

Ono Pharmaceutical claims in the application WO03/016254 the preparation of benzene acid or saturated carboxylic acid derivatives which are substituted by aryl or heterocycles, inter alia as PGE ₂ receptor antagonists. The disclosed compounds are claimed for the treatment of a large number of disorders, including allergic disorders, Alzheimer's disease, pain, abortion, painful menstruation, menorrhagia and dysmenorrhea, endometriosis, bone disorders, ischemia etc. The described compounds are, however, distinguished by a particularly high affinity for the EP ₃ receptor. A further application (WO04/032964) describes novel compounds which are likewise distinguished by a particularly high affinity for the EP ₃ receptor, but also have EP ₂ -antagonistic

effects and which are used for the treatment and prophylaxis of allergic disorders.

The application WO04/39807 of Merck Frosst, Canada, discloses the preparation of pyridopyrrolizines and pyridoindolizines. However, these compounds are distinguished by good binding to the PGD ₂ receptor, and this receptor represents a different subtype of the prostaglandin receptor.

Naphthalene derivatives as EP ₄ receptor ligands are disclosed in application US2004102508 of SmithKline Beecham Corporation. The claimed compounds are used for the treatment or prophylaxis of pain, allergic reactions and neurodegenerative disorders.

EP ₄ antagonists (γ-lactams) are claimed in the application WO03/103604 (Applied Research Systems). The compounds bind approximately 60-fold better to the EP ₄ than to the EP ₂ receptor and are claimed inter alia for the treatment of premature labor, dysmenorrhea, asthma, infertility or fertility impairments. The same company claims in the applications WO03/053923 (substituted pyrrolidines) or WO03/035064 (substituted pyrazolidinones) compounds for the treatment of disorders associated with prostaglandins, such as, for example, infertility, hypertension and osteoporosis. The compounds bind to the EP ₄ - and to the EP ₂ receptor subtypes. The application WO03/037433 claims ω- cycloalkyl, 17 heteroaryl prostaglandin derivatives as EP ₂ receptor antagonists, in particular for the treatment of elevated intraocular pressure.

The application WO03/064391 (Pfizer Products) describes metabolites of [3-[[N- (4-tert-butylbenzyl)(pyridin-3-ylsulfonyl)amino]methyl]aceti c acid which inhibit the binding of [ ³ H] prostaglandin E ₂ to the EP ₂ receptor. The use of these metabolites for the treatment of osteoporosis is disclosed. Tani et al. claim in the application US2005124577 8-azaprostaglandin derivatives for the treatment of immunological disorders, allergic disorders, premature labor, abortion, etc. The compounds bind to the EP ₂ and to the EP ₄ receptor.

- A -

European patent application EP 1306087 describes EP ₂ receptor agonists which are used for the treatment of erectile dysfunction (Ono Pharmaceuticals). The same class of structures is described in European patent EP 860430 (Ono Pharmaceuticals), and their use for the manufacture of a medicament for the treatment of immunological disorders, asthma and abortion is claimed. WO04/009117 describes EP ₂ and EP ₄ receptor agonists for the treatment of disorders caused by uterine contraction, for example painful menstruation (Ono Pharmaceuticals).

The applications WO03/74483 and WO03/09872 describe agonists which bind equally to the EP ₂ and to the EP ₄ receptor (Ono Pharmaceuticals).

Agonists of the EP ₂ and of the EP ₄ receptors are frequently described in connection with the treatment of osteoporosis (WO99/19300 (Pfizer),

US2003/0166631 (Dumont Francis), WO03/77910 (Pfizer), WO03/45371

(Pfizer), WO03/74483 and WO03/09872 (Ono Pharmaceuticals)) and for glaucoma treatment (WO04/37813, WO04/37786, WO04/19938, WO03/103772,

WO03/103664, WO03/40123, WO03/47513, WO03/47417 (Merck Frosst Canada)) and US6410591 and US6747037 (Allergan).

The patent application WO04/12656 (Applied Research Systems) claims EP ₂ receptor agonists in connection with inflammation.

The patent application WO03/77919 (Merck & Co. Inc.) claims EP ₄ receptor agonists for the treatment of fertility.

However, to date, no selective EP ₂ receptor agonists and antagonists which control the processes which are ultimately responsible for ovulation, fertilization, nidation and decidualization and thus contribute to promoting or inhibiting fertility are known.

It is therefore an object of the present invention to provide stable EP ₂ receptor antagonists.

This object is achieved by providing the compounds of the general formula I

in which A is an aryl or heteroaryl radical which may optionally be substituted one or more times by R ³ and/or R ⁴ ,

R ¹ is a hydrogen, a d-Cβ-alkyl radical which may optionally be substituted,

R ² is a hydrogen, halogen, cyano, an -S(O) _q -CH ₃ , where q is 0-2, a

Ci-C ₄ -alkoxy radical or Ci-C6-alkyl, where this radical can be substituted in any way,

R ³ is a hydrogen, halogen, amino, an -S(O) _p -Ci-C ₆ -alkyl group, where p is 0-2, a d-Cβ-acyl, NH-CO-NH ₂ , -O-CO-NH(C _r C ₆ -alkyl), -0-CO-N(C ₁ -

C ₆ -alkyl) ₂ or N H-CO-Ci -Cβ-alkyl radical, a Ci-Cθ-alkyl which may optionally be substituted one or more times, identically or differently, by C-i-Cβ-acyl, C-i-Cβ-alkoxy, hydroxy, cyano, CO ₂ -(C _r C ₆ -alkyl), N-(CrC ₆ -alkyl) ₂ , C ₅ -C ₁₂ - heteroaryl, COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl) or by CO-N(C ₁ -

C ₆ -alkyl) ₂ , a Ci-Cθ-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO ₂ -(C ₁ -C ₆ - alkyl), N-(Ci-C ₆ -alkyl) _2> NH-Ca-Cβ-cycloalkyl, COOH, CO-NH ₂ , CO-

NH(Ci-C ₆ -alkyl) or by CO-N(Ci-C ₆ -alkyl) _2> an O-C6-Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ ,

a CH ₂ O-C6-Ci2-aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , an O-C5-Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , a hydroxy, cyano, O-CO-(Ci-C ₆ -alkyl), CO-NH(C ₅ -Ci ₂ -heteroaryl),

NH-(Ci-C ₆ -alkyl), N-(Ci-C ₆ -alkyl) ₂ , a C6-Ci ₂ -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC ₆ -alkyl, C ₃ -C ₆ - cycloalkyl, C-ι-C ₆ -acyl, d-Cβ-alkoxy, C ₆ -Ci ₂ -aryl, C ₅ -Ci ₂ -heteroaryl, hydroxy, CH ₂ -OH, cyano, CH ₂ -CN, amino, CO ₂ -(Ci-C ₆ -alkyl), N-

(Ci-C ₆ -alkyl) ₂ , NHSO ₂ CH ₃ , SO ₂ NH ₂ , SO ₂ NH(Ci-C ₆ -alkyl), SO ₂ N(CrC ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-N H(C ₁ -C ₆ -alkyl), CO- N(Ci-C ₆ -alkyl) ₂ , CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-CO(Ci-C ₆ -alkyl), CH ₂ -NH-CO(Ci-C ₆ -alkyl), NH-CO(C ₅ -Ci ₂ -heteroaryl), CH ₂ -NH- CO(C ₅ -Ci ₂ -heteroaryl), styryl, or an -S(O) _n -CH ₃ , where r is 0-2, or two adjacent positions may be substituted by -0-CH ₂ -O- or -O- C(CHs) ₂ -O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by C-ι-C ₆ -alkyl, if R ² is cyano or if R ¹ and/or R ² is identically or differently a CrC ₆ -alkyl radical, where at least one of the radicals is substituted at least once, or if R ⁴ is -S(O) _p -Ci-C ₆ -alkyl, where p is 0-2, a Ci-C ₆ -acyl-, -O-CO- NH(C _r C ₆ -alkyl), -O-CO-N(C _r C ₆ -alkyl) ₂ , C ₆ -C ₁₂ -aryloxy, C ₅ -C ₁₆ - heteroaryloxy, hydroxy, cyano or N-(C-ι-C6-alkyl) ₂ , a monocyclic Cs-Cz-heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, CF ₃ , C ₁ - Ce-acyl, C _r C ₆ -alkoxy, hydroxy, CH ₂ -OH, cyano, CO ₂ -(C _r C ₆ -alkyl), N-(C ₁ -C ₆ ^IkYl) ₂ , COOH, CO-NH ₂ , CO-N H(C ₁ -C ₆ -alkyl) or CO- N(C ₁ -C ₆ -BIkYl) _2, a bi- or tricyclic Cs-C ₁₂ -heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by C-ι-C ₆ -alkyl, C-ι-C ₆ -acyl, CrCθ-alkoxy, hydroxy, cyano, CO ₂ -(C ₁ -

C ₆ -alkyl), N-(Ci-C ₆ -alkyl) _2> COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl) or CO-N(Ci-C ₆ -alkyl) ₂ , or a C3-C6-cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC ₆ -alkyl, hydroxy, cyano, CO ₂ -(Ci-C ₆ -alkyl), d-Cβ-acyl, N-(Ci-C ₆ -alkyl) _2> COOH, CO-

NH ₂ , CO-NH(Ci-C ₆ -alkyl), CO-N(Ci-C ₆ -alkyl) ₂ or Ci-C ₆ -alkoxy,

is a hydrogen, halogen, amino, -S(O) _p -Ci-C ₆ -alkyl, where p is

0-2, a d-Cβ-acyl, NH-CO-NH ₂ , N H-CO-Ci -C ₆ -alkyl, -0-CO-NH(Ci-C ₆ - alkyl), -O-CO-N(Ci-C ₆ -alkyl) ₂ or Ci-Cβ-alkyl group which may optionally be substituted one or more times, identically or differently, by Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, hydroxy, cyano, CO ₂ -(Ci- Cβ-alkyl), N-(Ci-C ₆ -alkyl) _2> C ₅ -Ci ₂ -heteroaryl, COOH, CO-NH ₂ , CO- NH(Ci-C ₆ -alkyl) or by CO-N(d-C ₆ -alkyl) _2> a CrC ₆ -alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO ₂ -(Ci-C ₆ - alkyl), N-(d-C ₆ -alkyl) _2> NH-C ₃ -C ₆ -cycloalkyl, COOH, CO-NH ₂ , CO- NH(Ci-C ₆ -alkyl) or by CO-N(Ci-C ₆ -alkyl) _2> an O-C ₆ -Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , a CH ₂ O-C ₆ -Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , an O-C ₅ -Ci ₆ -heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , a hydroxy, cyano, O-CO-(Ci-C ₆ -alkyl), CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-(Ci-C ₆ -alkyl), N-(Ci-C ₆ -alkyl) ₂ , a C ₆ -Ci ₂ -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C ₆ -alkyl, C ₃ -C ₆ - cycloalkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, C ₆ -Ci ₂ -aryl, C ₅ -Ci ₂ -heteroaryl, hydroxy, CH ₂ -OH, cyano, CH ₂ -CN, amino, CO ₂ -(d-C ₆ -alkyl), N- (Ci-C ₆ -alkyl) ₂ , NHSO ₂ CH ₃ , SO ₂ NH ₂ , SO ₂ NH(C _r C ₆ -alkyl), SO ₂ N(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl), CO-

N(Ci-C ₆ -alkyl) ₂ , CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-CO(Ci-C ₆ -alkyl), CH ₂ -NH-CO(Ci-C ₆ -alkyl), NH-CO(C ₅ -Ci ₂ -heteroaryl), CH ₂ -NH- CO(C ₅ -Ci ₂ -heteroaryl), styryl, or an -S(O) _n -CH ₃ , where r is 0-2, or two adjacent positions may be substituted by -0-CH ₂ -O- or -O- C(CHs) ₂ -O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by d-Cβ-alkyl, if R ² is cyano or if R ¹ and/or R ² is identically or differently a CrC ₆ -alkyl radical, where at least one of the radicals is substituted at least once, a monocyclic Cs-Cz-heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, CF ₃ , d- C ₆ -acyl, Ci-C ₆ -alkoxy, hydroxy, CH ₂ -OH, cyano, CO ₂ -(Ci-C ₆ -alkyl), N-(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl) or CO- N(Ci-C ₆ -alkyl) ₂ , a bi- or tricyclic C ₈ -Ci ₂ -heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-Cθ-alkyl, Ci-Cθ-acyl, Ci-Cθ-alkoxy, hydroxy, cyano, CO ₂ -(Ci- C ₆ -alkyl), N-(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl) or CO-N(Ci-C ₆ -alkyl) ₂ , or a C3-C6-cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C ₆ -alkyl, hydroxy, cyano, CO ₂ -(Ci-C ₆ -alkyl), Ci-C ₆ -acyl, N-(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl), CO-N(C _r C ₆ -alkyl) ₂ or C _r Cβ-alkoxy,

R ³ and R ⁴ are either in ortho,meta position or meta,para position relative to one another and together have the meaning -O-CO-S-, -S-CO-O-, CH ₂ -CO-O-, 0-CO-CH ₂ -, -CH ₂ -CO-NH-, -NH-CO-CH ₂ -, -O-CO-NH- , -NH-CO-O-, -CO-CH ₂ -(CH ₂ ) _m -, -CH ₂ -(CH ₂ ) _m -CO-, -O-(CH ₂ ) _m -O-, -

0-C-(CHs) ₂ -O-, -CH ₂ -(CH ₂ ) _m -CH ₂ -, where m is 1 -3,

Y is a -(CH ₂ )n- group, where n is 1 -3,

and the isomers, diastereomers, enantiomers and salts thereof, and cyclodexthn clathrates, which overcome the known disadvantages and have improved properties, i.e. good activity, good solubility and stability, where the following compounds are excluded:

N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3,4-dimethoxybenzamide

N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-methylbenzamide

4-bromo-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide.

The compounds of the invention have an antagonistic effect on the EP ₂ receptor and thus serve to control female fertility.

Ci-C ₄ -Alkyl or Ci-C _θ -alkyI means in each case a straight-chain or branched alkyl radical such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert-butyl, pentyl, isopentyl and hexyl.

The alkyl radicals may optionally be substituted one or more times, identically or differently, by halogen.

Ci-C ₄ -Alkoxy or d-Cβ-alkoxy means in each case a straight-chain or branched alkoxy radical such as, for example, methoxy-, ethoxy-, n-propoxy-, isopropoxy-, n-butoxy-, sec-butoxy-, isobutoxy-, tert-butyloxy-, pentoxy-, isopentoxy- and hexoxy-.

The alkoxy radicals may optionally be substituted one or more times, identically or differently, by halogen.

Ci -C ₄ -Acyl or C-i-Cβ-acyl means in each case a straight-chain or branched radical such as, for example, formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl and benzoyl.

The acyl radicals may optionally be substituted one or more times, identically or differently, by halogen.

C ₃ -C ₆ -Cycloal kyl means monocyclic alkyl rings such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The cycloalkyl radicals may, instead of the carbon atoms, comprise one or more heteroatoms such as oxygen, sulfur and/or nitrogen. Preferred heterocycloalkyls are those having 3 to 6 ring atoms, such as, for example, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl. Ring systems in which optionally one or more possible double bonds may be contained in the ring are for example cycloalkenyls such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cycloheptenyl, with the connection possibly taking place either at the double bond or at the single bonds.

Halogen means in each case fluorine, chlorine, bromine or iodine.

The C6-Ci2-aryl radical includes in each case 6-12 carbon atoms and may for example be benzo-fused. Examples which may be mentioned are: phenyl, tropyl, cyclooctadienyl, indenyl, naphthyl, biphenyl, fluorenyl, anthracenyl etc.

The monocyclic Cs-Cz-heteroaryl radical, the tricyclic C8-Ci2-heteroaryl radical and the Cs-C-m-heteroaryl radical mean ring systems which comprise in each case 5-16 ring atoms and which may, instead of the carbon, comprise one or more, identical or different, heteroatoms such as oxygen, sulfur or nitrogen, and where the Cs-C-m-heteroaryl radical may be mono-, bi- or tricyclic and may additionally in each case be benzo-fused. Examples which may be mentioned are: thienyl, furanyl, pyrrolyl, oxazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, etc. and benzo derivatives thereof, such as, for example, benzofuranyl, benzothienyl, benzooxazolyl, benzimdazolyl, indazolyl, indolyl, isoindolyl, etc; or pyridinyl, pyhdazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc. and benzo derivatives thereof such as, for example, quinolyl, isoquinolyl, etc; or azocinyl, indolizinyl, purinyl, etc. and benzo derivatives thereof; or quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyhdinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, xanthenyl, oxepinyl, benzotriazolyl, etc.

The heteroaryl radical may in each case be benzo-fused. Examples of 5- membered heteroaromatic rings which may be mentioned are: thiophene, furan, oxazole, thiazole, imidazole, pyrazole and benzo derivatives thereof, and of 6- membered heteroaromatic rings pyridine, pyrimidine, thazine, quinoline, isoquinoline and benzo derivatives.

Heteroatoms mean oxygen, nitrogen or sulfur atoms.

If an acidic function is present, suitable salts are the physiologically tolerated salts of organic and inorganic bases, such as, for example, the readily soluble alkali metal and alkaline earth metal salts, and N-methylglucamine, dimethylglucamine, ethylglucamine, lysine, 1 ,6-hexanediamine, ethanolamine, glucosamine, sarcosine, serinol, ths-hydroxymethylaminomethane, aminopropanediol, Sovak base, 1 -amino-2,3,4-butanethol.

If a basic function is present, the physiologically tolerated salts of organic and inorganic acids are suitable, such as hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, tartaric acid inter alia.

Preference is given to those compounds of the general formula (I) where

A is an aryl or heteroaryl radical which may optionally be substituted one or more times by R ⁴ and/or R ³ ,

R ¹ is a hydrogen or d-Cβ-alkyl radical which may be substituted one or more times by halogen,

R ² is a hydrogen, halogen, cyano, an -S(O) _q -CH ₃ , where q is 0-2, a Ci-C ₄ -alkoxy radical or Ci-C6-alkyl radical which may be substituted one or more times by halogen,

R ³ is a hydrogen, halogen, amino, -S(O) _p -Ci-C ₆ -alkyl, where p is 0-2,

a Ci-C ₆ -acyl, NH-CO-NH ₂ , NH-CO-d-Cβ-alkyl, -0-CO-NH(Ci-C ₆ - alkyl), -O-CO-N(Ci-C6-alkyl) ₂ , or Ci-C6-alkyl group which may optionally be substituted one or more times, identically or differently, by CrC ₆ -acyl, CrC ₆ -alkoxy, hydroxy, cyano, CO ₂ -(Cr Cβ-alkyl), N-(Ci-C ₆ -alkyl) ₂ , C ₅ -Ci ₂ -heteroaryl, COOH, CO-NH ₂ , CO-

NH(Ci-C ₆ -alkyl) or by CO-N(Ci-C ₆ -alkyl) ₂ , a Ci-Cθ-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO ₂ -(CrC ₆ - alkyl), N-(Ci-C ₆ -alkyl) ₂ , NH-C ₃ -C ₆ -cycloalkyl, COOH, CO-NH ₂ , CO- NH(Ci-C ₆ -alkyl) or by CO-N(Ci-C ₆ -alkyl) ₂ , an O-C6-Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , a CH ₂ O-C ₆ -Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , an O-C ₅ -Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , a hydroxy, cyano, O-CO-(Ci-C ₆ -alkyl), CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-(Ci-C ₆ -alkyl), N-(Ci-C ₆ -alkyl) ₂ , a C6-Ci ₂ -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC ₆ -alkyl, C ₃ -C ₆ - cycloalkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, C ₆ -Ci ₂ -aryl, C ₅ -Ci ₂ -heteroaryl, hydroxy, CH ₂ -OH, cyano, CH ₂ -CN, amino, CO ₂ -(Ci-C ₆ -alkyl), N- (Ci-C ₆ -alkyl) ₂ , NHSO ₂ CH ₃ , SO ₂ NH ₂ , SO ₂ NH(Ci-C ₆ -alkyl), SO ₂ N(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(C _r C ₆ -alkyl), CO- N(Ci-C ₆ -alkyl) ₂ , CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-CO(Ci-C ₆ -alkyl),

CH ₂ -NH-CO(Ci-C ₆ -alkyl), NH-CO(C ₅ -Ci ₂ -heteroaryl), CH ₂ -NH- CO(C ₅ -Ci ₂ -heteroaryl), styryl, or an -S(O) _n -CH ₃ , where r is 0-2, or two adjacent positions may be substituted by -0-CH ₂ -O- or - O-C(CH ₃ ) ₂ -O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by Ci-C ₆ -alkyl, if R ² is cyano or if R ¹ and/or R ² is identically or differently a CrC ₆ -alkyl

radical, where at least one of the radicals is substituted at least once, or if R ⁴ is -S(O) _p -Ci-C ₆ -alkyl, where p is 0-2, a d-C ₆ -acyl-, -O-CO- NH(CrC ₆ -alkyl), -O-CO-N(CrC6-alkyl) ₂ , C ₆ -C ₁₂ -aryloxy, C ₅ -C ₁₆ - heteroaryloxy, hydroxy, cyano or N-(Ci-C ₆ -alkyl) ₂ , a monocyclic Cs-Cz-heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, by CF ₃ , CrC ₆ -acyl, CrC ₆ -alkoxy, hydroxy, CH ₂ -OH, cyano, CO ₂ -(Ci -C ₆ - alkyl), N-(Ci-C ₆ -alkyl) _2> COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl) or CO-N(Ci-C ₆ -alkyl) ₂ , a bi- or tricyclic Cs-Ci ₂ -heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C ₆ -alkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, hydroxy, cyano, CO ₂ -(Ci- Cβ-alkyl), N-(Ci-C ₆ -alkyl) _2> COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl) or CO-N(Ci-C ₆ -alkyl) ₂ , or a C ₃ -C ₆ -cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C ₆ -alkyl, hydroxy, cyano, CO ₂ -(Ci-C ₆ -alkyl), d-Cβ-acyl, N-(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl), CO-N(Ci-C ₆ -alkyl) ₂ or Ci-C ₆ -alkoxy,

is a hydrogen, halogen, amino, -S(O) _p -Ci-C ₆ -alkyl, where p is

0-2, a Ci-C ₆ -acyl, NH-CO-NH ₂ , NH-CO-d-Cβ-alkyl, -0-CO-NH(Ci-C ₆ - alkyl), -O-CO-N(Ci-C ₆ -alkyl) ₂ , or Ci-C ₆ -alkyl group which may optionally be substituted one or more times, identically or differently, by Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, hydroxy, cyano, CO ₂ -(Ci-

Cβ-alkyl), N-(Ci-C ₆ -alkyl) _2> C ₅ -Ci ₂ -heteroaryl, COOH, CO-NH ₂ , CO-

NH(Ci-C ₆ -alkyl) or by CO-N(d-C ₆ -alkyl) _2> a Ci-C ₆ -alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO ₂ -(Ci-C ₆ - alkyl), N-(d-C ₆ -alkyl) _2> NH-C ₃ -C ₆ -cycloalkyl, COOH, CO-NH ₂ , CO-

NH(Ci-C ₆ -alkyl) or by CO-N(d-C ₆ -alkyl) _2>

an O-C6-Ci2-aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , a CH ₂ O-C6-Ci2-aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , an O-C ₅ -Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , a hydroxy, cyano, O-CO-(Ci-C ₆ -alkyl), CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-(CrC ₆ -alkyl), N-(CrC ₆ -alkyl) ₂ , a C6-Ci ₂ -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by d-Cβ-alkyl, C ₃ -C ₆ - cycloalkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, C ₆ -Ci ₂ -aryl, C ₅ -Ci ₂ -heteroaryl, hydroxy, CH ₂ -OH, cyano, CH ₂ -CN, amino, CO ₂ -(C _r C ₆ -alkyl), N- (Ci-C ₆ -alkyl) ₂ , NHSO ₂ CH ₃ , SO ₂ NH ₂ , SO ₂ NH(Ci-C ₆ -alkyl), SO ₂ N(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl), CO- N(Ci-C ₆ -alkyl) ₂ , CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-CO(Ci-C ₆ -alkyl),

CH ₂ -NH-CO(CrC ₆ -alkyl), NH-CO(C ₅ -C ₁₂ -heteroaryl), CH ₂ -NH- CO(C ₅ -Ci ₂ -heteroaryl), styryl, or an -S(O) _n -CH ₃ , where r is 0-2, or two adjacent positions may be substituted by -0-CH ₂ -O- or -O- C(CHs) ₂ -O-, a monocyclic C ₅ -C ₇ -heteroaryl which may optionally be substituted one or more times, identically or differently, by Ci-C ₆ -alkyl, if R ² is cyano or if R ¹ and/or R ² is identically or differently a Ci-C ₆ -alkyl radical, where at least one of the radicals is substituted at least once, a monocyclic C ₅ -C ₇ -heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, by CF ₃ , Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, hydroxy, CH ₂ -OH, cyano, CO ₂ -(Ci-C ₆ - alkyl), N-(C _r C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(C _r C ₆ -alkyl) or CO-N(Ci-C ₆ -alkyl) ₂ , a bi- or tricyclic Cs-Ci ₂ -heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC ₆ -alkyl, d-C ₆ -acyl, C _r C ₆ -alkoxy, hydroxy, cyano, CO ₂ -(Cr

C ₆ -alkyl), N-(Ci-C ₆ -alkyl) _2> COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl) or CO-N(Ci-C ₆ -alkyl) ₂ , or a C3-C6-cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC ₆ -alkyl, hydroxy, cyano, CO ₂ -(Ci-C ₆ -alkyl), Ci-C ₆ -acyl, N-(Ci-C ₆ -alkyl) ₂ ,

COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl), CO-N(Ci-C ₆ -alkyl) ₂ or d- C ₆ -alkoxy,

R ³ and R ⁴ are either in ortho,meta position or meta,para position relative to one another and together have the meaning of -O-CO-S-, -S-CO-

O-, CH ₂ -CO-O-, 0-CO-CH ₂ -, -CH ₂ -CO-NH-, -NH-CO-CH ₂ -, -0-C0- NH-, -NH-CO-O-, -CO-CH ₂ -(CH ₂ ) _m -, -CH ₂ -(CH ₂ ) _m -CO-, -O-(CH ₂ ) _m - O-, -0-C-(CHs) ₂ -O-, -CH ₂ -(CH ₂ ) _m -CH ₂ -, where m is 1 -3,

Y is a -(CH ₂ )n- group, where n is 1 -3,

and the isomers, diastereomers, enantiomers and salts thereof, and cyclodextrin clathrates.

Preference is likewise given to those compounds of the general formula (I) where

A is an aryl or heteroaryl radical which may optionally be substituted one or more times by R ⁴ and/or R ³ ,

R ¹ is a hydrogen or a C-i-Cβ-alkyl group which is substituted one or more times by halogen,

R ² is a hydrogen, halogen, cyano, an -S(O) _q -CH ₃ , where q is 0-2, a Ci-C ₄ -alkoxy radical or a C-i-Cβ-alkyl group which is substituted one or more times by halogen,

R ³ is a hydrogen, halogen, amino, -S(O) _P -CH ₃ , where p is 0-2,

an -S-CF ₃ , SO ₂ NH ₂ , d-C ₆ -acyl, NH-CO-NH ₂ , NH-CO-Ci-C ₆ -alkyl, -O-CO-NH(Ci-C ₆ -alkyl), -O-CO-N(Ci-C ₆ -alkyl) _2> or CrC ₆ -alkyl group which may optionally be substituted one or more times, identically or differently, by CrC ₄ -acyl, CrC ₄ -alkoxy, hydroxy, cyano, CO ₂ -(Ci-C ₄ -alkyl), N-(Ci-C ₄ -alkyl) ₂ , C ₅ -Ci ₂ -heteroaryl,

COOH, CO-NH ₂ , CO-NH(Ci-C ₄ -alkyl) or by CO-N(Ci-C ₄ -alkyl) _2> a Ci-Cθ-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO ₂ -(Ci -C ₆ - alkyl), N-(Ci-C ₆ -alkyl) _2> NH-C ₃ -C ₆ -cycloalkyl, COOH, CO-NH ₂ , CO- NH(Ci-C ₆ -alkyl) or by CO-N(Ci-C ₆ -alkyl) ₂ , an O-C6-Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , a CH ₂ O-C ₆ -Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , an O-C ₅ -Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, a hydroxy, cyano, O-CO-(Ci-C ₆ -alkyl), CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-(Ci-C ₆ -alkyl), N-(Ci-C ₆ -alkyl) ₂ , a C6-Ci ₂ -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC ₆ -alkyl, C ₃ -C ₆ - cycloalkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, C ₆ -Ci ₂ -aryl, C ₅ -Ci ₂ -heteroaryl, hydroxy, CH ₂ -OH, cyano, CH ₂ -CN, amino, CO ₂ -(Ci-C ₆ -alkyl), N- (Ci-C ₆ -alkyl) ₂ , NHSO ₂ CH ₃ , SO ₂ NH ₂ , SO ₂ NH(Ci-C ₆ -alkyl), SO ₂ N(Ci-C ₆ -alkyl) _2> COOH, CO-NH ₂ , CO-N H(C ₁ -C ₆ -alkyl), CO- N(Ci-C ₆ -alkyl) _2> CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-CO(Ci-C ₆ -alkyl),

CH ₂ -NH-CO(Ci-C ₆ -alkyl), NH-CO(C ₅ -Ci ₂ -heteroaryl), CH ₂ -NH- CO(C ₅ -Ci ₂ -heteroaryl), styryl, or an -S(O) _n -CH ₃ , where r is 0-2, or two adjacent positions may be substituted by -0-CH ₂ -O- or -O-C(CH ₃ ) ₂ -O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by Ci-C ₆ -alkyl, if R ² is cyano or if R ¹ and/or R ² is identically or differently a CrC ₆ -alkyl radical, where at least one of the radicals is substituted at least

once by halogen, or if R ⁴ is -S(O) _p -Ci-C ₆ -alkyl, where p is 0-2, Cr Cβ-acyl, -O-CO-NH(Ci-C ₆ -alkyl), -O-CO-N(Ci-C ₆ -alkyl) ₂ , C ₆ -Ci ₂ - aryloxy, Cs-Ciθ-heteroaryloxy, hydroxy, cyano or N-(Ci-C6-alkyl) ₂ , a monocyclic C ₅ -C ₇ -heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, by CF ₃ ,

Ci-C ₄ -acyl, Ci-C ₄ -alkoxy, hydroxy, CH ₂ -OH, cyano, CO ₂ -(CrC ₄ - alkyl), N-(Ci-C ₄ -alkyl) _2> COOH, CO-NH ₂ , CO-NH(Ci-C ₄ -alkyl) or CO-N(Ci-C ₄ -alkyl) _2, or a bi- or tricyclic Cs-Ci ₂ -heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-Cβ-alkyl, CrC ₆ -acyl, Ci-Cθ-alkoxy, hydroxy, cyano, CO ₂ -(Cr Cβ-alkyl), N-(Ci-C ₆ -alkyl) _2> COOH, CO-NH ₂ , CO-NH(C _r C ₆ -alkyl) or CO-N(Ci-C ₆ -alkyl) ₂ , or a C3-C6-cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C ₄ -alkyl, hydroxy, cyano, CO ₂ -(C _r C ₄ -alkyl), C _r C ₄ -acyl, N-(C _r C ₄ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₄ -alkyl), CO-N(Ci-C ₄ -alkyl) ₂ or Ci-C ₄ - alkoxy,

is a hydrogen, halogen, amino, -S(O) _p -Ci-C ₆ -alkyl, where p is 0-2, a d-Cβ-acyl, NH-CO-NH ₂ , N H-CO-Ci -C ₆ -alkyl, -0-CO-NH(CrC ₆ - alkyl), -O-CO-N(Ci-C ₆ -alkyl) ₂ , or Ci-C ₆ -alkyl group which may optionally be substituted one or more times, identically or differently, by CrC ₆ -acyl, CrC ₆ -alkoxy, hydroxy, cyano, CO ₂ -(Cr Cβ-alkyl), N-(Ci-C ₆ -alkyl) ₂ , C ₅ -Ci ₂ -heteroaryl, COOH, CO-NH ₂ ,

CO-NH(Ci-C ₆ -alkyl) or by CO-N(Ci-C ₆ -alkyl) ₂ , a Ci-C ₆ -alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO ₂ -(CrC ₆ - alkyl), N-(Ci-C ₆ -alkyl) _2> NH-C ₃ -C ₆ -cycloalkyl, COOH, CO-NH ₂ , CO-NH(CrC ₆ -alkyl) or by CO-N(Ci-C ₆ -alkyl) ₂ , an O-C ₆ -Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2,

a CH ₂ O-C6-Ci2-aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , an O-Cs-Ciθ-heteroaryl, which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, a hydroxy, cyano, O-CO-(Ci-C ₆ -alkyl), CO-NH(C ₅ -Ci ₂ -heteroaryl),

NH-(Ci-C ₆ -alkyl), N-(Ci-C ₆ -alkyl) ₂ or a C6-Ci ₂ -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC ₆ -alkyl, C ₃ -C ₆ - cycloalkyl, Ci-C _θ -acyl, Ci-C ₆ -alkoxy, C ₆ -Ci ₂ -aryl, C ₅ -Ci ₂ -heteroaryl, hydroxy, CH ₂ -OH, cyano, CH ₂ -CN, amino, CO ₂ -(Ci-C ₆ -alkyl),

N-(Ci-C ₆ -alkyl) ₂ , NHSO ₂ CH ₃ , SO ₂ NH ₂ , SO ₂ NH(Ci-C ₆ -alkyl),

SO ₂ N(Ci-C ₆ -alkyl) _2> COOH, CO-NH ₂ , CO-N H(C ₁ -C ₆ -alkyl), CO-

N(Ci-C ₆ -alkyl) ₂ , CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-CO(Ci-C ₆ -alkyl),

CH ₂ -NH-CO(Ci-C ₆ -alkyl), NH-CO(C ₅ -Ci ₂ -heteroaryl), CH ₂ -NH- CO(C ₅ -Ci ₂ -heteroaryl), styryl, or an -S(O) _n -CH ₃ , where r is 0-2, or two adjacent positions may be substituted by -0-CH ₂ -O- or

-O-C(CH ₃ ) ₂ -O-, a monocyclic Cs-Cz-heteroaryl which may optionally be substituted one or more times, identically or differently, by Ci-C ₆ -alkyl, if R ² is cyano or if R ¹ and/or R ² is identically or differently a CrC ₆ -alkyl radical, where at least one of the radicals is substituted at least once by halogen, a monocyclic Cs-Cz-heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, by CF ₃ , Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, hydroxy, CH ₂ -OH, cyano, CO ₂ -(Ci-C ₆ - alkyl), N-(Ci-C ₆ -alkyl) _2> COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl) or

CO-N(Ci-C ₆ -alkyl) _2, or a bi- or tricyclic C ₈ -Ci ₂ -heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C ₆ -alkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, hydroxy, cyano, CO ₂ -(Ci-

Cβ-alkyl), N-(Ci-C ₆ -alkyl) _2> COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl) or

CO-N(Ci-C ₆ -alkyl) ₂ , or

a C3-C6-cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by d-Cβ-alkyl, hydroxy, cyano, CO ₂ -(Ci-C ₆ -alkyl), Ci-C ₆ -acyl, N-(Ci-C ₆ -alkyl) ₂ , COOH, CO- NH ₂ , CO-NH(Ci-C ₆ -alkyl), CO-N(C _r C ₆ -alkyl) ₂ or Ci-C ₆ -alkoxy,

R ³ and R ⁴ are either in ortho,meta position or meta,para position relative to one another and together have the meaning -O-CO-S-, -S-CO-O-, CH ₂ -CO-O-, 0-CO-CH ₂ -, -CH ₂ -CO-NH-, -NH-CO-CH ₂ -, -O-CO-NH- , -NH-CO-O-, -CO-CH ₂ -(CH ₂ ) _m -, -CH ₂ -(CH ₂ ) _m -CO-, -O-(CH ₂ ) _m -O-, - O-C-(CH ₃ ) ₂ -O-, -CH ₂ -(CH ₂ ) _m -CH ₂ -, where m is 1-3,

Y is a -(CH ₂ ) _n - group, where n is 1 -3,

and the isomers, diastereomers, enantiomers and salts thereof, and cyclodexthn clathrates.

Preference is likewise given to those compounds of the general formula (I), where

A is an aryl or heteroaryl radical which may optionally be substituted one or more times by R ⁴ and/or R ³ ,

R ¹ is a hydrogen or a CrC ₆ -alkyl group which is substituted one or more times by halogen,

R ² is a hydrogen, halogen, cyano, an -S(O) _q -CH ₃ , where q is 0-2, a

CrC ₄ -alkoxy radical or CrC ₆ -alkyl group which is substituted one or more times by halogen,

R ³ is a hydrogen, halogen, amino, -S(O) _P -CH ₃ , where p is 0-2, an -S-CF ₃ , C _r C ₆ -acyl, NH-CO-NH ₂ , NH-CO-C _r C ₆ -alkyl, -0-C0- NHCH ₃ , -O-CO-N(CH ₃ ) ₂ or Ci-C _θ -alkyI group which may optionally

be substituted one or more times, identically or differently, by d- C ₄ -acyl, Ci-C ₄ -alkoxy, hydroxy, cyano, CO2-(Ci-C ₄ -alkyl), N-(Cr C ₄ -alkyl) ₂ , C5-C1 ₂ -heteroaryl, COOH, CO-NH ₂ , CO-NH(CrC ₄ -alkyl) or by CO-N(C _r C ₄ -alkyl) _2, a d-Cθ-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO ₂ -(CrC ₆ - alkyl), N-(Ci-C ₆ -alkyl) _2> NH-Ca-Cβ-cycloalkyl, COOH, CO-NH ₂ , CO- NH(Ci-C ₆ -alkyl) or by CO-N(C _r C ₆ -alkyl) _2, an O-C6-Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, a CH ₂ O-C6-Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, an O-C ₅ -Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , a hydroxy, cyano, O-CO-(CrC ₆ -alkyl), CO-NH(C ₅ -Ci ₂ -heteroaryl),

NH-(Ci-C ₆ -alkyl), N-(C _r C ₆ -alkyl) ₂ or a C6-Ci ₂ -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by d-Cβ-alkyl, C3-C3- cycloalkyl, d-Cs-acyl, d-Cβ-alkoxy, C ₆ -Ci ₂ -aryl, C ₅ -Ci ₂ -heteroaryl, hydroxy, CH ₂ -OH, cyano, CH ₂ -CN, amino, CO ₂ -(d-C ₆ -alkyl), N-

(CrC ₆ -alkyl) ₂ , NHSO ₂ CH ₃ , SO ₂ NH ₂ , SO ₂ NH(d-C ₆ -alkyl), SO ₂ N(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(d-C ₆ -alkyl), CO- N(Ci-C ₆ -alkyl) ₂ , CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-CO(d-C ₆ -alkyl), CH ₂ -NH-CO(d-C ₆ -alkyl), NH-CO(C ₅ -C ₁₂ -heteroaryl), CH ₂ -NH- CO(C ₅ -Ci ₂ -heteroaryl), styryl, or an -S(O) _n -CH ₃ , where r is 0-2, or two adjacent positions may be substituted by -0-CH ₂ -O- or -0-C(CHs) ₂ -O-, a monocyclic C ₅ -C ₇ -heteroaryl which may optionally be substituted one or more times, identically or differently, by d-Cs-alkyl, if R ² is cyano or if R ¹ and/or R ² is identically or differently a d-Cs-alkyl radical, where at least one of the radicals is substituted at least once by halogen, or if R ⁴ is -S(O) _p -d-C ₆ -alkyl, where p is 0-2, d-Cβ-acyl-, -O-CO-NH(CrC ₆ -alkyl), -O-CO-N(d-C ₆ -alkyl) _2>

C6-Ci2-aryloxy, Cs-Ciβ-heteroaryloxy, hydroxy, cyano or N-(CrCs- alkyl) _2> a monocyclic Cs-Cz-heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, by CF ₃ , Ci-C ₄ -acyl, Ci-C ₄ -alkoxy, hydroxy, CH ₂ -OH, cyano, CO ₂ -(CrC ₄ - alkyl), N-(Ci-C ₄ -alkyl) _2> COOH, CO-NH ₂ , CO-NH(Ci-C ₄ -alkyl) or

CO-N(Ci-C ₄ -alkyl) _2, or a bi- or tricyclic C ₈ -Ci ₂ -heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-Cθ-alkyl, Ci-Cθ-acyl, Ci-Cθ-alkoxy, hydroxy, cyano, CO ₂ -(Cr

Cβ-alkyl), N-(Ci-C ₆ -alkyl) _2> COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl) or

CO-N(Ci-C ₆ -alkyl) ₂ , or a C3-C6-cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C ₄ -alkyl, hydroxy, cyano, CO ₂ -(Ci-C ₄ -alkyl), Ci-C ₄ -acyl, N-(Ci-C ₄ -alkyl) ₂ ,

COOH, CO-NH ₂ , CO-NH(Ci-C ₄ -alkyl), CO-N(C _r C ₄ -alkyl) ₂ or C _r C ₄ - alkoxy,

is a hydrogen, halogen, amino, -S(O) _P -CH ₃ , where p is 0-2, an -S-CF ₃ , C _r C ₆ -acyl, NH-CO-NH ₂ , NH-CO-C _r C ₆ -alkyl, -0-C0-

NHCH ₃ , -O-CO-N(CH ₃ ) ₂ , or Ci-C ₆ -alkyl group which may optionally be substituted one or more times, identically or differently, by d- C ₄ -acyl, Ci-C ₄ -alkoxy, hydroxy, cyano, CO ₂ -(Ci -C ₄ -alkyl), N-(Cr C ₄ -alkyl) ₂ , C ₅ -Ci ₂ -heteroaryl, COOH, CO-NH ₂ , CO-NH(C _r C ₄ -alkyl) or by CO-N(CrC ₄ -alkyl) _2, a CrCβ-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO ₂ -(CrCs- alkyl), N-(C _r C ₆ -alkyl) ₂ , NH-C ₃ -C ₆ -cycloalkyl, COOH, CO-NH ₂ , CO- NH(CrC ₆ -alkyl) or by CO-N(Ci-C ₆ -alkyl) ₂ , an O-C6-Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, a CH ₂ O-C ₆ -Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ ,

an O-C5-Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , a hydroxy, cyano, O-CO-(d-C ₆ -alkyl), CO-NH(C ₅ -Ci ₂ -heteroaryl), N-(Ci-C ₆ -alkyl), N-(Ci-C ₆ -alkyl) ₂ or a C6-Ci2-aryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C ₆ -alkyl, C ₃ -C ₆ - cycloalkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, C ₆ -Ci ₂ -aryl, C ₅ -Ci ₂ -heteroaryl, hydroxy, CH ₂ -OH, cyano, CH ₂ -CN, amino, CO ₂ -(CrC ₆ -alkyl), N- (Ci-C ₆ -alkyl) ₂ , NHSO ₂ CH ₃ , SO ₂ NH ₂ , SO ₂ NH(Ci-C ₆ -alkyl), SO ₂ N(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl), CO-

N(Ci-C ₆ -alkyl) ₂ , CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-CO(Ci-C ₆ -alkyl), CH ₂ -NH-CO(CrC ₆ -alkyl), NH-CO(C ₅ -C ₁₂ -heteroaryl), CH ₂ -NH- CO(C ₅ -Ci ₂ -heteroaryl), styryl, or an -S(O) _n -CH ₃ , where r is 0-2, or two adjacent positions may be substituted by -0-CH ₂ -O- or -O-C(CH ₃ ) ₂ -O-, a monocyclic C ₅ -C ₇ -heteroaryl which may optionally be substituted one or more times, identically or differently, by d-C _θ -alkyl, if R ² is cyano or if R ¹ and/or R ² is identically or differently a C-i-Cβ-alkyl radical, where at least one of the radicals is substituted at least once by halogen, a monocyclic Cs-Ci ₂ -heteroaryl which may be substituted at least one or more times, identically or differently, by halogen, by CF ₃ , Ci-C ₄ -acyl, Ci-C ₄ -alkoxy, hydroxy, CH ₂ -OH, cyano, CO ₂ -(Ci-C ₄ - alkyl), N-(C _r C ₄ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(C _r C ₄ -alkyl) or CO-N(Ci-C ₄ -alkyl) _2, a bi- or tricyclic Cs-Ci ₂ -heteroaryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C ₆ -alkyl, Ci-C ₆ -acyl, CrC ₆ -alkoxy, hydroxy, cyano, CO ₂ -(Cr Cβ-alkyl), N-(Ci-C ₆ -alkyl) _2> COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl) or CO-N(Ci-C ₆ -alkyl) ₂ , or a C ₃ -C6-cycloalkyl which may optionally be substituted one or more times, identically or differently, by halogen, by CrC ₄ -alkyl, hydroxy, cyano, CO ₂ -(Ci-C ₄ -alkyl), Ci-C ₄ -acyl, N-(Ci-C ₄ -alkyl) ₂ ,

COOH, CO-NH ₂ , CO-NH(Ci-C ₄ -alkyl), CO-N(Ci-C ₄ -alkyl) ₂ or Ci-C ₄ - alkoxy,

R ³ and R ⁴ are either in ortho,meta position or meta,para position relative to one another and together have the meaning -O-CO-S-, -S-CO-O-,

CH ₂ -CO-O-, 0-CO-CH ₂ -, -CH ₂ -CO-NH-, -NH-CO-CH ₂ -, -O-CO-NH- , -NH-CO-O-, -CO-CH ₂ -(CH ₂ ) _m -, -CH ₂ -(CH ₂ ) _m -CO-, -O-(CH ₂ ) _m -O-, - 0-C-(CHs) ₂ -O-, -CH ₂ -(CH ₂ ) _m -CH ₂ -, where m is 1 -3,

Y is a -(CH ₂ )n- group, where n is 1 -3,

and the isomers, diastereomers, enantiomers and salts thereof, and cyclodextrin clathrates.

Preference is likewise given to those compounds of the general formula (I) where

A is a phenyl, naphthyl or heteroaryl radical which may optionally be substituted once or twice by R ³ and/or R ⁴ ,

R ¹ is a hydrogen or a d-Cβ-alkyl group which may be substituted one or more times by halogen,

R ² is a hydrogen, halogen, cyano, an -S(O) _q -CH ₃ , where q is 0-2, a Ci-C ₄ -alkoxy radical or Ci-C6-alkyl group,

R ³ is a hydrogen, halogen, amino, -S(O) _P -CH _3, where p is 0-2, an -S-CF ₃ , C _r C ₆ -acyl, NH-CO-NH ₂ , NH-CO-C _r C ₆ -alkyl, -O-CO- NHCH ₃ , -O-CO-N(CH ₃ ) ₂ , or Ci-C ₆ -alkyl group which may optionally be substituted once, twice, three, four or five times, identically or differently, by Ci-C ₄ -acyl, Ci-C ₄ -alkoxy, hydroxy, cyano, CO ₂ -(Ci- C ₄ -alkyl), N-(C _r C ₄ -alkyl) ₂ , C ₅ -Ci ₂ -heteroaryl, COOH, CO-NH ₂ , CO- NH(Ci-C ₄ -alkyl) or by CO-N(Ci-C ₄ -alkyl) _2,

a Ci-Cθ-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO ₂ -(Ci-C6- alkyl), N-(Ci-C ₆ -alkyl) _2> NH-Ca-Cβ-cycloalkyl, COOH, CO-NH ₂ , CO- NH(Ci-C ₆ -alkyl) or by CO-N(Ci-C ₆ -alkyl) ₂ , an O-C ₆ -Ci2-aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , a CH ₂ O-C ₆ -Ci2-aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, an O-C5-Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, a hydroxy, cyano, O-CO-(d-C ₆ -alkyl), CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-(CrC ₆ -alkyl), N-(CrC ₆ -alkyl) ₂ , a C6-Ci ₂ -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C ₆ -alkyl, C ₃ -C ₆ - cycloalkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, C ₆ -Ci ₂ -aryl, C ₅ -Ci ₂ -heteroaryl, hydroxy, CH ₂ -OH, cyano, CH ₂ -CN, amino, CO ₂ -(CrC ₆ -alkyl), N- (Ci-C ₆ -alkyl) ₂ , NHSO ₂ CH ₃ , SO ₂ NH ₂ , SO ₂ NH(Ci-C ₆ -alkyl), SO ₂ N(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl), CO- N(Ci-C ₆ -alkyl) ₂ , CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-CO(Ci-C ₆ -alkyl), CH ₂ -NH-CO(CrC ₆ -alkyl), NH-CO(C ₅ -C ₁₂ -heteroaryl), CH ₂ -NH-

CO(C ₅ -Ci ₂ -heteroaryl), styryl, or an -S(O) _n -CH ₃ , where r is 0-2, or two adjacent positions may be substituted by -0-CH ₂ -O- or

-O-C(CH ₃ )2-O-, a monocyclic C ₅ -C ₇ -heteroaryl which may optionally be substituted one or more times, identically or differently, by C-i-Cβ-alkyl, if R ² is cyano or if R ¹ and/or R ² is identically or differently a Ci-C ₄ -alkyl radical, where at least one of the radicals is substituted at least once by halogen, or if R ⁴ is -S(O) _p -CrC ₄ -alkyl, where p is 0-2, Ci-C ₄ -acyl-, -O-CO-NH(Ci-C ₄ -alkyl), -O-CO-N(Ci-C ₄ -alkyl) _2> C ₆ -Ci ₂ -aryloxy, C ₅ -Ci ₆ -heteroaryloxy, hydroxy, cyano or N-(CrC ₄ - alkyl) _2> a monocyclic C ₅ -C ₇ -heteroaryl which may be substituted at least once or else twice, three, four or five times, identically or

differently, by halogen, by CF ₃ , Ci-C ₄ -acyl, Ci-C ₄ -alkoxy, hydroxy, CH ₂ -OH, cyano, CO ₂ -(Ci -C ₄ -alkyl), N-(Ci-C ₄ -alkyl) _2> COOH, CO- NH ₂ , CO-NH(Ci-C ₄ -alkyl) or CO-N(Ci-C ₄ -alkyl) ₂ , or a bi- or tricyclic C ₈ -Ci ₂ -heteroaryl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by Ci-C ₆ -alkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, hydroxy, cyano, CO ₂ -(Ci-C ₆ -alkyl), N-(Ci-C ₆ -alkyl) ₂ , COOH, CO- NH ₂ , CO-NH(Ci-C ₆ -alkyl) or CO-N(Ci-C ₆ -alkyl) _2> a C3-C6-cycloalkyl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by Cr

C ₄ -alkyl, hydroxy, cyano, CO ₂ -(Ci-C ₄ -alkyl), Ci-C ₄ -acyl, N-(CrC ₄ - alkyl) _2> COOH, CO-NH ₂ , CO-NH(CrC ₄ -alkyl), CO-N(C _r C ₄ -alkyl) ₂ or CrC ₄ -alkoxy,

is a hydrogen, halogen, amino, -S(O) _P -CH ₃ , where p is 0-2, an -S-CF ₃ , C _r C ₆ -acyl, NH-CO-NH ₂ , NH-CO-C _r C ₆ -alkyl, -0-C0- NHCH ₃ , -O-CO-N(CH ₃ ) ₂ , or d-Cβ-alkyl group which may optionally be substituted once, twice, three, four or five times, identically or differently, by CrC ₄ -acyl, CrC ₄ -alkoxy, hydroxy, cyano, CO ₂ -(Cr C ₄ -alkyl), N-(C _r C ₄ -alkyl) ₂ , C ₅ -Ci ₂ -heteroaryl, COOH, CO-NH ₂ , CO-

NH(CrC ₄ -alkyl) or by CO-N(Ci-C ₄ -alkyl) ₂ , a d-Cθ-alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO ₂ -(CrC ₆ - alkyl), N-(C _r C ₆ -alkyl) ₂ , NH-C ₃ -C ₆ -cycloalkyl, COOH, CO-NH ₂ , CO- NH(CrC ₆ -alkyl) or by CO-N(Ci-C ₆ -alkyl) ₂ , an O-C6-Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, a CH ₂ O-C ₆ -Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , an O-C ₅ -Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , a hydroxy, cyano, O-CO-(C _r C ₆ -alkyl), CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-(CrC ₆ -alkyl), N-(CrC ₆ -alkyl) ₂ ,

a C6-Ci2-aryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrCβ-alkyl, C3-C6- cycloalkyl, CrCβ-acyl, d-Cβ-alkoxy, C6-Ci2-aryl, C5-Ci2-heteroaryl, hydroxy, CH ₂ -OH, cyano, CH ₂ -CN, amino, CO ₂ -(C _r C ₆ -alkyl), N- (Ci-C ₆ -alkyl) ₂ , NHSO ₂ CH ₃ , SO ₂ NH ₂ , SO ₂ NH(Ci-C ₆ -alkyl),

SO ₂ N(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl), CO- N(Ci-C ₆ -alkyl) ₂ , CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-CO(Ci-C ₆ -alkyl), CH ₂ -NH-CO(CrC ₆ -alkyl), NH-CO(C ₅ -C ₁₂ -heteroaryl), CH ₂ -NH- CO(C ₅ -Ci ₂ -heteroaryl), styryl, or an -S(O) _n -CH ₃ , where r is 0-2, or two adjacent positions may be substituted by -0-CH ₂ -O- or

-0-C(CHs) ₂ -O-, a monocyclic C ₅ -C ₇ -heteroaryl which may optionally be substituted one or more times, identically or differently, by C-i-Cβ-alkyl, if R ² is cyano or if R ¹ and/or R ² is identically or differently a Ci-C ₄ -alkyl radical, where at least one of the radicals is substituted at least once by halogen, a monocyclic C ₅ -C ₇ -heteroaryl which may be substituted at least once or else twice, three, four or five times, identically or differently, by halogen, by CF ₃ , Ci-C ₄ -acyl, Ci-C ₄ -alkoxy, hydroxy, CH ₂ -OH, cyano, CO ₂ -(C ₁ -C ₄ -alkyl), N-(C _r C ₄ -alkyl) ₂ , COOH, CO-

NH ₂ , CO-NH(Ci-C ₄ -alkyl) or CO-N(Ci-C ₄ -alkyl) _2, a bi- or tricyclic Cs-Ci ₂ -heteroaryl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by CrC ₆ -alkyl, C _r C ₆ -acyl, C _r C ₆ -alkoxy, hydroxy, cyano, CO ₂ -(Ci-C ₆ -alkyl), N-(Ci-C ₆ -alkyl) ₂ , COOH, CO-

NH ₂ , CO-NH(Ci-C ₆ -alkyl) or CO-N(Ci-C ₆ -alkyl) ₂ , a C ₃ -C6-cycloalkyl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by Cr C ₄ -alkyl, hydroxy, cyano, CO ₂ -(Ci-C ₄ -alkyl), Ci-C ₄ -acyl, N-(CrC ₄ - alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(CrC ₄ -alkyl), CO-N(Ci-C ₄ -alkyl) ₂ or CrC ₄ -alkoxy,

R ³ and R ⁴ are either in ortho,meta position or meta,para position relative to one another and together have the meaning of -O-CO-S-, -S-CO-O-, CH ₂ -CO-O-, 0-CO-CH ₂ -, -CH ₂ -CO-NH-, -NH-CO-CH ₂ -, -O-CO-NH-, -NH-CO-O-, -CO-CH ₂ -(CH ₂ ) _m -, -CH ₂ - (CH ₂ Jm-CO-, -0-(CH ₂ )m-0-, -0-C-(CHs) ₂ -O-, -CH ₂ -(CH ₂ ) _m -CH ₂ -, where m is 1 -3,

Y is a -(CH ₂ ) _n - group, where n is 1 -3,

and the isomers, diastereomers, enantiomers and salts thereof, and cyclodextrin clathrates.

Preference is likewise given to those compounds of the general formula (I), where

A is a phenyl, naphthyl or heteroaryl radical which may optionally be substituted once or twice by R ³ and/or R ⁴ ,

R ¹ is a hydrogen or a d-Cβ-alkyl radical which is substituted one or more times by halogen,

R ² is a hydrogen, halogen, cyano, an -S(O) _q -CH ₃ , where q is 0-2, a

Ci-C ₄ -alkoxy radical or Ci-Cβ-alkyl radical which is substituted one or more times by halogen,

R ³ is a hydrogen, halogen, amino, -S(O) _P -CH _3, where p is 0-2, an -S-CF ₃ , Ci-C ₆ -acyl, NH-CO-NH ₂ , NH-CO-d-Cβ-alkyl, -0-C0- NHCH ₃ , -O-CO-N(CH ₃ ) ₂ , or d-C ₆ -alkyl group which may optionally be substituted once, twice, three, four or five times, identically or differently, by Ci-C ₄ -acyl, Ci-C ₄ -alkoxy, hydroxy, cyano, CO ₂ -(Ci-

C ₄ -alkyl), N-(Ci-C ₄ -alkyl) _2> C ₅ -Ci ₂ -heteroaryl, COOH, CO-NH ₂ , CO- NH(Ci -C ₄ -alkyl) or by CO-N(C _r C ₄ -alkyl) _2,

a Ci-C ₄ -alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO ₂ -(Ci-C ₄ - alkyl), N-(Ci-C ₄ -alkyl) ₂ , NH-Cs-Ce-cycloalkyl, COOH, CO-NH ₂ , CO- NH(C _r C ₄ -alkyl) or by CO-N(C _r C ₄ -alkyl) ₂ , an O-C ₆ -Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, a CH ₂ O-C ₆ -Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, an O-C5-Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, a hydroxy, cyano, O-CO-(Ci-C ₄ -alkyl), CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-(C _r C ₄ -alkyl), N-(C _r C ₄ -alkyl) ₂ or a C6-Ci ₂ -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C ₆ -alkyl, C ₃ -C ₆ - cycloalkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, C ₆ -Ci ₂ -aryl, C ₅ -Ci ₂ -heteroaryl, hydroxy, CH ₂ -OH, cyano, CH ₂ -CN, amino, CO ₂ -(CrC ₆ -alkyl), N- (Ci-C ₆ -alkyl) ₂ , NHSO ₂ CH ₃ , SO ₂ NH ₂ , SO ₂ NH(Ci-C ₆ -alkyl), SO ₂ N(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl), CO- N(Ci-C ₆ -alkyl) ₂ , CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-CO(Ci-C ₆ -alkyl), CH ₂ -NH-CO(CrC ₆ -alkyl), NH-CO(C ₅ -C ₁₂ -heteroaryl), CH ₂ -NH-

CO(C ₅ -Ci ₂ -heteroaryl), styryl, or an -S(O) _n -CH ₃ , where r is 0-2, or two adjacent positions may be substituted by -0-CH ₂ -O- or

-O-C(CH ₃ ) ₂ -O-, a monocyclic C ₅ -C ₇ -heteroaryl which may optionally be substituted one or more times, identically or differently, by d-C _θ -alkyl, if R ² is cyano or if R ¹ and/or R ² is identically or differently a Ci-C ₄ -alkyl radical, where at least one of the radicals is substituted at least once by halogen, or if R ⁴ is -S(O) _p -CrC ₄ -alkyl, where p is 0-2, Ci-C ₄ -acyl-, -O-CO-NH(Ci-C ₄ -alkyl), -O-CO-N(Ci-C ₄ -alkyl) ₂ , C ₆ - Ci ₂ -aryloxy, C ₅ -Ci ₆ -heteroaryloxy, hydroxy, cyano or N-(CrC ₄ - alkyl) ₂ , a monocyclic C ₅ -C ₇ -heteroaryl which may be substituted at least once or else twice, three, four or five times, identically or

differently, by halogen, by CF ₃ , Ci-C ₄ -acyl, Ci-C ₄ -alkoxy, hydroxy, CH ₂ -OH, cyano, CO ₂ -(Ci -C ₄ -alkyl), N-(Ci-C ₄ -alkyl) _2> COOH, CO- NH ₂ , CO-NH(Ci-C ₄ -alkyl) or CO-N(Ci-C ₄ -alkyl) ₂ , or a bi- or tricyclic C ₈ -Ci ₂ -heteroaryl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by Ci-C ₆ -alkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, hydroxy, cyano, CO ₂ -(Ci-C ₆ -alkyl), N-(Ci-C ₆ -alkyl) ₂ , COOH, CO- NH ₂ , CO-NH(Ci-C ₆ -alkyl) or CO-N(Ci-C ₆ -alkyl) _2> or a C3-C6-cycloalkyl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by Cr

C ₄ -alkyl, hydroxy, cyano, CO ₂ -(Ci-C ₄ -alkyl), Ci-C ₄ -acyl, N-(CrC ₄ - alkyl) _2> COOH, CO-NH ₂ , CO-NH(CrC ₄ -alkyl), CO-N(C _r C ₄ -alkyl) ₂ or CrC ₄ -alkoxy,

is a hydrogen, halogen, amino, -S(O) _P -CH ₃ , where p is 0-2, an -S-CF ₃ , C _r C ₆ -acyl, NH-CO-NH ₂ , NH-CO-C _r C ₆ -alkyl, -0-C0- NHCH ₃ , -O-CO-N(CH ₃ ) ₂ , or d-Cβ-alkyl group which may optionally be substituted once, twice, three, four or five times, identically or differently, by CrC ₄ -acyl, CrC ₄ -alkoxy, hydroxy, cyano, CO ₂ -(Cr C ₄ -alkyl), N-(C _r C ₄ -alkyl) ₂ , C ₅ -Ci ₂ -heteroaryl, COOH, CO-NH ₂ , CO-

NH(CrC ₄ -alkyl) or by CO-N(Ci-C ₄ -alkyl) ₂ , a Ci-C ₄ -alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO ₂ -(CrC ₄ - alkyl), N-(C _r C ₄ -alkyl) ₂ , NH-C ₃ -C ₆ -cycloalkyl, COOH, CO-NH ₂ , CO- NH(CrC ₄ -alkyl) or by CO-N(Ci-C ₄ -alkyl) ₂ , an O-C6-Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, a CH ₂ O-C ₆ -Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , an O-C ₅ -Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH ₂ , a hydroxy, cyano, O-CO-(C _r C ₄ -alkyl), CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-(CrC ₄ -alkyl), N-(Ci-C ₄ -alkyl) ₂ or

a C6-Ci2-aryl which may optionally be substituted one or more times, identically or differently, by halogen, by CrCβ-alkyl, C3-C6- cycloalkyl, Ci-C _θ -acyl, d-Cβ-alkoxy, C ₆ -Ci ₂ -aryl, C ₅ -Ci ₂ -heteroaryl, hydroxy, CH ₂ -OH, cyano, CH ₂ -CN, amino, CO ₂ -(C _r C ₆ -alkyl), N- (Ci-C ₆ -alkyl) ₂ , NHSO ₂ CH ₃ , SO ₂ NH ₂ , SO ₂ NH(Ci-C ₆ -alkyl),

SO ₂ N(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl), CO- N(Ci-C ₆ -alkyl) ₂ , CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-CO(Ci-C ₆ -alkyl), CH ₂ -NH-CO(CrC ₆ -alkyl), NH-CO(C ₅ -C ₁₂ -heteroaryl), CH ₂ -NH- CO(C ₅ -Ci ₂ -heteroaryl), styryl, or an -S(O) _n -CH ₃ , where r is 0-2, or two adjacent positions may be substituted by -0-CH ₂ -O- or

-0-C(CHs) ₂ -O-, a monocyclic C ₅ -C ₇ -heteroaryl which may optionally be substituted one or more times, identically or differently, by d-Cs-alkyl, if R ² is cyano or if R ¹ and/or R ² is identically or differently a Ci-C ₄ -alkyl radical, where at least one of the radicals is substituted at least once by halogen, a monocyclic Cs-C ₇ -heteroaryl which may be substituted at least once or else twice, three, four or five times, identically or differently, by halogen, by CF ₃ , Ci-C ₄ -acyl, Ci-C ₄ -alkoxy, hydroxy, CH ₂ -OH, cyano, CO ₂ -(C ₁ -C ₄ -alkyl), N-(C _r C ₄ -alkyl) ₂ , COOH, CO-

NH ₂ , CO-NH(Ci-C ₄ -alkyl) or CO-N(Ci-C ₄ -alkyl) ₂ , a bi- or tricyclic Cs-Ci ₂ -heteroaryl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by CrC ₆ -alkyl, C _r C ₆ -acyl, C _r C ₆ -alkoxy, hydroxy, cyano, CO ₂ -(Ci-C ₆ -alkyl), N-(Ci-C ₆ -alkyl) ₂ , COOH, CO-

NH ₂ , CO-NH(Ci-C ₆ -alkyl) or CO-N(Ci-C ₆ -alkyl) _2> a C ₃ -C6-cycloalkyl which may optionally be substituted once, twice, three, four or five times, identically or differently, by halogen, by Cr C ₄ -alkyl, hydroxy, cyano, CO ₂ -(CrC ₄ -alkyl), Ci-C ₄ -acyl, N-(CrC ₄ - alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₄ -alkyl), CO-N(CrC ₄ -alkyl) ₂ or CrC ₄ -alkoxy,

R ³ and R ⁴ are either in ortho,meta position or meta,para position relative to one another and together have the meaning of -O-CO-S-, -S-CO-O-, CH ₂ -CO-O-, 0-CO-CH ₂ -, -CH ₂ -CO-NH-, -NH-CO-CH ₂ -, -O-CO-NH-, -NH-CO-O-, -CO-CH ₂ -(CH ₂ ) _m -, -CH ₂ - (CH ₂ Jm-CO-, -0-(CH ₂ )m-0-, -0-C-(CHs) ₂ -O-, -CH ₂ -(CH ₂ ) _m -CH ₂ -, where m is 1 -3,

Y is a -(CH ₂ ) _n - group, where n is 1 -3,

and the isomers, diastereomers, enantiomers and salts thereof, and cyclodextrin clathrates.

Preference is likewise given to those compounds of the general formula (I) where

A is a phenyl, naphthyl or heteroaryl radical which may optionally be substituted once or twice by R ³ and/or R ⁴ ,

R ¹ is a hydrogen or a Ci-C ₄ -alkyl radical which is substituted once, twice or three times by chlorine, fluorine, or bromine,

R ² is a hydrogen, chlorine, fluorine, bromine, cyano, an OCH ₃ group or a Ci-C ₄ -alkyl radical which is substituted once, twice or three times by chlorine, fluorine or bromine,

R ³ is a hydrogen, halogen, amino, -S(O) _P -CH _3, where p is 0-2, an -S-CF ₃ , Ci-C ₆ -acyl, NH-CO-NH ₂ , NH-CO-d-Cβ-alkyl, -0-C0- NHCH ₃ , -O-CO-N(CH ₃ ) ₂ , or d-C ₆ -alkyl group which may optionally be substituted once or twice, identically or differently, by Ci-C ₄ - acyl, Ci-C ₄ -alkoxy, hydroxy, cyano, CO ₂ -(Ci -C ₄ -alkyl), N-(Ci-C ₄ - alkyl) ₂ , C ₅ -Ci ₂ -heteroaryl, COOH, CO-NH ₂ , CO-NH(Ci-C ₄ -alkyl) or by CO-N(Ci-C ₄ -alkyl) _2,

a Ci-C ₄ -alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO ₂ -(Ci-C ₄ - alkyl), N-(Ci-C ₄ -alkyl) ₂ , NH-Cs-Ce-cycloalkyl, COOH, CO-NH ₂ , CO- NH(C _r C ₄ -alkyl) or by CO-N(C _r C ₄ -alkyl) ₂ , an O-C ₆ -Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, a CH ₂ O-C ₆ -Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, an O-C5-Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, a hydroxy, cyano, O-CO-(Ci-C ₄ -alkyl), CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-(C _r C ₄ -alkyl), N-(C _r C ₄ -alkyl) ₂ , a C6-Ci ₂ -aryl which may optionally be substituted one or more times, identically or differently, by halogen, by Ci-C ₆ -alkyl, C ₃ -C ₆ - cycloalkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, C ₆ -Ci ₂ -aryl, C ₅ -Ci ₂ -heteroaryl, hydroxy, CH ₂ -OH, cyano, CH ₂ -CN, amino, CO ₂ -(CrC ₆ -alkyl), N-(Ci-C ₆ -alkyl) ₂ , NHSO ₂ CH ₃ , SO ₂ NH ₂ , SO ₂ NH(Ci-C ₆ -alkyl), SO ₂ N(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl), CO- N(Ci-C ₆ -alkyl) ₂ , CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-CO(Ci-C ₆ -alkyl), CH ₂ -NH-CO(CrC ₆ -alkyl), NH-CO(C ₅ -C ₁₂ -heteroaryl), CH ₂ -NH-

CO(C ₅ -Ci ₂ -heteroaryl), styryl, or an -S(O) _n -CH ₃ , where r is 0-2, or two adjacent positions may be substituted by -0-CH ₂ -O- or

-O-C(CH ₃ ) ₂ -O-, a monocyclic C ₅ -C ₇ -heteroaryl which may optionally be substituted one or more times, identically or differently, by d-C _θ -alkyl, if R ² is cyano or if R ¹ and/or R ² is a CF ₃ radical, or if R ⁴ is -S(O) _p -Ci-C6- alkyl, where p is 0-2, Ci-C ₄ -acyl-, -O-CO-NH(Ci-C ₄ -alkyl), -O-CO- N(Ci-C ₄ -alkyl) ₂ , C ₆ -Ci ₂ -aryloxy, C ₅ -Ci ₆ -heteroaryloxy, hydroxy, cyano or N-(Ci-C ₄ -alkyl) ₂ , a monocyclic C ₅ -C ₇ -heteroaryl which may be substituted at least once or twice, identically or differently, by halogen, by CF ₃ , Ci-C ₄ - acyl, Ci-C ₄ -alkoxy, hydroxy, CH ₂ -OH, cyano, CO ₂ -(Ci -C ₄ -alkyl), N-

(Ci-C ₄ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₄ -alkyl) or CO-N(Cr C ₄ -alkyl) ₂ , a bi- or tricyclic Cs-Ci ₂ -heteroaryl which may optionally be substituted once or twice, identically or differently, by halogen, by Ci-C ₆ -alkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, hydroxy, cyano, CO ₂ -(Ci-C ₆ - alkyl), N-(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl) or CO-N(Ci-C ₆ -alkyl) ₂ , or a C ₃ -C ₆ -cycloalkyl which may optionally be substituted once or twice, identically or differently, by halogen, by Ci-C ₄ -alkyl, hydroxy, cyano, CO ₂ -(Ci-C ₄ -alkyl), Ci-C ₄ -alkyl, N-(Ci-C ₄ -alkyl) ₂ ,

COOH, CO-NH ₂ , CO-NH(Ci-C ₄ -alkyl), CO-N(Ci-C ₄ -alkyl) ₂ or Ci-C ₄ - alkoxy,

is a hydrogen, halogen, amino, -S(O) _P -CH ₃ , where p is 0-2, an -S-CF ₃ , Ci-C ₆ -acyl, NH-CO-NH ₂ , NH-CO-Ci-C ₆ -alkyl, -O-CO-

NHCH ₃ , -O-CO-N(CH ₃ ) ₂ , or d-C ₆ -alkyl group which may optionally be substituted once or twice, identically or differently, by Ci-C ₄ - acyl, Ci-C ₄ -alkoxy, hydroxy, cyano, CO ₂ -(Ci -C ₄ -alkyl), N-(Ci-C ₄ - alkyl) ₂ , C ₅ -Ci ₂ -heteroaryl, COOH, CO-NH ₂ , CO-NH(Ci-C ₄ -alkyl) or by CO-N(C _r C ₄ -alkyl) _2, a Ci-C ₄ -alkoxy which may optionally be substituted one or more times, identically or differently, by hydroxy, cyano, CO ₂ -(Ci-C ₄ - alkyl), N-(Ci-C ₄ -alkyl) ₂ , NH-C ₃ -C ₆ -cycloalkyl, COOH, CO-NH ₂ , CO- NH(Ci-C ₄ -alkyl) or by CO-N(C _r C ₄ -alkyl) _2, an O-C6-Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, a CH ₂ O-C6-Ci ₂ -aryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, an O-C ₅ -Ci6-heteroaryl which may optionally be substituted by hydroxy, cyano, COOH or CO-NH _2, a hydroxy, cyano, O-CO-(Ci-C ₄ -alkyl), CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-(Ci-C ₄ -alkyl), N-(C _r C ₄ -alkyl) ₂ or

a C6-Ci2-aryl which may optionally be substituted one or more times, identically or differently, by halogen, by d-Cβ-alkyl, C ₃ -C ₆ - cycloalkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, C ₆ -Ci ₂ -aryl, C ₅ -Ci ₂ -heteroaryl, hydroxy, CH ₂ -OH, cyano, CH ₂ -CN, amino, CO ₂ -(C _r C ₆ -alkyl), N- (Ci-C ₆ -alkyl) ₂ , NHSO ₂ CH ₃ , SO ₂ NH ₂ , SO ₂ NH(Ci-C ₆ -alkyl),

SO ₂ N(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl), CO- N(Ci-C ₆ -alkyl) ₂ , CO-NH(C ₅ -Ci ₂ -heteroaryl), NH-CO(Ci-C ₆ -alkyl), CH ₂ -NH-CO(CrC ₆ -alkyl), NH-CO(C ₅ -C ₁₂ -heteroaryl), CH ₂ -NH- CO(C ₅ -Ci ₂ -heteroaryl), styryl, or an -S(O) _n -CH ₃ , where r is 0-2, or two adjacent positions may be substituted by -0-CH ₂ -O- or

-0-C(CHs) ₂ -O-, a monocyclic C ₅ -C ₇ -heteroaryl which may optionally be substituted one or more times, identically or differently, by Ci-C ₆ -alkyl, if R ² is cyano or if R ¹ and/or R ² is a CF ₃ radical, a monocyclic C ₅ -C ₇ -heteroaryl which may be substituted at least once or twice, identically or differently, by halogen, by CF ₃ , d-C ₄ - acyl, Ci-C ₄ -alkoxy, hydroxy, CH ₂ -OH, cyano, CO ₂ -(Ci -C ₄ -alkyl), N-(Ci-C ₄ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₄ -alkyl) or CO- N(Ci-C ₄ -alkyl) _2, or a bi- or tricyclic C ₈ -Ci ₂ -heteroaryl which may optionally be substituted once or twice, identically or differently, by halogen, by Ci-C ₆ -alkyl, Ci-C ₆ -acyl, Ci-C ₆ -alkoxy, hydroxy, cyano, CO ₂ -(Ci-C ₆ - alkyl), N-(Ci-C ₆ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₆ -alkyl) or CO-N(Ci-C ₆ -alkyl) ₂ , or a C ₃ -C6-cycloalkyl which may optionally be substituted once or twice, identically or differently, by halogen, by Ci-C ₄ -alkyl, hydroxy, cyano, CO ₂ -(Ci-C ₄ -alkyl), Ci-C ₄ -acyl, N-(Ci-C ₄ -alkyl) ₂ , COOH, CO-NH ₂ , CO-NH(Ci-C ₄ -alkyl), CO-N(C _r C ₄ -alkyl) ₂ or C _r C ₄ - alkoxy,

R ³ and R ⁴ are either in ortho,meta position or meta,para position relative to one another and together have the meaning of -O-CO-S-, -S-CO-O-, CH ₂ -CO-O-, 0-CO-CH ₂ -, -CH ₂ -CO-NH-,

-NH-CO-CH ₂ -, -O-CO-NH-, -NH-CO-O-, -CO-CH ₂ -(CH ₂ ) _m -, -CH ₂ - (CH ₂ ) _m -CO-, -O-(CH ₂ ) _m -O-, -0-C-(CHs) ₂ -O-, -CH ₂ -(CH ₂ ) _m -CH ₂ -, where m is 1 -3,

Y is a -(CH ₂ )n- group, where n is 1 -3,

and the isomers, diastereomers, enantiomers and salts thereof, and cyclodextrin clathrates.

The following compounds corresponding to the present invention are very particularly preferred:

1. biphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

2. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3,4,5-thmethoxybenzamide 3. 4-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide

4. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-methylbenzamide

5. 2-chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide

6. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-trifluoromethylbenzamide

7. 3-chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 8. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-methoxybenzamide

9. 4-chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide

10. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-methylbenzamide

11.4-tert-butyl-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 12. benzo[1 ,3]dioxole-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

I S.thiophene^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide 14. quinoxaline-6-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide 15.5-phenylpyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide 16.5-phenyl-1 H-pyrrole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide

17. N-[2-(4,7-difluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4-dimethoxybenzamide

18. (±)-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-methanesulfinyl- benzamide

19. N-[2-(7-fluoro-1 H-indol-3-yl)ethyl]-3,4-dimethoxybenzamide 20. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-[1 ,2,4]triazol-

1 -ylmethylbenzamide 21.thieno[2,3-b]pyrazine-6-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide

22. N-[2-(7-fluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4-dimethoxybenzamide 23. N-[2-(4-chloro-7-fluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4-dimethoxy- benzamide

24. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-nnethanesulfonylbenzannide 25. N-[2-(4-bromo-7-fluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4-dimethoxy- benzamide 26.1 H-benzotriazole-5-carboxylic acid [2-(4,7-difluoro-2-methyl-1 H-indol-

3-yl)ethyl]amide 27.1 H-indole-2-carboxylic acid [2-(4,7-difluoro-2-methyl-1 H-indol-

3-yl)ethyl]amide

28.4'-fluorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

29. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-N'-pyridin-3-yl- terephthalamide

30.4-amino-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 31.5-bromofuran-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

32. N-[2-(7-fluoro-2,4 dimethyl-1 H-indol-3-yl)ethyl]-isonicotinamide

33. N-[2-(7-fluoro-2,4 dimethyl-1 H-indol-3-yl)ethyl]benzamide

34.2-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl) ethyl]benzamide 35.3-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 36.1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- amide

37. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-6-methylnicotinamide 38. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-methoxybenzamide

39.4-ethoxy-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 40. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-hydroxy-3,5-dimethoxy- benzamide

41.1 H-benzotriazole-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

42. δ-methylthiophene^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide 43.1 H-pyrrole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide 44. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-methylanninobenzannide 45.thiophene-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- amide

46.6-cyano-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]nicotinannide 47.1 H-benzoinnidazole-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

48. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-trifluoromethylbenzamide 49. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-hydroxy-3-methoxy- benzamide

50.4-dimethylannino-N-[2-(7-fluoro-2,4-dinnethyl-1 H-indol-3-yl)ethyl]benzannide 51.4-cyano-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide

52. isoxazole-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- amide

53.4-acetyl-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 54.4-chloro-3-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 55.4-chloromethyl-N-[2-(7-fluoro-2,4-dinnethyl-1 H-indol-3-yl)ethyl]benzannide 56. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3,5-dimethylbenzamide 57.3,4-difluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 58. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-propylbenzamide 59. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-hydroxy-4-methyl- benzamide

60.2,3-difluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 61.3,5-difluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide

62. naphthalene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- amide θS.δ-chlorothiophene^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide 64.6-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]nicotinamide

65.3-chloromethyl-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 66.4-butoxy-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 67.4-acetoxy-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzannide 68. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-methylsulfanylbenzamide 69.4-cyano-2-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzannide

70. isoquinoline-1 -carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- amide

71. isoquinoline-1 -carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- amide 72. isoquinoline-1 -carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- amide

73.3,5-dichloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 74.quinoline-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 75.quinoline-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 76.4-hydroxy-2-phenyl-2H-pyrazole-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-

1 H-indol-3-yl)ethyl]amide 77. benzo[b]thiophene-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide

78. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-hydroxybenzamide 79. pyrazine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 80.furan-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 81.quinoline-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 82.2-chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]nicotinamide 83.4-benzyloxy-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 84.5-bromo-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]nicotinamide 85.1 H-indole-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- amide

86.3-bromothiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide 87.2-chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3,4-dimethoxy- benzamide 88.2-methylfuran-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]_ amide 89.1 H-imidazole-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- amide

90.4-oxo-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

91.4'-bromobiphenyl-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide

92.2-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-6-iodobenzamide 93.2,3-dihydrobenzofuran-7-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

94.3-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-methylbenzamide 95. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2,5-dimethylbenzamide θθ.δ-acetylthiophene^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide 97.quinoline-8-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]annide 98.2-phenyl-2H-pyrazole-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide θθ.θ-phenylpyrimidine^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide 100. i-methyl-HH-indole-S-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide

101. 2-pyridin-3-ylthiazole-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

102. 2,5-dimethyl-2H-pyrazole-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

103. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-phenoxymethyl- benzamide

104. 2,3-dihydrobenzofuran-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

105. 1 H-indole-6-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- amide 106. 2-bromo-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4,5-dimethoxy- benzamide

107. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-pyrrolidin-1 -ylbenzamide

108. quinoline-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- amide 109. δ-phenyl-I H-pyrazole^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

110. pyridazine-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- amide

111. 5-phenyl-2H-pyrazole-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

112. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-5-pyrrol-1 -ylnicotinamide

113. pyrinnidine-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- amide

114. benzo[b]thiophene-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

115. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-piperidin-1 -ylbenzamide

116. pyrazolo[1 ,5-a]pyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

117. quinoxaline-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

118. 3-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-methoxy- benzamide

119. 3-chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-methyl- benzamide 120. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-phenoxbenzamide 121. thiazole-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- amide

122. 2-chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-methyl- benzamide

123. 3-chloro-2-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- benzamide 124. 5-methoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

125. 5-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

126. 5-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

127. 4-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

128. 6-methoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 129. 4-methoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

130. 4-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

131. 7-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

132. 6-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

133. 6-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 134. 5-methoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]- amide

135. 1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]amide

136. 5-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]amide

137. 5-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]- amide

138. 6-methoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]- amide

139. 4-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]- amide

140. 4-dimethylannino-N-[2-(7-fluoro-1 H-indol-3-yl)ethyl]benzamide

141. N-[2-(7-fluoro-1 H-indol-3-yl)ethyl]-4-pyrrolidin-1 -ylbenzamide 142. I H-indole-G-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]amide

143. 4-methoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]- amide

144. 4-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]amide

145. 6-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]amide 146. 6-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]- amide

147. 7-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-1 H-indol-3-yl)ethyl]- amide

148. 5-bromo-2,3-dihydrobenzofuran-7-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

149. 4-(1 H-benzoimidazol-2-yl)-N-[2-(7-fluoro-1 H-indol-3-yl)ethyl]benzamide

150. 4-(1 H-benzoimidazol-2-yl)-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]benzamide

151. N-[2-(4-cyano-7-fluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4-dimethoxy- benzamide

152. [1 ,1 ';4',1 "]terphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

153. S'-methylbiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 154. 3'-fluoro-4'-methylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

155. 2'-fluoro-4'-methylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

156. 4'-hydroxymethylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

157. 4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-biphenyl- 4-carboxylic acid

158. 4'-tert-butylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

159. 4'-chlorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 160. S'^'.δ'-trimethoxybiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

161. S'-trifluoromethoxybiphenyM-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

162. 4'-trifluoromethoxybiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

163. 3'-hydroxybiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

164. 4'-methanesulfinylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 165. 3'-cyanomethylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

166. 2'-acetylaminobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

167. 3'-fluoro-4'-methoxybiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

168. 3'-chloro-4'-fluorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

169. 3',4'-difluorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 170. 3',5'-difluorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

171. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-(5-hydroxymethyl- thiophen-2-yl)-benzamide

172. S'-methanesulfonylbiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

173. 4-fluoro-4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- biphenyl-3-carboxylic acid

174. 4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-3-methoxy- biphenyl-4-carboxylic acid methyl ester

175. 5-fluoro-4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- biphenyl-3-carboxylic acid 176. 3-chlorobiphenyl-4,4'-dicarboxylic acid 4-amide 4'-{[2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide}

177. 3-chlorobiphenyl-4,4'-dicarboxylic acid 4'-{[2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide} 4-methylamide

178. S'-dimethylsulfamoylbiphenyM-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

179. biphenyl-3,4'-dicarboxylic acid 4'-{[2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide} 3-thiazol-2-ylamide

180. 4'-methylsulfamoylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 181. 4'-dimethylsulfamoylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

182. biphenyl-3,4'-dicarboxylic acid 3-diethylamide 4'-{[2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide}

183. biphenyl-4,4'-dicarboxylic acid 4-diethylamide 4'-{[2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide}

184. 4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]biphenyl- 3-carboxylic acid

185. biphenyl-4,4'-dicarboxylic acid 4-amide 4'-{[2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide} 186. S'-methylsulfamoylbiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

187. S'-trifluoromethylbiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

188. 4'-methylsulfanylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

189. 4'-acetylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

190. 3'-anninobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

191. S'-acetylbiphenyM-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 192. S'-fluorobiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

193. [1 ,1 ';3',1 "]terphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

194. S'-hydroxymethylbiphenyM-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

195. 4-benzo[b]thiophen-3-yl-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]benzamide

196. 4'-trifluoromethylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 197. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-((E)-styryl)benzamide

198. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-quinolin-6-ylbenzamide

199. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-(6-methoxypyridin-3-yl)- benzamide

200. biphenyl-3,4'-dicarboxylic acid 4'-{[2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide} 3-methylannide

201. biphenyl-4,4'-dicarboxylic acid 4'-{[2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide} 4-methylannide

202. 2'-fluorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 203. 2'-methylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

204. S'-acetylaminobiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

205. 4-benzo[1 ,3]dioxol-5-yl-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- benzamide

206. S'-cyanobiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

207. 4'-cyanomethylbiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

208. biphenyl-3,4'-dicarboxylic acid 3-amide 4'-{[2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide} 209. S'.δ'-dimethylbiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

210. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-quinolin-3-ylbenzamide

211. 4'-acetylaminobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 212. S'-fluoro-δ'-nnethoxybiphenyl^-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

213. δ-fluorobiphenyl-S^'-dicarboxylic acid 4'-{[2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide} 3-methylannide

214. 3'-(acetylaminonnethyl)biphenyl-4-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

215. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-(1 -methyl-1 H-indol- 5-yl)benzamide

216. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-(1 -methyl-1 H-indol- 2-yl)benzamide 217. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-5-pyrrol-1 -ylnicotinamide

218. N-[2-(4-cyano-7-fluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4-dimethoxy- benzamide

219. 5-benzyloxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 220. 5-hydroxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

221. 5-methoxybenzofuran-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

222. 6-hydroxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

223. N-[2-(7-fluoro-2-methyl-4-trifluoromethyl-1 H-indol-3-yl)ethyl]- 3,4-dimethoxybenzamide

224. SH-benzotriazole-δ-carboxylic acid [2-(7-fluoro-2-methyl-4-trifluoromethyl- 1 H-indol-3-yl)ethyl]amide

225. δ-fluoro-I H-indole^-carboxylic acid [2-(7-fluoro-2-methyl- 4-trifluoronnethyl-1 H-indol-3-yl)ethyl]annide 226. quinoxaline-6-carboxylic acid [2-(7-fluoro-2-methyl-4-trifluoromethyl-1 H- indol-3-yl)ethyl]amide

227. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}acetic acid methyl ester

228. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}butanoic acid ethyl ester

229. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}pentanoic acid ethyl ester

230. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}hexanoic acid ethyl ester 231. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}acetic acid methyl ester

232. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}butanoic acid ethyl ester

233. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}pentanoic acid ethyl ester

234. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}hexanoic acid ethyl ester

235. θ-bromopyridine^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 236. δ-fluoro-I H-indole^-carboxylic acid [2-(7-fluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide

237. 4-bromopyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

238. 6-bromo-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]nicotinamide 239. {3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]phenoxy}acetic acid methyl ester

240. 4-{3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}butanoic acid ethyl ester

241. 5-{3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}pentanoic acid ethyl ester

242. 2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}acetic acid 243. 4-{2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}butanoic acid

244. 5-{2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}pentanoic acid

245. 6-{3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}hexanoic acid ethyl ester

246. 5-{2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}pentanoic acid

247. 6-{2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 5-yloxy}hexanoic acid 248. 4-{2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}butanoic acid

249. 6-{2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}hexanoic acid

250. 4-{3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxyjbutanoic acid

251. {2-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]-1 H-indol- 6-yloxy}acetic acid

252. 4-{4-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}butanoic acid ethyl ester 253. 5-{4-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxyjpentanoic acid ethyl ester

254. 6-{4-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}hexanoic acid ethyl ester

255. 6-{3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}hexanoic acid

256. 4-{4-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}butanoic acid

257. 5-{4-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}pentanoic acid

258. 6-{4-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxyjhexanoic acid 259. 5-{3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- phenoxy}pentanoic acid

260. 2-bromo-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]isonicotinamide

261. {4-[2-(7-fluoro-2,4-dimethyl-1 H-indol-S-yOethylcarbamoyllphenoxyJacetic acid 262. 5-bromo-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

263. 6-bromc-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

264. δ-bronnopyπdine^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

265. 6-(3-carbamoylphenyl)pyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

266. 6-(3-methylcarbannoylphenyl)pyπdine-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 267. 6-(3-hydroxyphenyl)pyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

268. 4-(3-carbamoylphenyl)pyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

269. 4-(3-methylcarbannoylphenyl)pyπdine-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

270. 4-(3-hydroxyphenyl)pyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

271. 4-(4-methylcarbannoylphenyl)pyπdine-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 272. 5-chloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-

3-yl)ethyl]amide

273. benzofuran-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

274. 5-chloro-benzofuran-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

275. 4-bromo-3-fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- benzamide 276. 4-chloro-4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- biphenyl-3-carboxylic acid

277. {3-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbannoyl]phenoxy}acetic acid

278. 5-(3-carbamoylphenyl)pyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

279. 5-(3-methylcarbannoylphenyl)pyπdine-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

280. 5-(3-hydroxyphenyl)pyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 281. 6-(3-carbamoylphenyl)-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- nicotinamide

282. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-6-(3-methylcarbamoyl- phenyl)nicotinamide

283. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-6-(3-hydroxyphenyl)- nicotinamide

284. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-6-(4-methylcarbamoyl- phenyl)nicotinamide

285. 5-(3-carbamoylphenyl)-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- nicotinamide 286. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-5-(3-methylcarbamoyl- phenyl)nicotinamide

287. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-5-(3-hydroxyphenyl)- nicotinamide

288. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-5-(4-methylcarbamoyl- phenyl)nicotinamide

289. 2-(3-carbamoylphenyl)-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]- isonicotinamide

290. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-(3-methylcarbamoyl- phenyl)isonicotinamide

291. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-(3-hydroxyphenyl)- isonicotinamide 292. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-2-(4-methylcarbamoyl- phenyl)isonicotinamide

293. benzo[b]thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

294. quinoline-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

295. [1 ,8]naphthyridine-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

296. isoquinoline-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 297. 5-pyridin-2-yl-thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

298. 5-trifluoromethoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

299. 5-fluoro-1 H-indole-2-carboxylic acid [2-(4,7-difluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide

300. biphenyl-3,4'-dicarboxylic acid 4'-{[2-(4,7-difluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide} 3-methylannide

301. 6-(3-trifluoromethoxyphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 302. 5-(4-methylcarbannoylphenyl)pyπdine-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

303. 4'-methoxybiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

304. 4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- 3-methoxybiphenyl-4-carboxylic acid

305. 4'-methoxybiphenyl-3-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

306. 4-(4-methylcarbannoylphenyl)thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

307. 4-(3-methylcarbannoylphenyl)thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 308. 4-(3-methylcarbannoylphenyl)thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

309. 4-(3-hydroxyphenyl)thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

310. 4-(3-carbamoylphenyl)thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

311. 4-bromothiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

312. 2-fluorobiphenyl-4,4'-dicarboxylic acid 4-{[2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide} 4'-nnethylannide 313. 2'-fluorobiphenyl-3,4'-dicarboxylic acid 3-amide 4'-{[2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide}

314. 2-fluoro-3'-hydroxybiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

315. 2'-fluorobiphenyl-3,4'-dicarboxylic acid 4'-{[2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide} 3-methylannide

316. 5-(3-methylcarbannoylphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

317. 5-bromothiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 318. 3'-hydroxybiphenyl-4-carboxylic acid [2-(7-fluoiO-2-methyl-1 H-indol- 3-yl)ethyl]amide

319. biphenyl-4,4'-dicarboxylic acid 4'-{[2-(7-fluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide} 4-methylannide

320. 4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- S-hydroxybiphenyl^-carboxylic acid methyl ester

321. N-[2-(7-fluoro-2-methyl-1 H-indol-3-yl)ethyl]-6-(3-methylcarbamoylphenyl)- nicotinamide

322. biphenyl-3,4'-dicarboxylic acid 4'-{[2-(7-fluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide} 3-methylannide

323. 5-(3-carbamoylphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 324. 5-(3-hydroxyphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

325. 5-(4-methylcarbamoylphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

326. 5-(3-methylcarbannoylphenyl)thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

327. 5-(3-carbamoylphenyl)thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

328. 5-(3-hydroxyphenyl)thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 329. 5-(4-methylcarbannoylphenyl)thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

330. 6-(3-methylcarbamoylphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

331. 6-(3-carbamoylphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

332. 6-(3-hydroxyphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

333. 6-(4-methylcarbannoylphenyl)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 334. 3'-cyano-2'-fluorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

335. 5-chloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide

336. 5-chloro-1 H-indole-2-carboxylic acid [2-(4,7-difluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide

337. 5-chloro-1 H-indole-2-carboxylic acid [2-(4-chloro-7-fluoro-2-methyl-1 H- indol-3-yl)ethyl]amide

338. 5-trifluoromethyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

339. 6-methanesulfonyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide 340. 7-chloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

341. 4-chloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

342. 6-chloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

343. 7-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

344. 5-bromo-1 H-indole-2-carboxylic acid [2-(7-fluoro-4-methyl- 2-trifluoromethyl-1 H-indol-3-yl)ethyl]amide 345. 5-trifluoromethyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-4-methyl- 2-trifluoromethyl-1 H-indol-3-yl)ethyl]amide

346. 5-chloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-4-methyl- 2-trifluoromethyl-1 H-indol-3-yl)ethyl]amide

347. 5-trifluoromethoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-4-methyl- 2-trifluoromethyl-1 H-indol-3-yl)ethyl]amide

348. N-[2-(7-fluoro-4-methyl-2-trifluoromethyl-1 H-indol-3-yl)ethyl]- 3,4-dimethoxybenzamide

349. biphenyl-3,4'-dicarboxylic acid 4'-{[2-(4-chloro-7-fluoro-2-methyl-1 H-indol- 3-yl)ethyl]amide} 3-methylamide 350. 5-fluoro-1 H-indole-2-carboxylic acid [2-(4-chloro-7-fluoro-2-methyl-1 H- indol-3-yl)ethyl]amide

351. 5-trifluoromethoxy-1 H-indole-2-carboxylic acid [2-(4-chloro-7-fluoro- 2-methyl-1 H-indol-3-yl)ethyl]amide

352. 4'-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylcarbamoyl]- 3-hydroxybiphenyl-4-carboxylic acid

353. 4-bromo-N-[2-(4-fluoro-2,7-dimethyl-1 H-indol-3-yl)ethyl]benzamide

354. 4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

355. N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4-hydroxybenzamide

356. 3'-(2,5-dioxoimidazolidin-4-yl)biphenyl-4-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

357. 3-bromo-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide 358. 5-bromobenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

359. 6-bromobenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

360. 6-trifluoromethylbenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

361. 6-trifluoromethoxybenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

362. 5-trifluoromethoxybenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 363. benzothiazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

364. 5-chlorobenzothiazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

365. 6-chlorobenzothiazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

366. 5-fluorobenzothiazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

367. 6-fluorobenzothiazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 368. 5-trifluoromethylbenzothiazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

369. 6-trifluoromethylbenzothiazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

370. 5-trifluoromethoxybenzothiazole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

371. 6-trifluoromethoxybenzothiazole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

372. δ-bromobenzothiazole^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

373. θ-bromobenzothiazole^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 374. benzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

375. 5-chlorobenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

376. 6-chlorobenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

377. 5-fluorobenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

378. 6-fluorobenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 379. 5-trifluoromethylbenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

380. 6-trifluoromethylbenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

381. 5-trifluoromethoxybenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

382. 6-trifluoromethoxybenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

383. 5-bromobenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide 384. 6-bromobenzoxazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

385. I H-benzinnidazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

386. 5-chloro-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

387. 6-chloro-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

388. 5-fluoro-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

389. 6-fluoro-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 390. 5-trifluoromethyl-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

391. 6-trifluoromethyl-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

392. 5-trifluoromethoxy-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

393. 6-trifluoromethoxy-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

394. 5-bromo-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 395. 6-bromo-1 H-benzimidazole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

396. 5-trifluoromethylsulfanyl-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

397. 5,6-dichloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

398. 5-chloro-6-fluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

399. 5-fluoro-6-chloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 400. 5,6-difluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

401. 4,6-dichloro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

402. 4,6-difluoro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

403. 5-acetylamino-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

404. 6-acetylamino-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

405. 5-(2,2-dimethylpropionylannino)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 406. 6-(2,2-dimethylpropionylannino)-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

407. 5-trifluoroacetylamino-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

408. 6-trifluoroacetylamino-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

409. 5-isopropyloxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

410. 6-isopropyloxy-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide 411. 5-isopropyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

412. 6-trifluoromethyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

413. 4,5,6,7-tetrahydro-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

414. 3-methyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

415. 5-trifluoromethylbenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 416. 5-fluorobenzo[b]thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

417. 5-amino-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

418. 6-amino-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

419. 6-dimethylcarbamoylnnethoxy-i H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

420. 5-dimethylcarbannoylnnethoxy-i H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

421. 6-methylcarbamoylnnethoxy-i H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide 422. 5-methylcarbannoylnnethoxy-i H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

423. 6-carbamoylmethoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

424. 5-carbamoylmethoxy-1 H-indole-2-carboxylic acid [2-(7-fluoro- 2,4-dimethyl-1 H-indol-3-yl)ethyl]amide

425. 6-tert-butyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

426. 5-tert-butyl-1 H-indole-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol- 3-yl)ethyl]amide

The present invention relates to the use of the compounds of the invention for manufacturing medicaments which comprise at least one of the compounds of formula I.

The present invention likewise relates to medicaments which comprise the compounds of the invention with suitable formulating substances and carriers.

Compared with known prostaglandin E ₂ ligands, the novel EP ₂ agonists and antagonists are distinguished by greater selectivity and stability.

The present invention relates to medicaments for the treatment and prophylaxis of disorders which include fertility impairments, infectious disorders, cancer, viral infections, cardiovascular disorders, elevated intraocular pressure, glaucoma, skeletal system disorders, angiogenetic disorders, uterine contraction impairments, pain, neuroinflammatory disorders, immunomodulatory infections and nephrological disorders.

Fertility impairments mean the disorders which lead to no ovulation taking place, that no nidation of a fertilized oocyte occurs and no decidualization takes place, infectious disorders mean disorders caused by unicellular parasites, cancer means solid tumors and leukemia, viral infections mean for example cytomegalievirus infections, hepatitis, hepatitis B and C and HIV disorders, immunomodulatory infections mean for example avian influenza, cardiovascular disorders mean ischemic reperfusion disorder, stenoses, arterioscleroses and restenoses, angiogenetic disorders mean for example endometriosis and fibrosis, elevated intraocular pressure means glaucoma, uterine contraction impairments mean for example painful menstruation, skeletal system disorders mean osteoporosis, neuroinflammatory disorders mean multiple sclerosis, Alzheimer's disease, pain and nephrological disorders mean glomerulonephritis.

The present invention likewise relates to medicaments for the treatment and prophylaxis of the disorders detailed above, which comprise at least one compound of the general formula I, and medicaments with suitable formulating substances and carriers.

For the compounds of the invention to be used as medicaments they are brought into the form of a pharmaceutical product which, besides the active ingredient, comprises inert organic or inorganic pharmaceutical carrier materials which are suitable for enteral or parenteral administration, such as, for example, water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols etc. The pharmaceutical products may be in solid form, for example as tablets, coated tablets, suppositories, capsules, in semisolid form, for example as ointments, creams, gels, suppositiories, emulsions or in liquid form, for example as solutions, suspensions or emulsions.

They comprise where appropriate excipients which are intended to act for example as fillers, binders, disintegrants, lubricants, solvents, solubilizers, masking flavors, colorant, emulsifiers. Examples of types of excipients for the purpose of the invention are saccharides (mono-, di-, tri-, oligo-, and/or polysaccharides), fats, waxes, oils, hydrocarbons, anionic, nonionic, cationic

natural, synthetic or semisynthetic surfactants. They additionally comprise where appropriate excipients such as preservatives, stabilizers, wetting agents or emulsifiers; salts to modify the osmotic pressure or buffers. The present invention likewise relates to these pharmaceutical products.

It is expedient to produce aerosol solutions for inhalation.

Suitable for oral use are in particular tablets, coated tablets or capsules with talc and/or hydrocarbon carriers or binders, such as, for example, lactose, corn starch or potato starch. Use can also take place in liquid form, such as, for example, as solution to which, where appropriate, a sweetener is added. Clathrates are likewise also suitable for oral use of such compounds, examples of clathrates which may be mentioned being those with alpha-, beta-, gamma- cyclodextrin or else beta-hydroxypropylcyclodextrin.

Sterile, injectable, aqueous or oily solutions are used for parenteral administration. Particularly suitable are injection solutions or suspensions, especially aqueous solutions of active compounds in polyethoxylated castor oil.

Examples suitable and customary for vaginal administration are pessaries, tampons or intrauterine device.

Appropriately prepared crystal suspensions can be used for intraarticular injection.

It is possible to use for intramuscular injection aqueous and oily injection solutions or suspensions and appropriate depot preparations.

For rectal administration, the novel compounds can be used in the form of suppositories, capsules, solutions (e.g. in the form of enemas) and ointments both for systemic and for local therapy.

The novel compounds can be used in the form of aerosols and inhalations for pulmonary administration.

For local use on the eyes, external auditory canal, middle ear, nasal cavity and paranasal sinuses, the novel compounds can be used as drops, ointments and tinctures in appropriate pharmaceutical preparations.

Formulations possible for topical application are gels, ointments, fatty ointments, creams, pastes, dusting powders, milk and tinctures. The dosage of the compounds of the general formula I should in these preparations be 0.01 % - 20% in order to achieve an adequate pharmacological effect.

The dosage of the active ingredients may vary depending on the route of administration, age and weight of the patient, nature and severity of the disorder to be treated and similar factors. Treatment can take place by single dosages or by a large number of dosages over a prolonged period. The daily dose is 0.5 - 1000 mg, preferably 50 - 200 mg, it being possible to give the dose as a single dose to be administered once or divided into 2 or more daily doses.

Carrier systems which can be used are also surface-active excipients such as salts of bile acids or animal or vegetable phospholipids, but also mixtures thereof, and liposomes or constituents thereof.

The present invention likewise relates to the formulations and dosage forms described above.

Administration of the compounds of the invention can take place by any conventional method, including oral and parenteral, e.g. by subcutaneous or intramuscular injections. The present invention likewise relates to enteral, parenteral, vaginal and oral administrations.

The compounds of the invention of the general formula I bind to the EP ₂ receptor and have agonistic or antagonistic effect. It is possible to determine whether an agonistic or an antagonistic effect is present by an agonism test (see Example 1.2.1. of the Biological Examples) or by an antagonism test (see Example 1.2.2. of the Biological Examples).

Antagonists mean molecules which bind to their corresponding receptors and which inhibit the initiation of the signal transduction pathway(s) coupled to the receptor by the naturally occurring ligand(s). The antagonists normally compete with the naturally occurring ligand of the receptor for binding to the receptor. However, other modifications of the receptor are also possible by molecules which prevent the signal transduction pathways coupled to the receptor being activated by the naturally occurring ligand(s) (e.g. non-competitive, steric modifications of the receptor).

Receptor antagonists typically bind selectively to their particular receptor and not to other receptors. They normally have a higher binding affinity than the natural ligand. Although antagonists which have a higher affinity for the receptor than the natural ligand are preferred, it is likewise possible to employ antagonists having a lower affinity.

The antagonists preferably bind reversibly to their corresponding receptors.

The EP ₂ receptor antagonist has a preferred affinity for the EP ₂ receptor compared with any other EP receptor. The antagonism is measured in the presence of the natural agonist (PGE ₂ ).

Agonists mean molecules which bind to their corresponding receptors and normally compete with the naturally occurring ligand of the receptor for binding to the receptor, and which stimulate the initiation of the signal transduction pathway coupled to the receptor. Agonists may also assist the binding of the natural ligand.

Receptor agonists typically bind selectively to their particular receptor and not to other receptors. They normally have a higher binding affinity than the natural ligand. Although agonists which have a higher affinity for the receptor than the natural ligand are preferred, it is likewise possible to employ agonists having a lower affinity.

The agonists preferably bind reversibly to their corresponding receptors.

The EP ₂ receptor agonist has a preferred affinity for the EP ₂ receptor compared with any other EP receptor.

Agonists are tested via the initiation of the signal transduction and/or physiological effect mediated by the corresponding receptor. The compounds or low molecular weight substances which bind to a receptor are referred to as ligands. Their binding is normally reversible. Binding of a ligand to the corresponding receptor activates or inactivates the signal transduction pathway coupled to the receptor. The ligand mediates its intracellular effect in this manner. Ligands mean agonists and antagonists of a receptor.

The substance of Example 29 shows no inhibition in the cellular agonism test but a good activity (IC50 = 1.2 x 10 E-6 M) in the antagonism test. The present invention likewise relates to the use of the substances of the invention as EP ₂ receptor antagonists for the treatment of disorders which are caused by disturbances in the signal transduction chain in which the EP ₂ receptor is involved, such as, for example, pain and fertility impairments, and which are likewise suitable for controlling fertility.

The oocyte is surrounded in the preovulatory antral follicle by cumulus cells which form a dense ring of cells around the oocyte. After the lutenizing hormone peak (LH peak), a series of processes is activated and leads to a large morphological change in this ring of cells composed of cumulus cells. In this case, the cumulus cells form an extracellular matrix which leads to so-called cumulus expansion (Vanderhyden et al. Dev Biol. 1990 Aug;140(2):307-317).

This cumulus expansion is an important constituent of the ovulatory process and of the subsequent possibility of fertilization.

Prostaglandins, and here prostaglandin E ₂ , whose synthesis is induced by the LH peak, are of crucial importance in cumulus expansion. Prostanoid EP ₂ knockout mice (Hizaki et al.. Proc Natl Acad Sci U S A. 1999 Aug 31 ;96(18):10501 -6.) show a distinctly reduced cumulus expansion and severe subfertility, demonstrating the importance of the prostanoid EP ₂ receptor for this process.

The substances of the invention have inhibitory effects in cumulus expansion tests.

The present invention relates to the use of the substances of the invention for controlling fertility.

Whereas the EP ₂ receptor antagonist AH 6809 inhibits cumulus expansion by about only 30% and not until the concentration is 100 - 200 μM, an about 20% inhibition of cumulus expansion can be achieved in the presence of the substance of Example 29 even at a concentration which is 10-20 times lower (10 μM). In these experiments, the test substances compete with the natural EP ₂ receptor agonist PGE ₂ .

The present invention relates to the use of the substances of the invention for inhibiting cumulus expansion and thus ovulation and fertilization for contraception.

Prostaglandins play an important part in angiogenesis (Sales, Jabbour, 2003, Reproduction 126, 559 - 567; Kuwano et al., 2004, FASEB J. 18, 300-310; Kamiyama et al., 2006, Oncogene 25, 7019-7028; Chang et al. 2005, Prostaglandins & other Lipid Mediators 76, 48-58).

Endometriosis is a chronic disorder caused by impairments of blood vessels.

About 10% of women regularly suffer from heavy bleeding during menstruation, caused by changes in the blood vessels of the endometrium. In addition,

structural differences in the blood vessels have been observed, such as, for example, incomplete formation of the smooth muscle cell layer (Abberton et al., 1999, Hum. Reprod. 14, 1072-1079). Since the blood loss during menstruation is partly controlled by constriction of the blood vessels, it is obvious that the defects in the smooth muscles make a substantial contribution to the bleeding.

The present invention relates to the use of the substances of the general formula I for treating endometriosis.

Prostaglandins play an important part in uterine contraction, and excessively strong contractions are responsible for painful menstruation (Sales, Jabbour, 2003, Reproduction 126, 559 - 567).

The present invention relates to the use of the substances of the general formula I for the treatment of painful menstruation.

Increasing research results also demonstrate the importance of EP receptors, and especially of the EP ₂ receptor, in a large number of types of cancer (e.g. breast cancer, colon carcinoma, lung cancer, prostate cancer, leukemia, skin cancer), suggesting future possibilities of employing modulators (antagonists or agonists) of the EP2 receptor for the therapy and prevention (prophylactic and/or adjuvant) of cancer (Fulton et al. Cancer Res 2006; 66(20): 9794-7; Castellone et al. Science VOL 310 2005, 1504-1510; Chang et al. Cancer Res 2005; 65(11 ): 4496-9); Hull et al. MoI Cancer Ther 2004;3(8):1031-9; Richards et al. J Clin Endocrinol Metab 88: 2810-2816, 2003; Sinha et al. 2007, Cancer Res; 67(9):4507-13; Wang et al. 2004, Seminars in Oncology, VoI 31 , No 1 , Suppl 3: pp 64-73).

The present invention relates to the use of the substances of the general formula I for the treatment and prevention of cancers.

Prostaglandins also play an important part in processes counteracting osteoporosis. The present invention therefore relates to the use of the substances of the invention for the treatment of osteoporosis.

Reinold et al. (J. Clin. Invest. 115, 673-679 (2005)) describes PGE ₂ receptors of the EP ₂ subtype as the key signaling elements in inflammatory hyperalgesia. Mice no longer having this receptor (EP ₂ ^" ' ^" ) do not experience spinal inflammatory pain. There is evidence that an inflammatory, increased pain sensitivity can be treated by targeted modulation of EP ₂ receptors.

The present invention relates to the use of the substances of the invention for the treatment of inflammatory hyperalgesia.

The invention additionally relates to a process for preparing the compounds of the invention of the general formula I, which comprises reacting a compound of the formula Il

in which R ¹ , R ² and Y have the meanings indicated above, with a carboxylic acid derivative of the general formula III

in which A, R ³ and R ⁴ have the meanings indicated above, and R ⁵ may be a hydroxy group, a chlorine or bromine atom or a Ci-C6-alkyl radical, with preference for hydrogen, chlorine, the methyl or ethyl radical, by methods known to the skilled worker, and subsequently eliminating protective groups required where appropriate.

In the case where R ⁵ is a hydroxy group, the reaction can initially take place by activating the acid function, and in this case for example the carboxylic acid of the formula III is initially converted in the presence of a tertiary amine such as, for example, triethylamine with isobutyl chloroformate into the mixed anhydride. Reaction of the mixed anhydride with the alkali metal salt of the appropriate amine takes place in an inert solvent or solvent mixture such as, for example, tetrahydrofuran, dimethoxyethane, dimethylformamide, hexamethylphosphohc triamide, at temperatures between -30 ⁰ C and + 60 ⁰ C, preferably at 0°C to 30 ⁰ C.

A further possibility is to activate the carboxylic acid by reagents such as, for example, HOBt or HATU. Reaction of the acid takes place for example with HATU in an inert solvent such as, for example, DMF in the presence of the appropriate amine of the general formula III and a tertiary amine such as, for example, ethyldiisopropylamine at temperatures between -50 and +60°C, preferably at 0°C to 30 ⁰ C.

In the case where R ⁵ is Ci-C6-alkyl it is also possible for example to carry out a direct amidolysis of the ester with the appropriate amine, possibly with the assistance of thalkylaluminum reagents, preferably thmethylaluminum.

In the case where R ⁵ is a chlorine or bromine atom it is possible for example to carry out the reaction for example in pyridine or an inert solvent such as, for example, DMF in the presence of the appropriate amine of the general formula Il and a tertiary amine such as, for example, ethyldiisopropylamine at temperatures between -50 and +60°C, preferably at 0°C to 30 ⁰ C.

It is possible where appropriate for the compounds of the general formula (I) with R ² = CN also to be prepared starting from the corresponding halides, preferably bromine or chlorine, by a Cu- or Pd-catalyzed (e.g. Pd(OAc) ₂ ) cyanide introduction with Zn(CN) ₂ or else K ₃ [Fe(CN) ₆ ] in an inert solvent such as dimethylacetamide, dimethylformamide or N-methylpyrrolidone at temperatures between 60°C and the boiling point of the respective solvent.

It is possible where appropriate for the compounds of the general formula (I) with R ³ or R ⁴ = aryl or heteroaryl, which may where appropriate be substituted by the radicals indicated previously, to be prepared starting from an appropriate halide, preferably bromine or chlorine, by a Pd-catalyzed (e.g. Pd(OAc) ₂ , Pd(PPh ₃ ) ₄ , Pd ₂ (dba) ₃ , PdCI ₂ (dppf)) reaction in the presence of a base such as, for example, sodium carbonate, cesium carbonate, potassium phosphate or ethyldiisopropylamine with an appropriate aryl- or heteroarylboronic acid or boronic acid derivative in a solvent such as, for example, toluene, dioxane, dimethylacetamide, dimethylformamide or N-methylpyrrolidone at temperatures between 60 ⁰ C and the boiling point of the respective solvent.

The compounds of the general formula Il which serve as starting materials are either known or can be prepared for example by reacting in a manner known per se the known hydrazines IV, where appropriate prepared from the corresponding known anilines by nitrosation followed by a reduction,

in which R ² has the meaning indicated above,

a) with a ketone of the general formula V in which R ¹ and Y have the meaning indicated above, and n = 2 and 3, in a Fischer indole cyclization

or

b) with an enol ether of the general formula Vl in which R ¹ and Y have the meaning indicated above, and n = 2 and 3, in a Fischer indole cyclization (Org. Lett. 2004, 79ff),

and converting the subsequently obtained alcohol by methods known to the skilled worker by conversion into a leaving group such as tosylate, mesylate, trifluoromesylate, chloride, bromide or iodide and subsequent reaction with, for example, sodium azide followed by a hydrolysis with PPh ₃ /H ₂ O in tetrahydrofuran into the amino function,

or

c) with a keto ester of the general formula VII in the case of Y with n = 1

in which R ¹ has the meaning indicated above, and R ⁶ is a CrC ₆ -alkyl radical, in a Fischer indole cyclization, and subsequently reducing the resulting ester by methods known to the skilled worker such as, for example, diisobutylaluminum hydride in an inert solvent at temperatures between -50 and 25°C, preferably between -30 and 0 ⁰ C, to the corresponding alcohol which is in turn converted into the amino function by conversion into a leaving group such as tosylate, mesylate, trifluoromesylate, chloride, bromide or iodide and subsequent reaction with, for example, sodium azide, followed by a hydrolysis with PPh ₃ /H ₂ O in tetrahydrofuran.

It is possible where appropriate for the compounds of the general formula (I) with R ² = CN also to be prepared starting from the corresponding halides, preferably bromine or chlorine, by a Cu- or Pd-catalyzed (e.g. Pd(OAc) ₂ ) cyanide

introduction with Zn(CN) ₂ or else K ₃ [Fe(CN) ₆ ] in an inert solvent such as dimethylacetamide, dimethylformamide or N-methylpyrrolidone at temperatures between 60 ⁰ C and the boiling point of the respective solvent.

Preparation of the compounds of the invention

The following examples illustrate the preparation of the compounds of the invention of the general formula (I) without restricting the scope of the claimed compounds to these examples.

The compounds of the invention of the general formula (I) can be prepared as described below.

Example 1 : Biphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide

0.10 ml of thethylamine is added to a solution of 70.0 mg of 2-(7-fluoro-2,4- dimethyl-1 H-indol-3-yl)ethylamine hydrochloride in 2.1 ml of dimethylformamide, and the mixture is stirred at 25°C for 10 minutes. Then, at this temperature, 61.9 mg of biphenyl-4-carbonyl chloride are added, and the mixture is stirred at 25°C for a further 45 minutes. The reaction solution is then added to ice-water and extracted twice with ethyl acetate. The combined organic phases are washed twice with water, dried over sodium sulfate and, after filtration, concentrated in vacuo. The residue obtained in this way is purified by medium pressure chromatography on silica gel with hexane/0-100% ethyl acetate. 72 g of the title compound are obtained in this way.

NMR (300 MHz, DMSO-d6): δ = 2.30 (3H), 2.93 (3H), 2.98 (2H), 3.36 (2H), 6.54- 6.68 (2H), 7.37 (1 H), 7.46 (2H), 7.67-7.78 (4H), 7.92 (2H), 8..67 (1 H), 11.10 (1 H).

Example 2: N-[2-(7-Fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3,4,5- trimethoxybenzannide

34 mg of the title compound are obtained in analogy to Example 1 from 70.0 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 65.9 mg of 3,4,5-thmethoxybenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.30 (3H), 2.60 (3H), 2.95 (2H), 3.33 (2H), 3.67 (3H), 3.79 (6H), 6.54-6.67 (2H), 7.15 (2H), 8.55 (1 H), 11.11 (1 H).

Example 3: 4-Fluoro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide

87 mg of the title compound are obtained in analogy to Example 1 from 70.0 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 33.3 μl of 4-fluorobenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.28 (3H), 2.58 (3H), 2.95 (2H), 3.33 (2H), 6.53- 6.65 (2H), 7.26 (2H), 7.88 (2H), 8.63 (1 H), 11.10 (1 H).

Example 4: 4-Methyl-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide

41 mg of the title compound are obtained in analogy to Example 1 from 70.0 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 37.8 μl of 4-methylbenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.28 (3H), 2.32 (3H), 2.58 (3H), 2.94 (2H), 3.32 (2H), 6.53-6.65 (2H), 7.23 (2H), 7.72 (2H), 8.52 (1 H), 11.09 (1 H).

Example 5: 2-Chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide

89 mg of the title compound are obtained in analogy to Example 1 from 70.0 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 36.2 μl of 2-chlorobenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.32 (3H), 2.57 (3H), 2.96 (2H), 3.29 (2H), 6.53- 6.66 (2H), 7.32-7.43 (3H), 7.46 (1 H), 8.53 (1 H), 11.12 (1 H).

Example 6: N-[2-(7-Fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4- thfluoromethylbenzamide

96 mg of the title compound are obtained in analogy to Example 1 from 70.0 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 42.5 μl of 4-trifluoromethylbenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.28 (3H), 2.59 (3H), 2.97 (2H), 3.36 (2H), 6.53- 6.66 (2H), 7.82 (2H), 8.01 (2H), 8.85 (1 H), 11.11 (1 H).

Example 7: 3-Chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide

76 mg of the title compound are obtained in analogy to Example 1 from 70.0 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 36.7 μl of 3-chlorobenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.32 (3H), 2.63 (3H), 2.99 (2H), 3.37 (2H), 6.56- 6.71 (2H), 7.52 (1 H), 7.62 (1 H), 7.83 (1 H), 7.90 (1 H), 8.80 (1 H), 11.17 (1 H).

Example 8: N-[2-(7-Fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4- methoxybenzamide

78 mg of the title compound are obtained in analogy to Example 1 from 70.0 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 48.1 mg of 4-methoxybenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.27 (3H), 2.58 (3H), 2.93 (2H), 3.31 (2H), 3.77 (3H), 6.53-6.66 (2H), 6.95 (2H), 7.79 (2H), 8.47 (1 H), 11.11 (1 H).

Example 9: 4-Chloro-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide

39 mg of the title compound are obtained in analogy to Example 1 from 70.0 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 36.3 μl of 4-chlorobenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.27 (3H), 2.58 (3H), 2.94 (2H), 3.32 (2H), 6.53- 6.66 (2H), 7.51 (2H), 7.83 (2H), 8.72 (1 H), 11.12 (1 H).

Example 10: N-[2-(7-Fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3- methylbenzannide

68 mg of the title compound are obtained in analogy to Example 1 from 70.0 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 37.6 μl of 3-methylbenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.33 (3H), 2.37 (3H), 2.63 (3H), 2.99 (2H), 3.36 (2H), 6.54-6.72 (2H), 7.31 -7.40 (2H), 7.61 -7.71 (2H), 8.61 (1 H), 11.16 (1 H).

Example 11 : 4-tert-Butyl-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]benzamide

72 mg of the title compound are obtained in analogy to Example 1 from 70.0 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 52.4 μl of 4-tert-butylbenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 1.26 (9H), 2.28 (3H), 2.58 (3H), 2.94 (2H), 3.32 (2H), 6.52-6.67 (2H), 7.43 (2H), 7.74 (2H), 8.54 (1 H), 11.11 (1 H).

Example 12: Benzo[1 ,3]dioxole-5-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

172 mg of N-[(dimethylannino)-1 /-/-1 ,2,3-tπazolo[4,5-ib]pyπdin-1 -ylnnethylene]-λ/- methylnnethananniniunn hexafluorophosphate N-oxide (HATU) and 100 mg of 2- (7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylannine hydrochloride are added to a solution of 68.4 mg of benzo[1 ,3]dioxole-5-carboxylic acid in 3 ml of dimethylformamide. Then, at 0 ⁰ C, 0.15 ml of ethyldiisopropylamine is added dropwise, and the mixture is stirred at 25°C for 20 hours. Then 40 ml of a mixture of ice and cone, aqueous bicarbonate solution are added, and the mixture is extracted three times with ethyl acetate. The combined organic phases are washed once with saturated sodium chloride solution, dried over sodium sulfate and, after filtration, concentrated in vacuo. The residue obtained in this way is purified by medium pressure chromatography on silica gel with hexane/0-100% ethyl acetate. 122 mg of the title compound are obtained in this way.

NMR (300 MHz, DMSO-d6): δ = 2.27 (3H), 2.58 (3H), 2.92 (2H), 3.30 (2H), 6.06 (2H), 6.52-6.66 (2H), 6.95 (1 H), 7.34 (1 H), 7.41 (1 H), 8.47 (1 H), 11.11 (1 H).

Example 13: Thiophene-2-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide

92 mg of the title compound are obtained in analogy to Example 1 from 75.0 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 33.0 μl of 2-thiophenecarbonyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.27 (3H), 2.58 (3H), 2.93 (2H), 3.29 (2H), 6.53- 6.67 (2H), 7.11 (1 H), 7.68 (1 H), 7.70 (1 H), 8.64 (1 H), 11.13 (1 H).

Example 14:Quinoxaline-6-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H-indol-3- yl)ethyl]amide

67 mg of the title compound are obtained in analogy to Example 12 from 75.0 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 59.5 mg of quinoxaline-6-carboxylic acid.

NMR (300 MHz, DMSO-d6): δ = 2.30 (3H), 2.61 (3H), 3.01 (2H), 3.41 (2H), 6.54- 6.68 (2H), 8.15 (1 H), 8.26 (1 H), 8.57 (1 H), 9.00 (2H), 9.07 (1 H), 11.15 (1 H).

Example 15: δ-Phenylpyhdine^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

91 mg of the title compound are obtained in analogy to Example 12 from 100 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 90.3 mg of δ-phenylpyridine^-carboxylic acid.

NMR (300 MHz, DMSO-d6): δ = 2.27 (3H), 2.65 (3H), 2.81 (2H), 3.20 (2H), 6.50- 6.65 (2H), 7.28-7.39 (5H), 7.53 (1 H), 7.81 (1 H), 8.54 (1 H), 8.65 (1 H), 11.12 (1 H).

Example 16: δ-Phenyl-I H-pyrrole^-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

74 mg of the title compound are obtained in analogy to Example 12 from 100 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 84.8 mg of 5-phenyl-1 H-pyrrole-2-carboxylic acid.

NMR (300 MHz, DMSO-d6): δ = 2.30 (3H), 2.69 (3H), 2.95 (2H), 3.29(2H), 6.51 -

6.68 (2H), 6.77 (1 H), 7.17 (1 H), 7.32 (2H), 7.77 (2H), 7.91 (1 H) 8.23 (1 H), 11.13

(1 H).

Example 17 N-[2-(4,7-Difluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4- dimethoxybenzamide

60 mg of the title compound are obtained in analogy to Example 1 from 100 mg of 2-(4,7-difluoro-2-methyl-1 H-indol-3-yl)ethylamine and 143 mg of 3,4- dimethoxybenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.24 (3H), 2.88 (2H), 3.37(2H), 3.74 (3H), 3.76

(3H), 6.60 (1 H), 6.72 (1 H), 6.96 (1 H), 7.37 (1 H), 7.40 (1 H), 8.38 (1 H), 11.43

(1 H).

The starting material for the above title compound is prepared as follows:

17a) 2-(4,7-Difluoro-2-methyl-1 H-indol-3-yl)ethylamine

2.0 g of 2,5-difluorophenylhydrazine are dissolved in 45 ml of a mixture of ethanol and water in the ratio 14 : 1 at 120 ⁰ C. Then, when boiling, 1.59 ml of 5-chloro-2-pentanone dissolved in 2 ml of ethanol are added, and the mixture is stirred at this temperature for 16 hours. Cooling is followed by concentration in vacuo, and the resulting residue is purified by column chromatography on silica gel with methylene chlohde/0-20% methanol/0.5% triethylamine. 516 mg of the title compound are obtained in this way. NMR (300 MHz, DMSO-d6): δ = 2.31 (3H), 2.85 (4H), 6.61 (1 H), 6.74 (1 H), 11.56 (1 H).

Example 18 (±)-N-[2-(7-Fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4- methanesulfinylbenzamide

61 mg of the title compound are obtained in analogy to Example 12 from 100 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 83.5 mg of (±)-4-methanesulfinylbenzoic acid. NMR (300 MHz, DMSO-d6): δ = 2.28 (3H), 2.59 (3H), 2.75 (3H), 2.96 (2H), 3.34(2H), 6.52-6.68 (2H), 7.74 (2H), 7.98 (2H), 8.79 (1 H), 11.12 (1 H).

Example 19 N-[2-(7-Fluoro-1 H-indol-3-yl)ethyl]-3,4-dinnethoxybenzannide

128 mg of the title compound are obtained in analogy to Example 12 from 100 mg of 2-(7-fluoro-1 H-indol-3-yl)ethylamine and 113 mg of 3,4-dimethoxy- benzoic acid.

NMR (300 MHz, DMSO-d6): δ = 2.91 (2H), 3.49(2H), 3.76 (6H), 6.85 (1 H), 6.91 (1 H), 6.97 (1 H), 7.20 (1 H), 7.38 (1 H), 7.39 (1 H), 7.43 (1 H), 8.44 (1 H), 11.27 (1 H).

Example 20 N-[2-(7-Fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3-[1 ,2,4]triazol-1 - ylmethylbenzamide

52 mg of the title compound are obtained in analogy to Example 12 from 100 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 83.7 mg of 3-[1 ,2,4]triazol-1 -ylmethylbenzoic acid.

NMR (300 MHz, DMSO-d6): δ = 2.27 (3H), 2.65 (3H), 2.94 (2H), 3.32(2H), 5.44 (2H), 6.52-6.67 (2H), 7.34-7.47 (2H), 7.71 -7.78 (2H), 7.97 (1 H), 8.65 (1 H), 8.66 (1 H), 11.12 (1 H).

Example 21 Thieno[2,3-b]pyrazine-6-carboxylic acid [2-(7-fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]amide

55 mg of the title compound are obtained in analogy to Example 12 from 100 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 74.2 mg of thieno[2,3-b]pyrazine-6-carboxylic acid.

NMR (300 MHz, DMSO-d6): δ = 2.29 (3H), 2.59 (3H), 2.99 (2H), 3.39(2H), 6.53- 6.69 (2H), 8.20 (1 H), 8.68 (1 H), 8.79 (1 H), 9.20 (1 H), 1 1 .16 (1 H).

Example 22 N-[2-(7-Fluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4- dimethoxybenzamide

69 mg of the title compound are obtained in analogy to Example 1 from 79 mg of

2-(7-fluoro-2-methyl-1 H-indol-3-yl)ethylamine and 123 mg of 3,4-dimethoxy- benzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.28 (3H), 2.83 (2H), 3.35 (2H), 3.75 (3H), 3.76

(3H), 6.76 (1 H), 6.85 (1 H), 6.97 (1 H), 7.27 (1 H), 7.38 (1 H), 7.41 (1 H), 8.42 (1 H),

1 1 .13 (1 H).

Example 23 N-[2-(4-Bromo-7-fluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4- dimethoxybenzamide

38 mg of the title compound are obtained in analogy to Example 1 from 100 mg of 2-(4-bromo-7-fluoro-2-methyl-1 H-indol-3-yl)ethylamine and 111 mg of 3,4- dimethoxybenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.26 (3H), 3.06 (2H), 3.42 (2H), 3.75 (3H), 3.76 (3H), 6.74 (1 H), 6.96 (1 H), 7.04 (1 H), 7.38 (1 H), 7.42 (1 H), 8.38 (1 H), 11.54 (1 H).

The starting material for the above title compound is prepared as follows:

23a) 2-Fluoro-5-bromophenylhydrazine hydrochloride

A solution of 2.8 g of sodium nitrite in 14 ml of water is added dropwise over the course of 30 minutes to a solution of 7.59 g of 2-fluoro-5-bromoaniline in 25 ml of hydrochloric acid (37% strength) at 0 ⁰ C. Then, at 0 ⁰ C, a solution of 24.6 g of tin chloride in 21 ml of hydrochloric acid (37% strength) is added dropwise, and the mixture is stirred at this temperature for a further 1.5 hours. Addition of 60 ml of sodium hydroxide solution (50% strength) and 60 ml of ice-water (pH >10) is followed by dilution with 150 ml of water and extraction three times with 100 ml of ether each time. The combined organic phases are washed with half- saturated sodium chloride solution, dried over sodium sulfate. The filtrate is acidified with 20 ml of 4.0M HCI in 1 ,4-dioxane solution, and the resulting precipitate is then filtered off and dried. 8.28 g of the title compound are obtained in this way. NMR (300 MHz, DMSO-d6): δ = 7.10-7.18 (1 H), 7.21 (1 H), 7.40 (1 H), 8.59 (1 H), 10.44 (3H).

23b) 2-(4-Bromo-7-fluoro-2-methyl-1 H-indol-3-yl)ethylamine

3.7 g of the title compound are obtained in analogy to Example 17a from 8.0 g of hydrazine hydrochloride prepared in Example 23a) and 3.8 ml of 5-chloro-2- pentanone.

NMR (300 MHz, DMSO-d6): δ = 2.31 (3H), 2.67 (2H), 2.85 (2H), 6.71 (1 H), 7.00 (1 H), 11.55 (1 H).

Example 24 N-[2-(4-Chloro-7-fluoro-2-methyl-1 H-indol-3-yl)ethyl]-3,4- dimethoxybenzamide

88 mg of the title compound are obtained in analogy to Example 1 from 100 mg of 2-(4-chloro-7-fluoro-2-methyl-1 H-indol-3-yl)ethylamine and 133 mg of 3,4- dimethoxybenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.26 (3H), 3.04 (2H), 3.41 (2H), 3.75 (3H), 3.76 (3H), 6.78 (1 H), 6.87 (1 H), 6.96 (1 H), 7.38 (1 H), 7.42 (1 H), 8.39 (1 H), 11.54 (1 H).

The starting material for the above title compound is prepared as follows:

24a) 2-Fluoro-5-chlorophenylhydrazine hydrochloride

12.2 g of the title compound are obtained in analogy to Example 23a from 10 g of 2-fluoro-5-chloroaniline.

NMR (300 MHz, DMSO-d6): δ = 6.96 (1 H), 7.21 (1 H), 7.17-7.26 (2H), 8.57 (1 H), 10.42 (3H).

24b) 2-(4-Chloro-7-fluoro-2-methyl-1 H-indol-3-yl)ethylamine

4.7 g of the title compound are obtained in analogy to Example 17a from 12.2 g of the hydrazine hydrochloride prepared in Example 24a) and 7.1 ml of 5-chloro-

2-pentanone.

NMR (300 MHz, DMSO-d6): δ = 2.31 (3H), 2.70 (2H), 2.86 (2H), 6.76 (1 H), 6.85

(1 H), 11.53 (1 H).

Example 25 N-[2-(7-Fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-4- methanesulfonylbenzamide

88 mg of the title compound are obtained in analogy to Example 12 from 100 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 91 mg of 4-methanesulfonylbenzoic acid.

NMR (300 MHz, DMSO-d6): δ = 2.28 (3H), 2.59 (3H), 2.97 (2H), 3.24 (3H), 3.36 (2H), 6.53-6.67 (2H), 7.99 (2H), 8.04 (2H), 8.91 (1 H), 11.14 (1 H).

Example 26 I H-Benzotriazole-5-carboxylic acid [2-(4,7-difluoro-2-methyl-1 H- indol-3-yl)ethyl]amide

25 mg of the title compound are obtained in analogy to Example 12 from 50 mg of 2-(4,7-difluoro-2-methyl-1 H-indol-3-yl)ethylamine and 39 mg of 1 H- benzotriazole-5-carboxylic acid.

NMR (300 MHz, DMSO-d6): δ = 2.24 (3H), 2.93 (2H), 3.44 (2H), 6.60 (1 H), 6.72 (1 H), 7.88 (2H), 7.91 (1 H), 8.35 (1 H), 8.71 (1 H), 11.44 (1 H).

Example 27 I H-lndole-2-carboxylic acid [2-(4,7-difluoro-2-methyl-1 H-indol-3- yl)ethyl]amide

37 mg of the title compound are obtained in analogy to Example 12 from 50 mg of 2-(4,7-difluoro-2-methyl-1 H-indol-3-yl)ethylamine and 38 mg of 1 H-indole-2- carboxylic acid.

NMR (300 MHz, DMSO-d6): δ = 2.24 (3H), 2.91 (2H), 3.43 (2H), 6.60 (1 H), 6.72

(1 H), 6.98 (1 H), 7.01 (1 H), 7.12 (1 H), 7.37 (1 H), 7.55 (1 H), 8.51 (1 H), 11.42

(1 H), 11.49 (1 H).

Example 28 N-[2-(7-Fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-3,4- dimethoxybenzamide

750 mg of the title compound are obtained in analogy to Example 1 from 500 mg of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 413 mg of

3,4-dimethoxybenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.28 (3H), 2.59 (3H), 2.93 (2H), 3.31 (2H), 3.76

(3H), 3.77 (3H), 6.52-6.67 (2H), 6.98 (1 H), 7.40 (1 H), 7.44 (1 H), 8.49 (1 H), 11.12

(1 H).

Example 29 4'-Fluorobiphenyl-4-carboxylic acid [2-(7-fluoro-2,4-dimethyl-1 H- indol-3-yl)ethyl]amide

0.51 ml of a 1 molar sodium carbonate solution and 30.5 mg of tetrakisthphenylphosphinepalladium are added to a mixture of 100 mg of the bromide from Example 29a) and 54 mg of 4-fluorophenylboronic acid in 3 ml of a mixture of ethanol and toluene in the ratio 1 : 1. This suspension is heated in a microwave (CEM) at 120°C/100 W under nitrogen for 15 min. The reaction mixture is added to 50 ml of saturated sodium bicarbonate solution and extracted three times with 50 ml of ethyl acetate each time. The combined organic phases are washed once with 50 ml of saturated sodium chloride solution, dried over sodium sulfate and, after filtration, concentrated in vacuo. The crude product obtained in this way is purified by medium pressure chromatography on silica gel with hexane/0-100% ethyl acetate. 37.9 mg of the title compound are obtained in this way.

NMR (300 MHz, DMSO-d6): δ = 2.29 (3H), 2.60 (3H), 2.97 (2H), 3.35 (2H), 6.53- 6.68 (2H), 7.28 (2H), 7.69-7.79 (4H), 7.91 (2H), 8.69 (1 H), 11.13 (1 H).

The starting material for the above title compound is prepared as follows:

29a) 4-Bromo-N-[2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]benzamide

975 mg of the title compound are obtained in analogy to Example 1 from 1.0 g of 2-(7-fluoro-2,4-dimethyl-1 H-indol-3-yl)ethylamine hydrochloride and 895 mg of 4- bromobenzoyl chloride.

NMR (300 MHz, DMSO-d6): δ = 2.27 (3H), 2.58 (3H), 2.94 (2H), 3.31 (2H), 6.52- 6.67 (2H), 7.65 (2H), 7.76 (2H), 8.71 (1 H), 11.12 (1 H).

Example 30 N-[2-(7-Fluoro-2,4-dimethyl-1 H-indol-3-yl)ethyl]-N'-pyridin-3-yl- terephthalamide

46 mg of the title compound are obtained in analogy to Example 12 from 50 mg of 2-(4,7-difluoro-2-methyl-1 H-indol-3-yl)ethylamine and 57 mg of N-pyridin-3-yl- terephthalamic acid. NMR (300 MHz, DMSO-d6): δ = 2.34 (3H), 2.65 (3H), 3.02 (2H), 3.42 (2H), 6.58- 6.72 (2H), 6.88 (1 H), 7.42 (1 H), 8.01 (2H), 8.07 (2H), 8.21 (1 H), 8.34 (1 H), 8.87 (1 H), 8.95 (1 H), 10.57 (1 H).

Required starting materials for compounds in the table which follows:

A) 2-(7-fluoro-2-methyl-4-thfluoromethyl-1 H-indol-3-yl)ethylamine

A1 ) In analogy to example 17a), 7.07 g of 2-fluoro-5-trifluoromethylphenylamine affords 9.1 g of (2-fluoro-5-trifluoromethylphenyl)hydrazine hydrochloride.

A2) In analogy to example 23a), 1 g of the hydrazine prepared above, by heating in a microwave at 120 ⁰ C for one hour, affords 460 mg of 2-(7-fluoro- 2-methyl-4-thfluoromethyl-1 H-indol-3-yl)ethylamine.

NMR (300 MHz, DMSO-d6): δ = 2.46 (3H), 2.80 (2H), 3.03 (2H), 7.01 (1 H), 7.38 (1 H), 8.09 (2H), 12.14 (1 H).

B) 2-(7-fluoro-2-trifluoromethyl-4-nnethyl-1 H-indol-3-yl)ethylamine

B1 ) N-(2-fluoro-5-nnethylphenyl)-2-[(E)-hydroxyinnino]acetannide

To a solution at 100 ⁰ C of 36.4 g of chloral hydrate and 230 g of sodium sulfate in 780 ml of water is added a solution of 25 g of 2-fluoro-4-methyl-aniline, 17 ml of concentrated hydrochloric acid in 120 ml of water and a hot solution of hydroxylamine hydrochloride in 100 ml of water. This mixture is left to stand at 25°C for 5 hours and then the precipitate formed is filtered off. The solid is washed with cold water and dried under air. In this way, 38 g of N-(2-fluoro- 5-methylphenyl)-2-[(E)-hydroxyimino]acetamide are obtained as a slightly brownish solid. NMR (300 MHz, DMSO-d6): δ = 2.25 (3H), 7.00 (1 H), 7.05 (1 H), 7.67 (2H), 9.67 (1 H).

B2) 7-fluoro-4-methyl-1 H-indole-2,3-dione

To a mixture of 386 g of 98% sulfuric acid and 43 ml of water are slowly added 36 g of the compound prepared above. During the addition, the temperature of the reaction mixture is kept between 75 and 80 ⁰ C and, after the addition, it is stirred at 80 ⁰ C for 15 minutes. Subsequently, the reaction mixture is added to

2 liters of ice-water and the precipitate formed is filtered off. The solid is washed with cold water and dried under air. In this way, 28.2 g of the title compound are obtained as a dark red solid.

NMR (300 MHz, DMSO-d6): δ = 2.48 (3H), 6.82 (1 H), 7.35 (1 H), 11.43 (1 H).

B3) (2-amino-3-fluoro-6-methylphenyl)methanol

To a solution of 37.4 g of sodium hydroxide in 800 ml of water are added 27 g of the compound prepared above. To this mixture is added dropwise an aqueous H2O2 solution (prepared from 41.6 ml of 30% H2O2 solution and 360 ml of water), and the temperature is maintained between 25 and 30 ⁰ C during the dropwise addition. Subsequently, the mixture is stirred at 25°C for 16 hours, acidified to pH approx. 5 with 36% hydrochloric acid and then concentrated under reduced pressure. The crude product thus obtained (2-amino-3-fluoro- 6-methylbenzoic acid) is used further without additional purification. To a solution of 10 g of lithium aluminum hydride in 1 liter of tetrahydrofuran is slowly added, in portions of approx. 2 g, the acid prepared above at 10 to 15°C. After the complete addition, the reaction mixture is heated at reflux for 2 hours. After cooling, 10 ml of cold water are very cautiously added dropwise, followed by a solution of 3.3 g of sodium hydroxide in 10 ml of water. The mixture is heated at reflux and, after cooling, the precipitate formed is filtered off. The filtrate is concentrated under reduced pressure and the residue thus obtained is purified by column chromatography on silica gel with an eluent mixture of chloroform/methanol = 19:1. In this way, 9 g of the title compound are obtained as a white solid.

NMR (300 MHz, DMSO-d6): δ = 2.20 (3H), 4.45 (2H), 4.86 (3H), 6.46 (1 H), 6.82 (1 H).

B4) N-(6-fluoro-2-hydroxymethyl-3-methylphenyl)trifluoroacetamid e

To a solution of 1.O g of the aniline prepared above in 30 ml of methylene chloride are added dropwise 2.68 g of trifluoroacetic anhydride at 0°C with stirring. On completion of addition, the mixture is allowed to warm up to 25°C and is stirred at this temperature for 16 hours. The organic phase is then washed with 15% potassium carbonate solution, dried over sodium sulfate and, after filtration, concentrated under reduced pressure. The residue thus obtained is extracted with hot hexane and then the hexane phases are concentrated cautiously under reduced pressure. The trifluoroacetamide thus obtained is used in the next stage without further purification. NMR (300 MHz, DMSO-d6): δ = 2.33 (3H), 5.41 (2H), 7.37 (2H), 11.25 (1 H).

B5) 7-fluoro-4-methyl-2-trifluoromethyl-1 H-indole

A mixture of 1 g of the compound prepared above and 1.51 g of thphenylphosphine hydrobromide in 50 ml of acetonithle is heated under reflux for 17 hours. Subsequently, this mixture is concentrated under reduced pressure and washed with 50 ml of diethyl ether, and the residue is dried under air. In this way, 1.88 g of (2-trifluoroacetylamino-3-fluoro-

6-methylbenzyl)triphenylphosphonium bromide are obtained as a yellow solid which is used in the next stage without further purification.

A solution of 18.9 g of the phosphonium salt prepared above in 600 ml of DMF is heated under reflux for 20 hours. After cooling, the mixture is concentrated under reduced pressure and the residue thus obtained is purified by means of column chromatography on silica gel with hexane. In this way, 4.3 g of the title compound are obtained as a pale yellow oil.

NMR (300 MHz, DMSO-d6): δ = 2.45 (3H), 6.84 (1 H), 6.98 (1 H), 7.20 (1 H), 12.72 (1 H).

B6) (7-fluoro-4-methyl-2-tπfluoromethyl-1 H-indol-3-ylmethyl)dimethylamine

To a solution of 0.47 g of potassium carbonate in 7.5 ml of acetic acid are added, at -10 ⁰ C, 0.56 g of dimethylamine hydrochloride in 7.5 ml of dioxane, followed by 0.42 ml of 40% formaldehyde solution and 1 g of the indole prepared above in 7.5 ml of dioxane. Subsequently, this mixture is stirred at 25°C for 2 hours and then heated to 80 ⁰ C for a further 5 hours. After cooling, the reaction mixture is then concentrated under reduced pressure and added to 15% potassium carbonate solution. After extraction three times with 30 ml each time of ethyl acetate, the combined organic phases are dried over sodium sulfate. After filtration, the mixture is concentrated under reduced pressure and the residue thus obtained is purified by means of column chromatography on silica gel with 19:1 hexane/ethyl acetate. In this way, 0.5 g of the title compound is obtained as a white solid. NMR (300 MHz, DMSO-d6): δ = 2.18 (6H), 2.71 (3H), 3.58 (2H), 6.78 (1 H), 6.98 (1 H), 7.20 (1 H), 12.41 (1 H).

B7) (7-fluoro-4-methyl-2-trifluoromethyl-1 H-indol-3-yl)acetonitrile

To a solution of 0.51 g of the amine prepared above in 10 ml of DMF is added a solution of 1.24 g of potassium cyanide in 100 ml of water, and this mixture is heated under reflux for 2 hours. After cooling, the mixture is concentrated under reduced pressure and the residue thus obtained is purified by column chromatography on silica gel with 9:1 hexane/ethyl acetate. In this way, 0.22 g of the title compound is obtained as a white solid.

NMR (300 MHz, DMSO-d6): δ = 2.72 (3H), 4.30 (2H), 6.89 (1 H), 7.07 (1 H), 12.90 (1 H).

B8) 2-(7-fluoro-2-trifluoromethyl-4-methyl -1 H-indol-3-yl)ethylamine

To a solution of 1.8 g of the nitrile prepared above in 40 ml of ethanol are added, with stirring at 25°C, a solution of 3.49 g of cobalt diacetate tetrahydrate in 40 ml of ethanol, followed by 2.65 g of sodium borohydride, and then the mixture is stirred at this temperature for 17 hours. The mixture is then concentrated under reduced pressure and the residue thus obtained is purified by column chromatography on silica gel with chloroform/methanol/aq. NH ₃ in a ratio of

100:10:1. In this way, 1.37 g of the title compound are obtained as a gray-yellow solid.

NMR (300 MHz, DMSO-d6): δ = 2.63 (3H), 2.77 (2H), 3.00 (2H), 4.98 (2H), 6.76 (1 H), 6.95 (1 H), 12.90 (1 H).

The following examples are prepared in analogy to Example 1 or 29 and purified by HPLC:

HPLC-method:

Instrument: analytical 4-channel MUX system with CTC Pal injector, Waters 1525 pumps, Waters 2488 UV detector and Waters ZQ 2000 single quad MS detector.

Column X-Bridge RP C18 4.6x50 3.5μm; detection wavelength 214 nm; flow rate 2 ml/min; eluents A: 0.1 % TFA in H2O, B 0.1 % TFA in ACN; gradient based in each case on B: 1 % to 99% (5') to 99% (1 ') to 1 % (0.25') to 1 % (1.75')

or

in the case of the retention times below 2 minutes: detection: UV = 200 - 400 nm

(Waters Acquity HPLC)/ MS 100-800 Daltons; 20 V (Micromass / Waters ZQ 4000); column: X Bridge (Waters), 2.1 x 50 mm, BEH 1.7 μm; eluents: A:

H2O/0.05% HCOOH, B: CH3CN/0.05% HCOOH. Gradient: 10-90% B in 1.7 min, 90% B for 0.2 min, 98-2% B in 0.6 min; flow rate: 1.3 ml/min.

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

36 3-fluoro-N-[2-(7- 329 330 9.27 fluoro-2,4-dimethyl- 1 H-indol-3- yl)ethyl]benzamide

37 1 H-indole-2- 350 351 9.42 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

38 N-[2-(7-fluoro-2,4- 326 327 6.25 dimethyl-1 H-indol-3- yl)ethyl]-6-methyl- nicotinamide

39 N-[2-(7-fluoro-2,4- 341 342 9.15 dimethyl-1 H-indol-3- yl)ethyl]-3-methoxy- benzamide

40 4-ethoxy-N-[2-(7- 355 356 9.5 fluoro-2,4-dimethyl- 1 H-indol-3- yl)ethyl]benzamide

41 N-[2-(7-fluoro-2,4- 387 388 7.94 dimethyl-1 H-indol-3- yl)ethyl]-4-hydroxy-

3,5-dimethoxy- benzamide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

42 1 H-benzotriazole-5- 352 353 7.45 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

43 5-methylthiophene- 331 332 9.37 2-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

44 1 H-pyrrole-2- 300 301 8.25 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

45 N-[2-(7-fluoro-2,4- 340 341 8.24 dimethyl-1 H-indol-3- yl)ethyl]-2- methylamino- benzamide

46 thiophene-3- 317 318 8.84 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

47 6-cyano-N-[2-(7- 337 338 8.65 fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]- nicotinamide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

48 1 H-benzoimidazole- 351 352 6.28 5-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

49 N-[2-(7-fluoro-2,4- 379 380 9.94 dimethyl-1 H-indol-3- yl)ethyl]-3-trifluoro- methylbenzamide

50 N-[2-(7-fluoro-2,4- 357 358 8.02 dimethyl-1 H-indol-3- yl)ethyl]-4-hydroxy-

3-methoxy- benzamide

51 4-dimethylamino-N- 354 355 7.89 [2-(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]benzamide

52 4-cyano-N-[2-(7- 336 337 9.02 fluoro-2,4-dimethyl- 1 H-indol-3- yl)ethyl]benzamide

53 isoxazole-5- 302 303 8.17 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

54 4-acetyl-N-[2-(7- 353 354 8.75 fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]- benzamide

55 4-chloro-3-fluoro-N- 363 364 10.12 [2-(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]benzamide

56 4-chloromethyl-N-[2- 359 360 9.37 (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]benzamide

57 N-[2-(7-fluoro-2,4- 339 340 9.88 dimethyl-1 H-indol-3- yl)ethyl]-3,5- dimethylbenzamide

58 3,4-difluoro-N-[2-(7- 347 348 9.63 fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]- benzamide

59 N-[2-(7-fluoro-2,4- 353 354 10.44 dimethyl-1 H-indol-3- yl)ethyl]-4- propylbenzamide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

60 N-[2-(7-fluoro-2,4- 341 342 8.4 dimethyl-1 H-indol-3- yl)ethyl]-3-hydroxy- 4-methylbenzamide

61 2,3-difluoro-N-[2-(7- 347 348 9.49 fluoro-2,4-dimethyl- 1 H-indol-3- yl)ethyl]benzamide

62 3,5-difluoro-N-[2-(7- 347 348 9.77 fluoro-2,4-dimethyl- 1 H-indol-3- yl)ethyl]benzamide

63 naphthalene-2- 361 362 9.92 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

64 5-chlorothiophene- 351 352 10.05 2-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

65 6-fluoro-N-[2-(7- 330 331 8.59 fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]- nicotinamide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

66 3-chloromethyl-N-[2- 359 360 9.55 (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]benzamide

67 4-butoxy-N-[2-(7- 383 384 10.55 fluoro-2,4-dimethyl- 1 H-indol-3- yl)ethyl]benzamide

68 4-acetoxy-N-[2-(7- 369 370 8.85 fluoro-2,4-dimethyl- 1 H-indol-3- yl)ethyl]benzamide

69 N-[2-(7-fluoro-2,4- 357 358 9.55 dimethyl-1 H-indol-3- yl)ethyl]-4- methylsulfanyl- benzamide

70 4-cyano-2-fluoro-N- 354 355 9.2 [2-(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]benzamide

71 isoquinoline-1- 362 363 9.79 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

72 isoquinoline-1- 350 351 8.44 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

73 isoquinoline-1- 364 365 10.25 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

74 3,5-dichloro-N-[2-(7- 379 380 10.85 fluoro-2,4-dimethyl- 1 H-indol-3- yl)ethyl]benzamide

75 quinoline-4- 361 362 8.38 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

76 quinoline-4- 343 344 7.08 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

77 4-hydroxy-2-phenyl- 392 393 8.61

2H-pyrazole-3- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

84 4-benzyloxy-N-[2-(7- 416 417 10.8 fluoro-2,4-dimethyl- 1 H-indol-3- yl)ethyl]benzamide

85 5-bromo-N-[2-(7- 390 391 9.44 fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]- nicotinamide

86 1 H-indole-3- 349 350 8.98 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

87 3-bromothiophene- 395 396 10.25 2-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

88 2-chloro-N-[2-(7- 405 406 9.47 fluoro-2,4-dimethyl-

1 H-indol-3-yl)ethyl]-

3,4-dimethoxy- benzamide

89 2-methylfuran-3- 314 315 9.35 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

90 1 H-imidazole-4- 300 301 6.35 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

91 4-oxo-4,5,6,7- 384 385 9.42 tetrahydro- benzo[b]thiophene-

2-carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

92 4'-bromobiphenyl-2- 465 466 10.83 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

93 2-fluoro-N-[2-(7- 454 455 9.82 fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]- 6-iodobenzamide

94 2,3-dihydro- 352 353 9.86 benzofuran-7- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

95 3-fluoro-N-[2-(7- 342 343 9.8 fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]- 2-methylbenzamide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

102 2-pyridin-3- 394 395 9.17 ylthiazole-4- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

103 2,5-dimethyl-2H- 328 329 8.83 pyrazole-3- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

104 N-[2-(7-fluoro-2,4- 416 417 10.67 dimethyl-1 H-indol-3- yl)ethyl]-2- phenoxymethyl- benzamide

105 2,3-dihydro- 352 353 9.33 benzofuran-5- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

106 1 H-indole-6- 349 350 9.17 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

107 2-bromo-N-[2-(7- 449 450 9.38 fluoro-2,4-dimethyl-

1 H-indol-3-yl)ethyl]-

4,5-dimethoxy- benzamide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

108 N-[2-(7-fluoro-2,4- 379 380 10.31 dimethyl-1 H-indol-3- yl)ethyl]-4-pyrrolidin- 1-ylbenzamide

109 quinoline-5- 361 362 6.88 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

1 10 5-phenyl-1 H- 376 377 8.53 pyrazole-4- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

1 1 1 pyridazine-4- 312 313 7.57 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

1 12 5-phenyl-2H- 376 377 9.38 pyrazole-3- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

1 13 N-[2-(7-fluoro-2,4- 376 377 9.27 dimethyl-1 H-indol-3- yl)ethyl]-5-pyrrol-1- yl-nicotinamide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

1 14 pyrimidine-5- 312 313 7.85 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

1 15 benzo[b]thiophene- 366 367 10.1 1 5-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

1 16 N-[2-(7-fluoro-2,4- 394 395 7.25 dimethyl-1 H-indol-3- yl)ethyl]-3-piperidin- 1-ylbenzamide

1 17 pyrazolo[1 ,5- 350 351 9.33 ajpyridine-2- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

1 18 quinoxaline-2- 362 363 10.13 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

1 19 3-fluoro-N-[2-(7- 358 359 10.07 fluoro-2,4-dimethyl-

1 H-indol-3-yl)ethyl]-

2-methoxy- benzamide

120 3-chloro-N-[2-(7- 359 360 10.23 fluoro-2,4-dimethyl- 1 H-indol-3-yl)ethyl]- 2-methylbenzamide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

127 5-methyl-1 H-indole- 363 364 9.84 2-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

128 4-methyl-1 H-indole- 363 364 9.83 2-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

129 6-methoxy-1 H- 379 380 9.41 indole-2-carboxylic acid [2-(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

130 4-methoxy-1 H- 379 380 9.41 indole-2-carboxylic acid [2-(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

131 4-fluoro-1 H-indole- 367 368 9.85 2-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

132 7-methyl-1 H-indole- 363 364 10.67 2-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

133 6-fluoro-1 H-indole- 367 368 9.66 2-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

134 6-methyl-1 H-indole- 363 364 9.92 2-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

135 5-methoxy-1 H- 351 352 8.73 indole-2-carboxylic acid [2-(7-fluoro-1 H- indol-3- yl)ethyl]amide

136 1 H-indole-2- 321 322 8.87 carboxylic acid [2- (7-fluoro-1 H-indol-3- yl)ethyl]amide

137 5-fluoro-1 H-indole- 339 340 8.95 2-carboxylic acid [2- (7-fluoro-1 H-indol-3- yl)ethyl]amide

138 5-methyl-1 H-indole- 335 336 9.2 2-carboxylic acid [2- (7-fluoro-1 H-indol-3- yl)ethyl]amide

139 6-methoxy-1 H- 351 352 8.74 indole-2-carboxylic acid [2-(7-fluoro-1 H- indol-3- yl)ethyl]amide

140 4-methyl-1 H-indole- 335 336 9.18 2-carboxylic acid [2- (7-fluoro-1 H-indol-3- yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

141 4-dimethylamino-N- 325 326 7.63 [2-(7-fluoro-1 H- indol-3- yl)ethyl]benzamide

142 N-[2-(7-fluoro-1 H- 351 352 9.22 indol-3-yl)ethyl]-4- pyrrolidin-1- ylbenzamide

143 1 H-indole-6- 321 322 8.21 carboxylic acid [2- (7-fluoro-1 H-indol-3- yl)ethyl]amide

144 4-methoxy-1 H- 351 352 8.88 indole-2-carboxylic acid [2-(7-fluoro-1 H- indol-3- yl)ethyl]amide

145 4-fluoro-1 H-indole- 339 340 9.02 2-carboxylic acid [2- (7-fluoro-1 H-indol-3- yl)ethyl]amide

146 6-fluoro-1 H-indole- 339 340 9.03 2-carboxylic acid [2- (7-fluoro-1 H-indol-3- yl)ethyl]amide

147 6-methyl-1 H-indole- 335 336 9.28 2-carboxylic acid [2- (7-fluoro-1 H-indol-3- yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

155 2'-fluoro-4'-methyl- 418.4846 419 4.72 biphenyl-4- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

156 4'-hydroxymethyl- 416.4935 417 3.81 biphenyl-4- carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

157 4'-[2-(7-fluoro-2,4- 430.4767 431 3.86 dimethyl-1 H-indol-3- yl)ethylcarbamoyl]- biphenyl-4- carboxylic acid

158 4'-tert-butylbiphenyl- 442.5749 444 5.12 4-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

159 4'-chlorobiphenyl-4- 420.9128 422 4.72 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

160 3',4',5'-trimethoxy- 476.5451 478 4.19 biphenyl-4- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

161 3'-trifluoromethoxy- 470.4638 471 4.84 biphenyl-4- carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

162 4'-trifluoromethoxy- 470.4638 471 4.8 biphenyl-4- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

163 3'-hydroxybiphenyl- 402.4667 403 3.97 4-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

164 4'-methanesulfinyl- 448.5595 450 3.64 biphenyl-4- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

165 3'-cyanomethyl- 425.5046 427 4.17 biphenyl-4- carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

166 2'-acetylamino- 443.5194 445 3.72 biphenyl-4- carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

167 3'-fluoro-4'-methoxy- 434.4836 435 4.36 biphenyl-4- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

168 3'-chloro-4'-fluoro- 438.9029 440 4.74 biphenyl-4- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

169 3',4'-difluoro- 422.4479 423 4.55 biphenyl-4- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

170 3',5'-difluoro- 422.4479 423 4.57 biphenyl-4- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

171 N-[2-(7-fluoro-2,4- 422.5217 424 3.82 dimethyl-1 H-indol-3- yl)ethyl]-4-(5- hydroxymethyl- thiophen-2-yl)- benzamide

172 3'-methanesulfonyl- 464.5585 466 3.94 biphenyl-4- carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

173 4-fluoro-4'-[2-(7- 448.4668 449 3.89 fluoro-2,4-dimethyl-

1 H-indol-3- yl)ethylcarbamoyl]- biphenyl-3- carboxylic acid

174 4'-[2-(7-fluoro-2,4- 474.5293 476 4.2 dimethyl-1 H-indol-3- yl)ethylcarbamoyl]- 3-methoxybiphenyl- 4-carboxylic acid methyl ester

175 5-fluoro-4'-[2-(7- 448.4668 449 fluoro-2,4-dimethyl-

1 H-indol-3- yl)ethylcarbamoyl]- biphenyl-3- carboxylic acid

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

183 biphenyl-4,4'- 485.5998 487 4.1 dicarboxylic acid A- diethylamide 4'-{[2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide}

184 4'-[2-(7-fluoro-2,4- 430.4767 431 3.87 dimethyl-1 H-indol-3- yl)ethylcarbamoyl]- biphenyl-3- carboxylic acid

185 biphenyl-4,4'- 429.4926 430 3.59 dicarboxylic acid 4-amide 4'-{[2-(7- fluoro-2,4-dimethyl- 1 H-indol-3- yl)ethyl]amide}

186 3'-methylsulfamoyl- 479.5734 481 3.97 biphenyl-4- carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

187 3'-trifluoromethyl- 454.4648 455 4.73 biphenyl-4- carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

188 4'-methylsulfanyl- 432.5605 434 4.62 biphenyl-4- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

189 4'-acetylbiphenyl-4- 428.5045 430 4.21 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

198 N-[2-(7-fluoro-2,4- 437.5156 439 3.32 dimethyl-1 H-indol-3- yl)ethyl]-4-quinolin- 6-ylbenzamide

199 N-[2-(7-fluoro-2,4- 417.4816 418 4.1 dimethyl-1 H-indol-3- yl)ethyl]-4-(6- methoxypyridin-3- yl)-benzamide

200 biphenyl-3,4'- 443.5194 445 3.72 dicarboxylic acid 4'- {[2-(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide} 3- methylamide

201 biphenyl-4,4'- 443.5194 445 3.69 dicarboxylic acid 4'- {[2-(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide} A- methylamide

202 2'-fluorobiphenyl-4- 404.4578 405 4.45 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

203 2'-methylbiphenyl-4- 400.4945 401 4.62 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

204 3'-acetylamino- 443.5194 445 3.84 biphenyl-4- carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

205 4-benzo[1 ,3]dioxol- 430.4767 431 4.38

5-yl-N-[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3- yl)ethyl]benzamide

206 3'-cyanobiphenyl-4- 411.4778 412 4.27 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

207 4'-cyanomethyl- 425.5046 427 4.12 biphenyl-4- carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

208 biphenyl-3,4'- 429.4926 430 3.79 dicarboxylic acid 3- amide 4'-{[2-(7- fluoro-2,4-dimethyl- 1 H-indol-3- yl)ethyl]amide}

209 3',5'-dimethyl- 414.5213 416 4.89 biphenyl-4- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

210 N-[2-(7-fluoro-2,4- 437.5156 439 3.52 dimethyl-1 H-indol-3- yl)ethyl]-4-quinolin- 3-ylbenzamide

21 1 4'-acetylamino- 443.5194 445 3.75 biphenyl-4- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

212 3'-fluoro-5'-methoxy- 434.4836 435 4.62 biphenyl-4- carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

213 5-fluorobiphenyl- 461.5095 463 3.88

3,4'-dicarboxylic acid 4'-{[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3- yl)ethyl]amide} 3- methylamide

214 3'-(acetylamino- 457.5462 459 3.71 methyl)biphenyl-4- carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

215 N-[2-(7-fluoro-2,4- 439.5314 441 4.47 dimethyl-1 H-indol-3- yl)ethyl]-4-(1-methyl-

1 H-indol-5-yl)- benzamide

216 N-[2-(7-fluoro-2,4- 439.5314 441 4.69 dimethyl-1 H-indol-3- yl)ethyl]-4-(1-methyl-

1 H-indol-2-yl)- benzamide

217 N-[2-(7-fluoro-2,4- 376 377 9.27 dimethyl-1 H-indol-3- yl)ethyl]-5-pyrrol-1- yl-nicotinamide

218 N-[2-(4-cyano-7- 381 382 1.10 fluoro-2-methyl-1 H- indol-3-yl)ethyl]-3,4- dimethoxy- benzamide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

260 2-bromo-N-[2-(7- 390 390 1.26 fluoro-2,4-dimethyl-

1 H-indol-

3-yl)ethyl]isonicotin- amide

261 {4-[2-(7-fluoro-2,4- 384 385 0.90 dimethyl-1 H-indol- 3-yl)ethylcarbamoyl] phenoxy}acetic acid

262 5-bromo-1 H-indole- 427 426 [M-H] 1.30 2-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol- 3-yl)ethyl]amide

263 6-bromo-1 H-indole- 427 426 [M-H] 1.30 2-carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol- 3-yl)ethyl]amide

264 5-bromopyridine-2- 464 465 1.26 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol- 3-yl)ethyl]amide

265 6-(3-carbamoyl- 430 431 1.16 phenyl)pyridine-2- carboxylic acid [2-

(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)- ethyljamide

266 6-(3-methyl- 444 445 1.23 carbamoylphenyl)- pyridine-2-carboxylic acid [2-(7-fluoro-

2,4-dimethyl-1 H- indol-3- yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

289 2-(3-carbamoyl- 430 431 1.10 phenyl)-N-

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- isonicotinamide

290 N-[2-(7-fluoro- 444 445 1.14

2,4-dimethyl-1 H- indol-3-yl)ethyl]-

2-(3-methylcarbamo ylphenyl)isonicotin- amide

291 N-[2-(7-fluoro- 403 404 1.17

2,4-dimethyl-1 H- indol-3-yl)ethyl]-

2-(3-hydroxyphenyl)i sonicotinamide

292 N-[2-(7-fluoro- 444 445 1.12

2,4-dimethyl-1 H- indol-3-yl)ethyl]-

2-(4-methylcarbamo ylphenyl)isonicotin- amide

293 benzo[b]thiophene- 366 365 1.37

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-

3-yl)ethyl]amide

294 quinoline-2- 361 362 1.47 carboxylic acid [2-

(7-fluoro-

2,4-dimethyl-1 H- indol-

3-yl)ethyl]amide

295 [1 ,8]naphthyridine- 362 363 1.23

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-

3-yl)ethyl]amide

296 isoquinoline-3- 361 362 1.37 carboxylic acid [2- (7-fluoro-2,4- dimethyl-1 H-indol- 3-yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

303 4'-methoxybiphenyl- 416 417 4.42

4-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

304 4'-[2-(7-fluoro- 460 462 3.84

2,4-dimethyl-1 H- indol-3-yl)ethyl- carbamoyl]-

3-methoxybiphenyl-

4-carboxylic acid

305 4'-methoxybiphenyl- 416 417 4.44

3-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

307 4-(4-methyl- 449 450 1.22 carbamoylphenyl)- thiophene-

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

308 4-(3-methyl- 449 450 1.25 carbamoylphenyl)- thiophene-

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

315 2-fluoro-3'-hydroxy- 420 421 1.32 biphenyl-

4-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

316 2'-fluorobiphenyl- 461 462 1.25

3,4'-dicarboxylic acid 4'-{[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide} 3-methyl- amide

317 5-(3-methyl- 482 483 1.25 carbamoylphenyl)-

1 H-indole-

2-carboxylic acid

[2-(7-fluoro- 2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

318 5-bromothiophene- 394 395 1.38

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

319 3'-hydroxybiphenyl- 388 389 1.22 4-carboxylic acid [2-(7-fluoro- 2-methyl-1 H-indol- 3-yl)ethyl]amide

320 biphenyl- 429 430 1.14

4,4'-dicarboxylic acid 4'-{[2-(7-fluoro-

2-methyl-1 H-indol-

3-yl)ethyl]amide}

4-methylamide

321 4'-[2-(7-fluoro- 460 459 1.44

2,4-dimethyl-1 H- indol-3-yl)ethyl- carbamoyl]-

3-hydroxybiphenyl-

4-carboxylic acid methyl ester

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

335 3'-cyano- 429 430 1.38

2'-fluorobiphenyl-

4-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

336 5-chloro-1 H-indole- 369 370 1.35 2-carboxylic acid [2-(7-fluoro- 2-methyl-1 H-indol- 3-yl)ethyl]amide

337 5-chloro-1 H-indole- 387 388 1.37 2-carboxylic acid [2-(4,7-difluoro- 2-methyl-1 H-indol- 3-yl)ethyl]amide

338 5-chloro-1 H-indole- 404 404 1.44 2-carboxylic acid [2-(4-chloro-7-fluoro- 2-methyl-1 H-indol- 3-yl)ethyl]amide

339 5-trifluoromethyl-1 H- 417 416 [M-H] 1.44 indole-2-carboxylic acid [2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

340 6-methanesulfonyl- 427 428 1.19

1 H-indole-

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

341 7-chloro-1 H-indole- 383 382 1.39

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

342 4-chloro-1 H-indole- 383 382 [M-H] 1.40

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

343 6-chloro-1 H-indole- 383 382 1.39

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

344 7-fluoro-1 H-indole- 367 368 1.33

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

345 5-bromo-1 H-indole- 483 484 1.46

2-carboxylic acid

[2-(7-fluoro-

4-methyl-2-trifluoro- methyl-1 H-indol-

3-yl)ethyl]amide

346 5-trifluoromethyl-1 H- 471 472 1.48 indole-2-carboxylic acid [2-(7-fluoro-

4-methyl-2-trifluoro- methyl-1 H-indol-

3-yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

347 5-chloro-1 H-indole- 437 438 1.44

2-carboxylic acid

[2-(7-fluoro-

4-methyl-2-trifluoro- methyl-1 H-indol-

3-yl)ethyl]amide

348 5-trifluoromethoxy- 487 488 1.49

1 H-indole-

2-carboxylic acid

[2-(7-fluoro-

4-methyl-2-trifluoro- methyl-1 H-indol-

3-yl)ethyl]amide

349 N-[2-(7-fluoro- 424 425 1.26

4-methyl-2-trifluoro- methyl-1 H-indol-

3-yl)ethyl]-

3,4-dimethoxy- benzamide

350 biphenyl- 463 464 1.25

3,4'-dicarboxylic acid 4'-{[2-(4-chloro-

7-fluoro-2-methyl-

1 H-indol-3-yl)ethyl]- amide} 3-methyl- amide

351 5-fluoro-1 H-indole- 387 388 1.36 2-carboxylic acid [2-(4-chloro-7-fluoro- 2-methyl-1 H-indol- 3-yl)ethyl]amide

352 5-trifluoromethoxy- 453 454 1.48

1 H-indole-

2-carboxylic acid

[2-(4-chloro-7-fluoro-

2-methyl-1 H-indol-

3-yl)ethyl]amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

359 5-isopropyl-1 H- 391 392 1.49 indol-2-carboxylic acid [2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

360 6-trifluoromethyl-1 H- 417 418 1.44 indole-2-carboxylic acid [2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

361 4,5,6,7-tetrahydro- 353 354 1.34

1 H-indole-

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

362 5-methanesulfonyl- 427 428 1.18

1 H-indole-

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

363 3-methyl-1 H-indole- 363 364 1.38

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

364 5-fluoro- 384 385 1.44 benzo[b]thiophene-

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

365 5-trifluoromethyl- 434 433 [M-H] 1.52 benzo[b]thiophene-

2-carboxylic acid [2-

(7-fluoro-2,4- dimethyl-1 H-indol-3- yl)ethyl]amide

366 5-trifluoromethoxy- 450 449 [M-H] 1.53 benzo[b]thiophene-

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

367 6-trifluoromethoxy- 433 434 1.46

1 H-indole-

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

368 6-tert-butyl-1 H- 405 406 1.53 indole-2-carboxylic acid [2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

369 benzothiazole- 367 368 1.44

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

370 benzoxazole- 351 352 1.31

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

371 3'-(2,5-dioxo- 484 485 1.16 imidazolidin-4-yl)- biphenyl-

4-carboxylic acid

[2-(7-fluoro- 2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

372 6-amino-1 H-indole- 364 365 0.94

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

373 5-dimethyl- 450 451 1.16 carbamoylmethoxy-

1 H-indole-

2-carboxylic acid [2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

374 6-dimethyl- 450 451 1.19 carbamoylmethoxy-

1 H-indole-

2-carboxylic acid

[2-(7-fluoro- 2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

375 6-acetylamino-1 H- 406 407 1.14 indole-2-carboxylic acid [2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

376 6-(2,2-dimethyl- 448 449 1.30 propionylamino)-1 H- indole-2-carboxylic acid [2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

377 5-(2,2-dimethyl- 448 449 1.28 propionylamino)-1 H- indole-2-carboxylic acid [2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

Theoretical Mass found Retention

Ex- Structure Name mass m/z [M+H] ⁺ time ampl m/z [M+H] ⁺ [min.] e

378 5-acetylamino-1 H- 406 407 1.10 indole-2-carboxylic acid [2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

379 5-bromo- 446 447 1.51 benzo[b]thiophene-

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

380 6-bromo- 446 447 1.51 benzo[b]thiophene-

2-carboxylic acid

[2-(7-fluoro- 2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

381 6-trifluoromethyl- 434 433 1.52 benzo[b]thiophene-

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

382 6-chloro- 400 399 [M-H] 1.50 benzo[b]thiophene-

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

383 6-methylcarbamoyl- 436 437 1.17 methoxy-1 H-indole-

2-carboxylic acid

[2-(7-fluoro-

2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

384 5-methylcarbamoyl- 436 437 1.15 methoxy-1 H-indole-

2-carboxylic acid

[2-(7-fluoro- 2,4-dimethyl-1 H- indol-3-yl)ethyl]- amide

Biological Examples:

1. Detection of the antagonism of the human prostaglandin E? (subtype EP?) receptor signal 1.1 Principle of detection

The binding of PGE2 to the EP2 subtype of the human PGE2 receptor induces activation of membrane-associated adenylate cyclases and leads to the formation of cAMP. In the presence of the phosphodiesterase inhibitor IBMX, cAMP which has accumulated due to this stimulation and been released by cell lysis is employed in a competitive detection method. In this assay, the cAMP in the lysate competes with cAMP-XL665 for binding of an Eu cryptate-labelled anti-cAMP antibody.

This results, in the absence of cellular cAMP, in a maximum signal which derives from coupling of this antibody to the CAMP-XL665 molecule. After excitation at 337 nm, this results in a FRET (fluorescence resonance energy transfer)-based, long-lived emission signal at 665 nm (and at 620 nM). The two signals are measured in a suitable measuring instrument with a time lag, i.e. after the background fluorescence has declined. Any increase in the low FRET signal caused by prostaglandin E ₂ addition (measured as well ratio change = emission ₆ 65 _n m/emission ₆₂ o nm ^* 10 000) shows the effect of antagonists.

1.2. Detection method

1.2.1 Antagonism assay (data for each well of a 384-well plate):

The substance solutions (0.75 μl) introduced into an assay plate and 30% DMSO are dissolved in 16 μl of a KRSB+IBMX stimulation solution (1 X Krebs- Ringer Bicarbonate Buffer; Sigma-Aldrich # K-4002; including 750 μM 3-isobutyl- 1 -methylxanthine Sigma-Aldrich # 1-7018), and then 15 μl thereof are transferred into a media-free cell culture plate which has been washed with KRSB shortly beforehand. After preincubation at room temperature (RT) for 30 minutes, 5 μl of a 4 x PGE2 solution (11 nM) are added, and incubation is carried out in the presence of the agonist at RT for a further 60 min (volume: -20 μl) before the reaction is then stopped by adding 5 μl of lysis buffer and incubated at RT for a further 20 min

(volume: -25 μl). The cell lysate is then transferred into a measuring plate and measured in accordance with the manufacturer's information (cyclic AMP kit Cisbio International # 62AMPPEC).

1.2.2 Agonism assay (data for each well of a 384-well plate):

The substance solutions (0.75 μl) introduced into an assay plate and 30% DMSO are dissolved in 16 μl of a KRSB+IBMX stimulation solution (1 X Krebs- Ringer Bicarbonate Buffer; Sigma-Aldrich # K-4002; including 750 μM 3-isobutyl- 1 -methylxanthine Sigma-Aldrich # 1-7018), and then 15 μl thereof are transferred into a media-free cell culture plate which has been washed with KRSB shortly beforehand.

After incubation at room temperature (RT; volume: -15 μl) for 60 minutes, the reaction is then stopped by adding 5 μl of lysis buffer and incubated at RT for a further 20 min (volume: -20 μl). The cell lysate is then transferred into a measuring plate and measured in accordance with the manufacturer's information (cyclic AMP kit Cisbio International # 62AMPPEC).

2. The EP2 subtype of the PGE2 receptor and the preovulatory cumulus expansion

2.1. Background:

In the preovulatory antral follicle, the oocyte is surrounded by cumulus cells which form a dense ring of cells around the oocyte. After the LH peak (lutenizing hormone), a series of processes is activated and leads to a large morphological change in this ring of cells composed of cumulus cells. In this case, the cumulus cells form an extracellular matrix which leads to so-called cumulus expansion (Vanderhyden et al. Dev Biol. 1990 Aug;140(2):307-317). This cumulus expansion is an important component of the ovulatory process and of the subsequent possibility of fertilization.

Prostaglandins, and here prostaglandin E ₂ , whose synthesis is induced by the LH peak, are of crucial importance in cumulus expansion. Prostanoid EP ₂ knockout mice (Hizaki et al. Proc Natl Acad Sci U S A. 1999 Aug 31 ;96(18):10501 -6.) show a markedly reduced cumulus expansion and severe

subfertility, demonstrating the importance of the prostanoid EP ₂ receptor for this process.

2.2 Cumulus expansion assay in vitro Folliculogenesis is induced in immature female mice (strain: CD1 (ICR) from Charles River) at an age of 14-18 days by a single dose (intraperitoneal) of 10 I. U. of PMSG (Pregnant Mare Serum Gonadotropine; Sigma G-4877, Lot 68H0909). 47-50 hours after the injection, the ovaries are removed and the cumulus-oocyte complexes are removed. The cumulus complex is not yet expanded at this stage.

The cumulus-oocyte complexes are then incubated with prostaglandin E2 (PGE2) (0.3 μM), vehicle control (ethanol) or test substances for 20-24 hours. Medium: alpha-MEM medium with 0.1 mM IBMX, pyruvates (0.23 mM) glutamines (2 mM), pen/strep 100 IU/ml pen. and 100 μg/ml strep.) and HSA (8 mg/ml)). Cumulus expansion is then established through the division into four stages (according to Vanderhyden et al. Dev Biol. 1990 Aug;140(2):307-317).

Table 1 : Example of the biological activity of the compounds of the invention (measured by the cAMP antagonism assay):

Previous Patent: COATING DEVICE, COATING STATION, AND METHOD FOR COATING AN OBJECT

Next Patent: HOLLOW WINDOW OR DOOR SECTION